Astrocyte-specific gene recombination in vivo : Tamoxifen-induced and -independent recombination by Kasakow, Carmen Vanessa
 
 
Astrocyte-specific gene recombination in vivo -  







zur Erlangung des akademischen Grades des Doktors 
der Naturwissenschaften (Dr. rer. nat.) 
der Medizinischen Fakultät, Institut für Physiologie, 




vorgelegt von  
Carmen Vanessa Kasakow 
geb. Bohn 




Homburg, September 2018 
II 
 
The experimental work depicted in this thesis has been carried out at the Center for 
Integrative Physiology and Molecular Medicine in the Department of Molecular 
Physiology at the University of Saarland, Germany. The work was done independently 















Prof. Dr. Frank Kirchhoff 
University of Saarland 
Center for Integrative Physiology and Molecular Medicine 





Prof. Dr. Carola Meier 
University of Saarland 













































List of Figures…………………………………………………………………………………..X 
List of Tables………………………………………………………………………………….XII 
1. Summary ............................................................................................................ 1 
2. Zusammenfassung............................................................................................ 3 
3. Introduction ....................................................................................................... 5 
3.1. Multiple astrocytic functions in the mouse central nervous system .................... 5 
3.2. Expression of astrocytic metobotropic and ionotropic ion channels ................... 7 
3.3. ATP induced Ca2+ signaling in astrocytes ....................................................... 11 
3.4. Tamoxifen metabolism .................................................................................... 12 
4. Aim ................................................................................................................... 15 
4.1. Astrocyte-specific gene recombination and the influence of tamoxifen- 
induced recombination .................................................................................... 15 
5. Materials and Methods .................................................................................... 16 
5.1. Materials ......................................................................................................... 16 
5.1.1. Reagents ...................................................................................................... 16 
5.1.2. Consumables and kits .................................................................................. 16 
5.1.3. Devices......................................................................................................... 16 
5.1.4. Buffers, aqueous solutions and media .......................................................... 17 
5.1.5. Purchased buffers ........................................................................................ 18 
5.1.6. Enzymes ....................................................................................................... 19 
5.1.7. Drugs ............................................................................................................ 19 
5.1.8. Antibodies ..................................................................................................... 19 
5.1.9. Primers ......................................................................................................... 20 
5.1.10. Animals ...................................................................................................... 22 
5.1.11. Hard- und Software .................................................................................... 24 
5.1.12. Mouse administration ................................................................................. 28 
5.1.13. Statistical analysis ...................................................................................... 29 
5.1.14. Cell and receptor schemes of the introduction ............................................ 29 
5.2. Methods .......................................................................................................... 30 
5.2.1. Tail biopsies ................................................................................................. 30 
5.2.2. Mouse perfusion ........................................................................................... 30 
V 
 
5.2.3. Tamoxifen treatment ..................................................................................... 30 
5.3. Sample preparation for LC-HR-MS/MS analysis ............................................. 31 
5.4. LC-HR-MS/MS analysis .................................................................................. 31 
5.4.1. Isolation and analysis of genomic DNA ......................................................... 32 
5.4.2. Immunohistochemical analysis ..................................................................... 33 
5.4.3. Processing of DNA and RNA samples .......................................................... 33 
5.5. Cell sorting ...................................................................................................... 39 
5.5.1. Magnetic activated cell sorting (MACS) ........................................................ 39 
5.6. Injury models .................................................................................................. 39 
5.6.1. Anesthesia and mouse preparation for injury models.................................... 39 
5.6.2. Cortical stab wound injury ............................................................................. 40 
5.6.3. Cranial window ............................................................................................. 40 
5.6.4. Microscopy ................................................................................................... 41 
5.7. Next generation sequencing (NGS) ................................................................ 43 
5.7.1. Laboratory and animal handling .................................................................... 44 
6. Results ............................................................................................................. 45 
6.1. Refined protocols of tamoxifen application for DNA recombination in  
mouse astrocytes ............................................................................................ 45 
6.1.1. Fast uptake and clearance of tamoxifen and its bioactive metabolite 4-OH-
TAM .............................................................................................................. 45 
6.1.2. Maximal recombination levels are reached by three or five days of TAM 
injections in cortex or cerebellum, respectively ............................................. 49 
6.1.3. GLAST-CreERT2 mediated DNA recombination to quantify astroglial cell 
numbers ....................................................................................................... 54 
6.2. Tamoxifen-independent recombination ........................................................... 58 
6.2.1. IHC analysis and quantification of different astrocyte-specific CreERT2 driver 
lines crossbred to the reporter mouse lines GCaMP3 and tdTomato ............ 58 
6.2.2. Quantitative real time PCR analysis of the same mouse lines confirm  
results of Orbit image quantification .............................................................. 69 
6.2.3. Pathological conditions can trigger tamoxifen-independent recombination in 
GFAP-CreERT2 mice ....................................................................................... 75 
6.3. P2Y1 receptor cKO mice ................................................................................. 76 
6.3.1. High reduction of P2Y1R mRNA on astrocytes ............................................. 76 
VI 
 
6.3.2. DNA data of MACS isolated astrocytes and mRNA expression data from  
NGS confirm observations of total homogenates .......................................... 78 
6.3.3. Differentially expressed genes after P2Y1R ablation .................................... 81 
6.4. Astroglial P2Y1 receptor knockout had no impact on acute injuries ................ 83 
6.4.1. Loss of astroglial P2Y1 receptors without impact on acute brain injury ......... 83 
6.4.2. GCaMP3 reporter expression led to an increase in GFAP expression upon 
astroglial P2Y1R ablation ............................................................................. 86 
6.5. Ca2+ signaling in astrocytes ............................................................................. 89 
6.5.1. Smaller and shorter Ca2+ signals in cKO mice under anesthetized and  
awake conditions .......................................................................................... 89 
7. Discussion ....................................................................................................... 97 
7.1. Tamoxifen-induced recombination .................................................................. 97 
7.1.1. Pharmacokinetic profile of tamoxifen and its metabolites revealed fast 
accumulation and clearance of all metabolites in the brain ........................... 97 
7.1.2. TAM injections for three or five consecutive days revealed highest 
recombination efficiencies dependent on brain region and floxed allele ........ 99 
7.1.3. GLAST-CreERT2-driven recombination to determine the percentage of 
astrocytes in different brain regions ............................................................ 101 
7.2. Tamoxifen-independent recombination had no effect on floxed receptor  
alleles in the cortex ....................................................................................... 101 
7.3. P2Y1 receptor ablation and its impact on astrocytes ..................................... 105 
7.4. Ca2+ signaling of astrocytes in vivo ............................................................... 108 
7.4.1. Differences in astrocytic Ca2+ signaling after P2Y1 receptor ablation in  
gliapil and soma .......................................................................................... 108 
8. Outlook .......................................................................................................... 111 
9. References ..................................................................................................... 112 
10. Appendix ǀ ...................................................................................................... 119 
10.1. No tamoxifen-independent recombination of non-astrocytic CreERT2  
driver lines .................................................................................................... 119 
10.2. Heatmaps of in vivo Ca2+ imaging ................................................................. 120 
10.3. Detailed procedure of Ca2+ imaging analysis using MSparkles...................... 127 
10.4. Comparison of anesthetized and awake Ca2+ signals revealed higher signal 
amplitudes in gliapil and soma ...................................................................... 130 
10.5. Raw data of in vivo Ca2+ imaging .................................................................. 132 
VII 
 
11. Appendix ǁ ..................................................................................................... 134 
11.1. List of Publication .......................................................................................... 134 
11.1.1. Publication ............................................................................................... 134 
11.1.2. Posters/ Oral presentations ...................................................................... 134 




AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ATP  Adenosine triphosphate 
bp  base pairs 
BSA  bovine serum albumin 
cKO  conditional knockout 
cl  contralateral 
CLSM  confocal laser-scanning microscopy 
CNS  central nervous system 
con  control 
DAPI  4',6-diamidino-2-phenylindole 
DNA   desoxyribonucleic acid 
dNTP  2´-Desoxyribonucleosid-5´-triphosphate 
dpi  days post injection 
dpw  days post window 
EDTA  ethylenediaminetetraacetic acid 
EGFP  enhanced green fluorescent Protein 
END  endoxifen 
ER  estradiol receptor 
EYFP  enhanced yellow fluorescent Protein 
GFAP  glial fibrillary acidic protein 
GFP  green fluorescent protein 
GLAST  glutamate aspartate transporter 
GLT1  glutamate transporter 1 
hpi  hours post injection 
HRP  horse radish peroxidase 
HS  horse serum 
HSP  heat shock protein 
il  ipsilateral 
kb  kilobase pairs 
LC-HR-MS/MS liquid chromatography-high resolution-mass spectrometry 
loxP  Locus of crossover x 
mc  monoclonal 
IX 
 
MIP  maximum intensity projection 
mRNA  messenger ribonucleic acid 
n  number 
NDM-TAM  N-desmethyl-tamoxifen 
NGS  next generation sequencing 
NMDA  N-methyl-D-aspartate 
ns  non significant 
4-OH-TAM  4-hydroxytamoxifen 
o.n.  over night 
2P-LSM  two-photon laser-scanning microscopy 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
P2Y1R  P2Y purinoceptor 1 
PFA  paraformaldehyde 
pc  polyclonal 
pi  post injury 
RT  room temperature 
RT-PCR  real time polymerase chain reaction 
SDS  sodium dodecyl sulfate 
SEM   standard error of the mean 
SD   standard deviation 
SWI  stab wound injury 
tg  transgene 
Taq  Thermophilus Aquaticus 
TAM  tamoxifen 
TgH  transgenic mouse, generated by homologous recombination 
TgN  transgenic mouse, generated by non-homologous recombination 
Tris  tris(hydroxymethyl)aminomethane 
UV  ultraviolet light 
w  week 
wt  wild type 
The dimensions of this thesis are consistent with the International System of Units (SI). 
X 
 
LIST OF FIGURES 
Figure 1. Multiple tasks of astrocytes .................................................................... 6 
Figure 2. Distribution and function of diverse metabotropic and ionotropic ion 
channels at the tripartite synapse .......................................................... 8 
Figure 3. Purinergic signaling in the CNS ............................................................10 
Figure 4. P2Y and P2X receptor mRNA expression of glial cells .........................11 
Figure 5. Tamoxifen metabolism in mice .............................................................13 
Figure 6. Expression of CreERT2 in astrocytes of the GLAST locus .......................14 
Figure 7. Analysis of SWI experiments of cKO and control animals with the 
ImageJ plugin LRoi ...............................................................................25 
Figure 8. 2P-LSM imaging of awake mice and data processing of Ca2+ signals  
via MSparkles .......................................................................................27 
Figure 9. Treatment protocols for LC-HR-MS/MS analysis ..................................31 
Figure 10. Primer efficiencies to amplify various gene loci .....................................38 
Figure 11. TAM injection protocol, surgery and imaging preparation .....................43 
Figure 12. Brain concentrations of TAM and its derivatives peaked between 8  
and 24 hpi and showed clearance within 7 dpi ......................................46 
Figure 13. Serum concentrations of TAM and its metabolites ................................49 
Figure 14. Three to five daily TAM injections give maximal DNA  
recombination depending on the brain region .......................................51 
Figure 15. Interval injections every second day or every 8 h revealed  
differences in recombination efficiencies of floxed loci ..........................53 
Figure 16. Recombination efficiencies were constant for target and  
reporter genes ......................................................................................56 
Figure 17. Inducible DNA recombination in mouse astroglia ..................................58 
Figure 18. Tamoxifen-independent recombination of the GLAST-CreERT2 line 
indicated by high GCaMP3 reporter expression ....................................60 
Figure 19. Tamoxifen-independent recombination of  
GLAST-CreERT2 x Rosa26-tdTomato mice ............................................62 
Figure 20. Quantification of tamoxifen-independent recombination of the  
GLAST-CreERT2 driver line revealed high reporter expression ...............63 
Figure 21. Negligible non-tamoxifen-induced recombination of GCaMP3 in  
GFAP-CreERT2 mice ...............................................................................65 
XI 
 
Figure 22. Fewer cells expressed tdTomato in GFAP-CreERT2 mice .......................66 
Figure 23. Quantification of low reporter expression after tamoxifen-independent 
recombination in GFAP-CreERT2 mice....................................................67 
Figure 24. Primarily GLAST-CreERT2 driven tamoxifen-independent  
recombination of the reporter GCaMP3 in the cerebellum ....................70 
Figure 25. Tamoxifen-independent recombination of the floxed reporter ...............73 
Figure 26. Tamoxifen-independent recombination after GFAP upregulation  
under pathological conditions ...............................................................76 
Figure 27. Reduction of P2Y1R mRNA in homogenates of various  
brain regions .........................................................................................77 
Figure 28. Reduction of floxed p2ry1 alleles at the DNA and mRNA level of  
MACS isolated astrocytes .....................................................................79 
Figure 29. Contamination of astrocytic population after MACS with  
microglia, neurons, NG2 glia and oligodendrocytes ..............................80 
Figure 30. Next generation sequencing revealed 50 % reduction of p2ry1  
alleles in the cKO and an upregulation of p2rx6 ....................................81 
Figure 31. No difference between cKO and control mice after SWI on glial 
activation ..............................................................................................85 
Figure 32. Quantification of astroglial and microglial activation after acute injury 
revealed no differences between cKO and control mice .......................86 
Figure 33. Differences between cKO and control mice after SWI on glial  
activation when GCaMP3 is expressed ................................................88 
Figure 34. GFAP upregulation ipsilaterally and contralaterally of P2Y1R  
cKO mice ..............................................................................................89 
Figure 35. Anesthetized P2Y1 cKO mice had smaller and shorter Ca2+ signals  
in gliapil and soma ................................................................................92 
Figure 36. Smaller and shorter Ca2+ signals of awake P2Y1R cKO mice in gliapil 
and soma .............................................................................................94 
Figure 37. Stronger and shorter Ca2+ signals in gliapil and soma ...........................96 
Figure 38. Overview and conclusion of the tamoxifen study ..................................99 
Figure 39. Length of floxed sequence influences tamoxifen-independent 
recombination ..................................................................................... 103 
Figure 40. Negligible tamoxifen-independent recombination of the PLP- and  
NG2-CreERT2 driver line ....................................................................... 119 
XII 
 
Figure 41. Heatmaps of in vivo Ca2+ data revealed no pattern changes in  
Ca2+ signals ........................................................................................ 127 
Figure 42. Composition of Ca2+ data representing each imaging session,  
animal and Ca2+ signal of the gliapil .................................................... 128 
Figure 43. Composition of Ca2+ data representig each animal, imaging session  
and Ca2+ signal of the soma ................................................................ 129 
Figure 44. Differences of Ca2+ signals in gliapil and soma between anesthetized 
and awake mice.................................................................................. 131 
LIST OF TABLES 
Table 1. Devices ................................................................................................16 
Table 2. Primary antibodies ................................................................................19 
Table 3. Secondary Antibodies ...........................................................................19 
Table 4. Genotyping primers ..............................................................................20 
Table 5. mRNA expression primers ....................................................................21 
Table 6. DNA recombination primers ..................................................................21 
Table 7. Mouse lines ..........................................................................................24 
Table 8. Setup for reverse transcriptase PCR ....................................................35 
Table 9. Components for qRT-PCR for gene expression and  
DNA recombination ..............................................................................36 
Table 10. qRT-PCR program for the light cycler ...................................................36 
Table 11. qRT-PCR program of tdTomato, p2ry1, gria1 and GCaMP3 for  
the light cycler ......................................................................................37 
Table 12. Brain and serum concentrations of TAM and its metabolites.................49 
Table 13. Different tamoxifen injection protocols for recombination of the  
p2ry1 and gria1 locus ...........................................................................54 
Table 14. Percentage of fluorescence intensities of the GLAST-CreERT2 and  
GFAP-CreERT2 mouse lines (median; standardized to ct2/wt/+TAM) .....68 
Table 15. Statistical comparison of the different mouse lines and  
CreERT2 genotypes ................................................................................68 
Table 16. GLAST-CreERT2 and GFAP-CreERT2 driven recombination of gcamp3 
alleles ...................................................................................................71 
Table 17. Recombination of floxed p2ry1, gria1 and gcamp3 alleles  
in ctx and cb .........................................................................................74 
XIII 
 
Table 18. Statistical comparison of the floxed alleles with different GLAST 
genotype ..............................................................................................74 
Table 19. Data of Figure 35 ................................................................................ 132 
Table 20. Data of Figure 36 ................................................................................ 132 






Astrocytes express a plethora of neurotransmitter receptors that form “microdomains” 
for signaling pathways along their processes. The purinergic P2Y1 receptor (P2Y1R) is 
involved in long-range intercellular signaling of astrocytes involving gliotransmitter 
release. In neuropathological situations, blocking of P2Y1R can provide 
neuroprotection against glutamatergic excitotoxicity as occurring in stroke models. 
To investigate and temporally control the expression of the main purinergic receptor 
P2Y1 in cortical astrocytes, we took advantage of GLAST-CreERT2 x P2Y1fl/fl receptor 
mice. For precise temporal control of gene recombination, we explored the 
pharmacokinetic properties of tamoxifen after intraperitoneal injections using mass 
spectrometry (HPLC-MS). In addition, successful astroglial recombination was 
determined by quantitative real time PCR (qRT-PCR) of genomic DNA and mRNA in 
conditional knockout (cKO) mice. Our HPLC-MS analysis showed a fast uptake of TAM 
and its most active metabolite 4-hydroxytamoxifen (4-OH-TAM) in the brain peaking 
already at eight hours post injection. The clearance of TAM and 4-OH-TAM was 
similarily fast. Both were almost completely excreted 48 hours after injection. The 
efficiency of TAM-induced recombination was also determined by qRT-PCR of genomic 
DNA purified from brain homogenates of cKO mice, and in addition, by quantifying 
reporter-positive cells in GLAST-CreERT2 x tdTomato mice, revealing the percentage of 
astrocytes among all neural cells. In the cortex 20 % of all cells were GLAST-positive, 
whereas in the cerebellum only 6 % account for astrocytes. The astroglial p2ry1 gene 
deletion resulted in mRNA reductions of 43 % in the cortex and 61 % in the cerebellum, 
revealing a high amount of astrocytic P2Y1R among all neural cells.  
MACS isolated astrocytes showed a higher percentage of receptor ablation compared 
to total brain homogenates but did not reach 100 % reduction. A reduction of about 
60 % in the cortex and about 30 % in the cerebellum was detected, indicating that not 
all sorted cells were recombined. Next generation sequencing results revealed about 
50 % reduction of P2Y1R mRNA in cKOs in cortex and cerebellum. 
To investigate the impact of P2Y1R under pathological conditions, we performed the 
stab wound injury model to cKO and control mice. Staining of the glial fibrillary acidic 
protein (GFAP) of coronal sections revealed no impact of the P2Y1R on lesion size and 




The characterization and comparison of spontaneous-evoked Ca2+ signals was 
performed in anesthetized and awake P2Y1R control and cKO mice. We demonstrated 
a burst of Ca2+ signals upon ATP application on control astrocytes with enhanced and 
shortened signals in gliapil and soma. In contrast, Ca2+ signals of the P2Y1R cKO were 
smaller and shorter compared to controls, reflecting the reduction of purinergic 
signaling in astrocytes. We observed changes in Ca2+ signaling in the gliapil of the cKO, 
indicating alterations of Ca2+ signals in astrocytic microdomains. Ca2+ signals were even 
shorter and smaller in awake mice, revealing the influence of anesthesia on astrocytic 
Ca2+ signaling.  
In summary, ablation of the P2Y1R could be demonstated at the molecular level. A 
functional analysis of cKO mice revealed changes in the in vivo Ca2+ signals, indicating 





Astrozyten exprimieren eine Reihe von Neurotransmitter-Rezeptoren, die 
Mikrodomänen für die intrazelluläre Signaltransduktion entlang ihrer Fortsätze 
ausbilden. Der purinerge P2Y1-Rezeptor (P2Y1R) ist an raumgreifenden astrozytären 
Signalen beteiligt und schützt Neurone vor glutamaterger Überstimulation, wie sie bei 
Infarkten vorkommt.  
Zur Untersuchung und zeitlichen Kontrolle der P2Y1-Rezeptor-Expression, wurden 
Tamoxifen-induzierbare GLAST-CreERT2 x P2Y1fl/fl Mäuse verwendet. Für die präzise 
zeitliche Induktion der Genrekombination, wurden die pharmakokinetischen 
Eigenschaften von Tamoxifen nach einer intraperitonealen Injektion mittels 
Massenspektrometrie (HPLC-MS) ermittelt. Zusätzlich wurde die erfolgreiche 
astrogliale Rekombination mittels quantitativer Real-time PCR (qRT-PCR) mit 
genomische DNA und mRNA in konditionalen Knockout-Mäusen (cKO) ermittelt.  
Die HPLC-MS-Analyse zeigte eine schnelle Aufnahme von Tamoxifen und dessen 
Hauptmetabolit 4-Hydroxy-Tamoxifen (4-OH-TAM) in das Gehirn, mit erreichten 
Höchstwerten schon acht Stunden nach der Injektion. Ähnlich schnell sanken die 
Werte von TAM und 4-OH-TAM auch wieder und waren 48 h nach der Injektion kaum 
noch detektierbar. Die TAM-induzierte Rekombinationseffizienz wurde auch in 
Gehirnhomogenaten von cKOs durch qRT-PCR Analyse genomischer DNA ermittelt. 
Zudem wurden Reporter-positive Zellen in GLAST-CreERT2 x tdTomato Mäusen zur 
Quantifizierung des Astrozytenanteils im Vergleich zu allen anderen neuralen Zellen 
verwendet. Im Kortex wurden 20 % GLAST-positive Zellen (= Astrozyten) über qRT-
PCR rekombinierter Allele sowie Auszählung Reporter-positiver Zellen ermittelt, 
wohingegen im Zerebellum nur 6 % Astrozyten detektiert werden konnten. Im cKO 
wurde die Reduktion der P2Y1R mRNA mittels qRT-PCR überprüft. In Kortex und 
Zerebellum resultierte die astrogliale Deletion des p2ry1 Gens in einer Reduktion der 
P2Y1R mRNA um 43 % in Kortex- und 61 % in Zerebellum-Homogenaten.  
In MACS isolierten Astrozyten konnte, im Vergleich zu den Gehirnhomogenaten, eine 
stärkere Deletion des Rezeptors nachgewiesen werden, jedoch wurde auch hier keine 
100 %ige Reduktion erreicht. Auf DNA Ebene konnte eine Reduktion um 60 % im 
Kortex und 30 % im Zerebellum detektiert werden. Dies weist darauf hin, dass nicht 




bestätigen für Kortex und Zerebellum eine Reduktion der P2Y1R mRNA in den cKOs 
(50 %).  
Der Einfluss des P2Y1R unter pathologischen Bedingungen wurde mittels einer akuten 
Verletzung (Stichverletzung) von cKOs und Kontrollen analysiert. Das Anfärben 
koronaler Hirnschnitte mit dem sauren Gliafaserprotein Marker (glial fibrillary acidic 
protein, GFAP) zeigte keinen Einfluss des P2Y1R auf die Läsionsgröße und 
astrozytäre Aktivierung. 
Ein weiterer Punkt in dieser Studie stellte die Charakterisierung und der Vergleich von 
spontan-auftretenden Ca2+ Signalen in anästhesierten und wachen P2Y1R Kontroll- 
und cKO Mäusen dar. Die Applikation von ATP zeigte eine deutliche Veränderung der 
Ca2+ Signale von Kontroll-Astrozyten mit verstärkten aber kürzeren Signalen von Gliapil 
und Soma. Im Gegensatz dazu, waren die Ca2+ Signale des P2Y1R cKOs schwächer 
aber ebenfalls kürzer als die Signale der Kontrollen, was auf einen Verlust des 
purinergen Signalwegs in Astrozyten hinweist. Veränderungen der Ca2+ Signale im 
Gliapil des cKOs weisen auf veränderte Ca2+ Signale in den astrozytären 
Mikrodomänen in den Fortsätzen hin. Die Ca2+ Signale von wachen cKO Mäusen 
waren noch schwächer und stärker verkürzt, was den starken Einfluss der Anästhesie 
auf die Ca2+ Signale zeigt.  
Zusammenfassend konnten wir die Deletion des P2Y1R auf molekularer Ebene 
nachweisen. Die funktionelle Analyse des cKOs zeigte Veränderungen der Ca2+ 






3.1. Multiple astrocytic functions in the mouse central nervous 
system 
Astrocytes are the main macroglia in the central nervous system with several unique 
functions. They enwrap blood vessels with their endfeet to take up nutrients from the 
blood and provide them for neurons (Faulkner et al., 2004, Liu et al., 2018). Astrocytes 
are actively involved in the regulation of cerebral blood flow. The release of glutamate 
from synapses can activate metabotropic glutamate receptors (mGluR) on astrocytes 
and can induce intracellular Ca2+ elevations. This increase induces the generation of 
arachidonic acid (AA). Metabolites of AA are released from astrocytes and cause either 
vasodilation or vasoconstriction in adjacent arterioles. Which pathway is activated by 
the increase of Ca2+, depends on the level of pO2 and lactate in the tissue (Attwell et 
al., 2010, Gordon et al., 2011, MacVicar & Newman, 2015). 
Astrocytes enwrap the pre- and postsynapses of neurons with their processes to form 
tripartite synapses (Araque et al., 1999). In these microdomains, they clear the 
extracellular space from substances and ions like glutamate and potassium. By uptake 
of neurotransmitters, they prevent neurotoxicity caused by prolonged activation of 
receptors (Danbolt, 2001, Becerra-Calixto & Cardona-Gómez, 2017). This structure 
also enables the direct communication between neurons and astrocytes. The neuronal 
presynapse releases transmitters which can activate several neurotransmitter 
receptors located on astroglial processes. Activation of these receptors leads to a Ca2+ 
influx and intracellular Ca2+ increase (Araque et al., 1999, Araque, 2008, Perea & 
Araque, 2005, Guerra-Gomes et al., 2017). These Ca2+ signals cause the release of 
gliotransmitters (e.g. glutamate, ATP, D-serine) that can influence neuronal activity and 
plasticity (Kirchhoff et al., 2001, Ricci et al., 2009, Harada et al., 2015). Ca2+ elevations 
that originate from one astrocyte can propagate to neighboring astrocytes. This Ca2+ 
wave can spread over the astrocytic syncitium as a long-range intercellular 
communication between astrocytes (Alberdi et al., 2005, Cornell-Bell & Finkbeiner, 
1991, Charles et al., 1991, Cornell-Bell et al., 1990, Scemes & Giaume, 2006, 
Bazargani & Attwell, 2016). Mechanisms responsible for cell-to-cell signal transduction 




These agonists induce a Ca2+ increase in neighboring cells (Scemes & Giaume, 2006, 
Koizumi, 2010, Bazargani & Attwell, 2016). 
Changes in intracellular Ca2+ concentrations can activate diverse transcription factors 
acting on gene expression, leading to long-term changes in protein expression. 
Intracellular Ca2+ oscillations can induce e.g. morphological changes or alterations in 
gap junction coupling thereby modulating astrocytic plasticity (Pirttimaki & Parri, 2013, 
Papouin et al., 2017).  
To analyze protein functions on a cellular level the inducible Cre recombinase 
represents a reliable tool. The CreERT2 system leads to changes on the DNA level upon 
tamoxifen treatment. With this tool it is possible to knockout target genes and/or to 
express fluorescent proteins in a cell type and time specific manner, to analyze and 
influence Ca2+ signals, modulate transcription factors or glial signaling cascade (Fig. 1). 
 
Figure 1. Multiple tasks of astrocytes 
Astrocytes have multiple functions in the central nervous system (CNS): (A) Astrocytic 
processes with contact to neuronal synapses form the tripartite synapse. Glial 
glutamate uptake from the synaptic cleft prevents neuronal excitotoxicity. Glutamate 




signaling cascades. (B) Astrocytes with contact to blood vessels take up nutrients and 
provide them for neurons. They modify the blood vessel diameter via release of 
metabolites of arachidonic acid. (C) Astrocytes build cell-to-cell contacts with other 
astrocytes forming the astrocytic syncytium. They are connected via gap junctions to 
exchange ions, metabolites and water. Ca2+ signals can spread over wide distances via 
this network to transfer information. (D) Astrocytes modify neuronal plasticity and 
sensitivity by the release of gliotransmitters like ATP, D-serine and glutamate. 
Subsequently, they control and support synaptic transmission. (E) CreERT2 induces 
changes on the DNA level upon tamoxifen treatment, leading to excision of floxed 
alleles or expression of transgenic proteins. Neuronal signals lead to changes in DNA 
transcription due to activation of various transcription factors.  
3.2. Expression of astrocytic metobotropic and ionotropic ion 
channels 
Astrocytes express various types of ionotropic and metabotropic receptors. The 
ionotropic glutamate receptors are subdivided in receptors of the NMDA-(N-methyl-D-
aspartate), AMPA-(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and KA-
type (kainic acid) (Matthias et al., 2003, Grass et al., 2004, Schipke et al., 2001, Mayer, 
2005). These subtypes are permeable for different cations. AMPA and KA receptors 
are mainly permeable for Na+ and K+ while NMDA receptors are also permeable for 
Ca2+ ions (Mayer & Westbrook, 1987, Hollmann et al., 1991, Karakas & Furukawa, 
2014, Wright & Vissel, 2012). AMPA receptors are commonly expressed in glia and in 
many brain regions like the cerebellum, cortex, hippocampus and brainstem. They can 
be assembled out of four different subunits: GluA1-4. Depending on the brain region 
the receptor composition can vary which also leads to distinct receptor function 





Figure 2. Distribution and function of diverse metabotropic and ionotropic 
ion channels at the tripartite synapse 
The tripartite synapse consists of the neuronal pre- and postsynapse and the astrocytic 
processes. Perisynaptic activation leads to the release of transmitters (e.g. glutamate) 
from synaptic vesicles into the synaptic cleft. These transmitters activate diverse 
ionotropic or metabotropic neuronal receptors located on the postsynapse (e.g. 
AMPAR, NMDAR, mGluR). Astrocytes also express a plethora of purinergic 
metabotropic and ionotropic receptors like P2Y (P2Y1R), P1 adenosine (A1R, A2AR, 
A2BR, A3R), P2X (P2X6R, P2X7R) and AMPA receptors (Abbracchio et al., 2009, 
Verkhratsky & Kirchhoff, 2007). Astrocytes release gliotransmitters, like ATP or D-
serine to activate ionotropic P2X or NMDA receptors located at the postsynapse 
(Gordon & Bains, 2006).  
Purinergic receptor types such as the metabotropic P1 adenosine and P2Y receptors 
as well as the ionotropic P2X purinoceptors are expressed by astrocytes.  
P2X receptors are trimeric ion channels that open within milliseconds upon ATP 
binding, causing a conformational change so that Ca2+ and Na+ enter the cell in 




subtypes (P2X1-7) involved in several functions like synaptic transmission and secretion 
of transmitters (Hattori & Gouaux, 2012) (Fig. 3). 
Adenosine receptors (P1R) consist of seven transmembrane domains and are 
classified in four different receptor types: A1, A2A, A2B and A3. These G protein coupled 
receptors mediate adenosine controlled modulation of neuronal and glial function and 
neuron-glia signaling (Abbracchio et al., 2009, Sheth et al., 2014) (Fig. 3). 
G protein coupled P2Y receptors are divided in two groups: P2Y1,2,4,6,11, and P2Y12,13,14 
based on their G protein subfamily. P2Y1R are broadly distributed on glial cells. They 
are expressed by astrocytes, oligodendrocytes and microglia (Butt, 2011). The binding 
of their ligand adenosine diphosphate (ADP) activates P2Y1R (Kirischuk et al., 1995, 
Franke et al., 2012). The receptors are Gq/11 coupled and lead to the activation of 
phospholipases (PLA2, PLC) and protein kinase C (PKC). PLC activity results in the 
cleavage of phosphatidylinositol 4.5-bisphosphate (PIP2) into inositoltriphosphate (Ins-
P3) and diacylglycerol (DAG). DAG activates PKC whereas Ins-P3 binds to the Ins-P3 
receptor on the surface of the endoplasmatic reticulum mediating Ca2+ release into the 
cytoplasma (Verkhratsky et al., 2009, Franke et al., 2012). The increase of intracellular 
Ca2+ influences the bi-directional communication between neurons and astrocytes by 
release of gliotransmitters. Astrocytes itself are capable of releasing ATP as response 
to neuronal ATP release thereby modulating synaptic transmission (Lalo et al., 2011, 
Pascual et al., 2005). P2Y1 also activates signal transduction mechanisms like the 
mitogen-activated protein (MAP) kinase or the phoshoinositide-3-kinase (PI3K) 
pathway (Franke et al., 2012) (Fig 3). 
The exact function of astrocytic P2Y1 receptors under pathological conditions, like 
brain injury or cytotoxic edema, is a matter of debate in literature. Some studies claim 
the beneficial role of P2Y1 receptors during pathological circumstances, whereas 
others describe a neuroprotective effect after receptor downregulation (Shinozaki et al., 





Figure 3. Purinergic signaling in the CNS 
Purinergic receptors are devided in two main classes: ionotropic and metabotropic 
purinoceptors. The ionotropic P2X receptors consist of three subunits that undergo a 
conformational change upon ATP binding which leads to the influx of Na+ and Ca2+ and 
K+ efflux. The metabotropic receptors are further classified into P2Y and adenosine 
receptors. They consist of seven transmembrane domaines and are G protein coupled. 
Upon ligand binding a intracellular signaling cascade is induced. 
Astrocytes, neurons and myelinating oligodendrocytes express p2ry1 mRNA 
(www.brainrnaseq.com of the Ben Barres laboratory (Zhang et al., 2014)). Astrocytes 
express about 9 % of the p2ry1 mRNA compared to neurons and oligodendrocytes. 
The ionotropic receptors P2X6 and P2X7 are highly expressed in astrocytes whereas 
P2X7 is mainly expressed in OPCs and microglia/macrophages but only low 
expression was found in neurons (Fig. 4 A). During development and aging p2ry1 
mRNA expression in mouse cortical astrocytes starts to be detectable at P7 and then 
remains on same levels until two years of age (0.8 ± 0.6 - 0.3 ± 0.04 fragments per 





Figure 4. P2Y and P2X receptor mRNA expression of glial cells 
(A) P2Y1R mRNA is mainly expressed by neurons (5.9 ± 0.3 FPKM) and myelinating 
oligodendrocytes (FPKM 4.9 ± 1.5) but also by astrocytes (1.1 ± 0.06 FPKM). Higher 
expressed in astrocytes are the ionotropic receptors P2X6 (2.0 ± 0.4 FPKM) and P2X7 
(5.1 ± 0.4 FPKM). P2X7R is mainly expressed in OPCs (21.0 ± 0.4 FPKM) and 
microglia/macrophages (27.8 ± 0.3 FPKM) but only low expressed in neurons 
(0.7 ± 0.3 FPKM). (B) P2ry1 mRNA expression in mouse cortical astrocytes varies 
slightly between P7 and 2 years of age (P7: 0.8 ± 0.6; P32: 0.4 ±0.1; 10 w: 0.3 ± 0.003; 
9.5 m: 0.6 ± 0.007 and 2 y: 0.3 ± 0.04 FPKM). Data modified after (Zhang et al., 2014, 
Clarke et al., 2018). 
3.3. ATP induced Ca2+ signaling in astrocytes 
Astrocytes are involved in the generation and maintenance of Ca2+ waves. 
Extracellularly induced astrocytic Ca2+ signals are mediated by ATP released by 
adjacent neurons, leading to the activation of purinergic receptors, like P2Y1. Binding 
of the ligand to the purinergic receptor triggers an internal signaling cascade leading to 
the release of Ca2+ from the endoplasmatic reticulum (ER) (Fields & Burnstock, 2006, 
Abbracchio et al., 2009, Cotrina et al., 2000). 
Astrocytes are able to generate spontaneous Ca2+ signals as well as Ca2+ signals 
induced by neuronal activity. Spontaneous Ca2+ signals mainly depend on the vesicular 




receptors (Ding et al., 2013). These Ca2+ signals originate in astroglial processes and 
propagate to the soma. The main Ca2+ activity was found in astroglial processes and 
not in the soma. In general, Ca2+ signals are very diverse, depending on the astrocytic 
subpopulations or the different microdomains of astrocytic processes. In vivo, astrocytic 
Ca2+ elevations are triggered by external stimuli, like whisker stimulation, visual stimuli 
or locomotion of the animal (Nimmerjahn et al., 2004, Wang et al., 2006, Agulhon et al., 
2008). Different types of Ca2+ signals were characterized in cerebellar Bergmann glia 
as well as the influence of anesthesia on these signals (Nimmerjahn et al., 2009). 
Astrocytic Ca2+ signals of awake mice can be divided in three signal types. First, Ca2+ 
sparkles as smaller, localized signals, second Ca2+ bursts including signals of around 
40 cells and third Ca2+ flares involving large networks of astrocytes and appearing only 
under locomotion. Under anesthesia, flares are completely absent and sparkles mainly 
abolished. Ca2+ bursts require purinergic signaling whereas flares and sparkles either 
need activation of Na+ channels or glutamatergic transmission (Nimmerjahn et al., 
2009). 
3.4. Tamoxifen metabolism 
Tamoxifen (TAM), used for more than 30 years in the therapy of hormone-dependent 
breast cancer, has become an important component of the CreERT2/loxP system, for the 
analysis of gene functions in inducible conditional mouse mutants. TAM as a prodrug is 
oxidized in the liver by cytochrome P450 isoenzymes (CYPs) to several primary and 
secondary metabolites: N-desmethyl-tamoxifen (NDM-TAM), 4-hydroxytamoxifen (4-
OH-TAM) and endoxifen (END) (Caldas & Tannock, 2013, Goetz et al., 2008, Stearns 
& Rae, 2008) (Fig. 5). TAM and its metabolites bind to estrogen receptors (ER) with 
different affinities. In human, suppression of the estrogen-dependent cell proliferation 
by 4-OH-TAM is 30- to 100-fold higher compared to TAM (Borgna & Rochefort, 1981, 
Jordan et al., 1977, Robertson et al., 1982), although it represents less than 10 % of all 
primary oxidation products of TAM (Desta et al., 2004). END shares identical properties 
but is present in concentrations up to 10-fold higher than 4-OH-TAM (Johnson et al., 
2004, Stearns et al., 2003).  
In mice, the pharmacokinetic profile of TAM appears significantly different, mainly due 
to the lower expression and activity levels of cytochrome P450 isoenzymes (CYP) 
(Reid et al., 2014, McLaughlin et al., 2008). TAM is mainly metabolized to NDM-TAM 




be further metabolized to END by CYP2D6, whereas 4-OH-TAM is converted into END 
by CYP3A (Chang et al., 2016) (Fig. 5). 
 
Figure 5. Tamoxifen metabolism in mice 
TAM is converted by CYP3A to NDM-TAM, which is one major primary TAM 
metabolite. This metabolite undergoes multiple oxidation steps including 4-
hydroxylation to END by CYP2D6. 4-Hydroxylation of TAM to 4-OH-TAM by CYP2D6 
represents another primary metabolic route, with significant importance for 
experimental biology in mice. A small proportion of endoxifen appears to result from N-
demethylation of 4-OH-TAM by CYP3A (modified after (Jahn, Kasakow et al., 2018).  
The Cre DNA recombinase mediates site-specific recombination between two loxP 
sites (“floxed” sequence). Advantage of the Cre/loxP system is the independency of 
any co-factors or other sequence elements for efficient recombination (Nagy, 2000). 
Therefore, this system is well adapted for a foreign environment e.g. the mouse cell 
(Lewandoski, 2001).  
An improved version of Cre recombination is the CreERT2/loxP system to achieve not 
only spatially but also temporally controlled gene recombination. CreERT2 is a fusion 
protein consistent of the mutant ligand binding domain of the estradiol receptor (ER) 
and the Cre DNA recombinase. Mutation of the estradiol receptor inhibits the binding of 
its natural ligand β-estradiol, but enables binding of the synthetic ligand 4-hydroxy-
tamoxifen (4-OH-TAM) (Leone et al., 2003, Metzger & Chambon, 2001). The 
translocation of CreERT2 into the nucleus is induced by TAM. In absence of the ligand 




into the nucleus. Upon TAM treatment HSP90 dissociates from the complex, CreERT2 
translocates and mediates recombination between loxP sites (Feil et al., 1997, Metzger 
& Chambon, 2001, Weber et al., 2001, Hirrlinger et al., 2006). The advantage of the 
inducible CreERT2/loxP is the temporally determination of the recombination event. Many 
astrocytic promoters, e.g. the regulatory elements of the glutamate aspartate 
transporter (GLAST), are already active in embryonic progenitors leading to 
recombinant oligodendrocytes and neurons in the adult mouse brain (Regan et al., 
2007).  
Since its introduction, the inducible Cre/loxP system was used either for the generation 
of conditional gene-deficient mice or for the induction of cell type-specific reporter 
expression (www.jax.org, www.networkglia.eu/en/animal_models) (Fig. 6).  
 
Figure 6. Expression of CreERT2 in astrocytes of the GLAST locus 
A mutant ligand binding domain of the estradiol receptor was fused to the Cre DNA 
recombinase. Activation can be induced by application of the synthetic ligand TAM. In 
absence of this ligand the heat shock protein HSP90 keeps the CreERT2 fusion protein 
in the cytoplasm. Through TAM application HSP90 dissociates from the complex and 
induces the translocation of CreERT2 into the nucleus, where recombination between 
two loxP sites, which flank a region of interest („floxed“) can start. Schematic 
illustration of the recombination strategy, representative for the P2Y1R knockout, 
where CreERT2 was knocked into the locus of the astrocyte-specific locus of GLAST 






4.1. Astrocyte-specific gene recombination and the influence of 
tamoxifen-induced recombination 
Astrocytes are the main glial cell type in the brain. They express a range of 
neurotransmitter receptors localized along their processes that cover synapses, blood 
vessels and constitute “microdomains” for signaling pathways.  
First, to identify the optimal tamoxifen-injection protocol for maximal recombination 
efficiency, the pharmacokinetic profile of TAM and its metabolites was determined. 
Diverse injection protocols were tested for different gene loci. In this context, the extent 
of tamoxifen-independent recombination, caused by adverse CreERT2 activity, was 
evaluated. Therefore, various CreERT2 driver lines were analyzed at the DNA and 
protein level. 
Second, the influence of astroglial purinergic P2Y1 receptors was investigated by 
taking advantage of conditional knockout mice (cKO), where gene recombination of 
floxed P2Y1 receptors was controlled by an astrocyte-specific and tamoxifen-inducible 
Cre DNA recombinase (GLAST-CreERT2). The effect of P2Y1R ablation was evaluated 
by the analysis of in vivo Ca2+ signals. Therefore, changes in signal amplitudes and 
duration of anesthetized and awake animals were investigated. Characterization of 
cKO mice and its consequences was additionally analyzed by next generation 
sequencing to identify changes in mRNA expression pattern. P2Y1 receptor ablation 
was also examined under pathological conditions by utilizing the established cortical 
stab wound injury (SWI) model. 
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5. MATERIALS AND METHODS 
5.1. Materials 
5.1.1. Reagents 
Standard chemicals were purchased from customary companies like Sigma Aldrich 
(Taufkirchen), Eppendorf (Hamburg), Merck (Darmstadt), BioRad (München), 
Invitrogen (Karlsruhe), Roche (Penzberg), Carl Roth (Karlsruhe), Amersham 
Biosciences (Freiburg), Serva (Heidelberg), Thermo Fisher Scientific (Karlsruhe) and 
BD Falcon (Heidelberg). 
5.1.2. Consumables and kits 
Pipette tips, Sarstedt (Nümbrecht); glas pipettes, VWR International (Darmstadt); 
Falcontubes, Greiner Bio-One (Frickenhausen); Eppendorf reaction tubes, Eppendorf 
(Hamburg); Venomix canulas, Braun (Melsungen); 96-well-PCR-reaction-tubes, 4titude 
(Berlin); 24-well-culture-plates, Sarstedt (Nümbrecht); object slides and cover slips, 
Menzel-Gläser (Braunschweig); RT-PCR 96-well plates, Axon (Kaiserslautern); 
REDExtract-N-AmpTM Tissue PCR Kit, Sigma-Aldrich (Taufkirchen); All prep 
DNA/RNA Mini Kit, Qiagen (Hilden); All prep DNA/RNA Micro Kit, Qiagen (Hilden), 
Invisorb Spin Tissue Mini Kit, Invitek (Berlin); Precellys homogeneizing tubes, 
Precellys-Keramik-Kit, peqlab (Erlangen); Super Signal West Pico Chemiluminescent 
Substrate and Pierce BCA Protein Assay Kit, Thermo Scientific (Rockford); Adult Brain 
Dissociation Kit, Anti-ACSA-2 MicroBead Kit, Miltenyi (Bergisch Gladbach). 
5.1.3. Devices 
Table 1. Devices 
Device Producer 
Gel chambers, combs and casting trays for agarose gels Workshop of the institute 
Confocal microscope LSM 710 Zeiss 
AxioScan.Z1 Zeiss 
Precellys 24 (Homogenizer) peqlab Biotechnologie GmbH 
Thermomixer comfort Eppendorf 
Vibratom VT1000S/VT1200S Leica 
Centrifuges Eppendorf 




Scales (CPA 8201/CPA 2245) Sartorius 
Infinite PRO 200 microplate reader Tecan 
Preparations- and perfusion instruments F.S.T., Pharmacia  
peqSTAR Thermo Cycler  peqlab Biotechnologie GMBH 
Quantum gel documentation system  peqlab Biotechnologie GMBH 
BioSpectrometer Eppendorf 
CFX96 Real-Time PCR Detection System BioRad 
Device Producer 
Vacuum pump Integra Biosciences 
Pipettes Brand 
Shaker DRS-12 neoLab 
Water facility Milli-Q or GenPure  Merck/Thermo Scientific 
Intelli Mixer neoLab 
IKA C MAG HS 7 digital (magnetic mixer) ChemLabz 
Spectrophotometer Eppendorf 
NanoPhotometer DeNovix 
Electrophoresis Power Supply Consort 
gentleMACS Octo Dissociator with heaters Miltenyi 
5.1.4. Buffers, aqueous solutions and media 
All buffers and aqueous solutions were prepared with deionized water (dH2O) (Milli-Q 
(Merck) or GenPure (Thermo Scientific)). All concentrations are final concentrations. 
5.1.4.1. General buffers 
PBS (Phosphate-buffered saline, 10x; pH 7.4) 
NaCl                                                                                   1.37 M 
KCl 27 mM 
Na2HPO4 100 mM 
KH2PO4 18 mM 
(pH was adjusted with HCl solution (37 %))  
 
4 % PFA in 1x PBS (pH 7.4) 
Paraformaldehyde 4 % (w/v) 
NaOH 10 M 
(added until PFA is dissolved) 
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Tris-Acetate-EDTA-Buffer (TAE 50 x) 
Tris-Base Tris(hydroxylmethylaminomethan) 2 M 
Acetic acid (100 %) 1 mM 
EDTA (Ethylendiamintetraacetate, 0.5 M, pH 8) 1 mM 
5.1.4.2. Immunhistochemistry (IHC) 
Standard protocol 
Permeabilization-/blocking buffer and buffer for primary antibodies 
4 % horse serum (HS), 0.3 % Triton-X-100 in 1x PBS 
 
Buffer for secondary antibodies 
2 % HS in 1x PBS 
5.1.4.3. Induction of recombination 
Tamoxifen 
Tamoxifen in Miglyol (Caesar & Loretz) 10 mg/ml 
5.1.4.4. Perfusion for qRT-PCR samples/ cortical window surgery 
ACSF (artificial cerebrospinal fluid)/ cortex buffer (pH 7.4) 
NaCl 124 mM 
KCl 3 mM 
NaH2PO                                                                             1.2 mM 
NaHCO3 26 mM 
MgCl2 2 mM 
CaCl2 2 mM 
Carbogen gas 
Oxygen 95 % 
Carbon dioxide 5 % 
5.1.5. Purchased buffers 
Hanks’ Balanced Salt Solution (HBSS, w/o Ca2+ and Mg2+, Sigma-Aldrich) 
Dulbecco´s Phosphate Buffered Saline (1x D-PBS, Sigma-Aldrich) 
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For MACS 0.5 % Bovine Serum Albumin (BSA, Sigma-Aldrich) was added to the D-
PBS buffer (1x D-PBS-BSA buffer). 
5.1.6. Enzymes 
REDTaq™DNA Polymerase (Sigma-Aldrich Co.) 
5x Hot Start Taq Eva Green® (Axon) 
Omniscript (Qiagen) 
5.1.7. Drugs 
Tetrodotoxin (TTX) (Alemone Labs) 1 µM 
ATP (Na+) (Sigma Aldrich) 10 µM 
5.1.8. Antibodies 
5.1.8.1. Primary antibodies 
Table 2. Primary antibodies 
Antibody Producer Clonality Species Dilution 
GFAP DakoCytomation pc rabbit 1:1000 
GFAP Abcam pc goat 1:1000 
GFAP Novocastra mc mouse 1:1000 
Iba1 Wako pc rabbit 1:500 
DsRed Clontech pc rabbit 1:500 
GFP Abcam mc mouse 1:1000 
GFP Rockland pc goat 1:1000 
5.1.8.2. Secondary antibodies 
Secondary antibodies for immmunohistochemistry were purchased from Invitrogen 
(Molecular Probes)/Abcam and used in a dilution 1:1000 or 1:500. 
Table 3. Secondary Antibodies 
Antibody Producer Dilution 
Donkey α-rabbit Alexa 488-conjugated Invitrogen 1:1000 
Donkey α-mouse Alexa 555 conjugated Invitrogen 1:1000 
Donkey α-goat Alexa 488conjugated Invitrogen 1:1000 
Donkey α-goat Alexa 546 conjugated Invitrogen 1:1000 
Donkey α.goat Alexa 647conjugated Invitrogen 1:1000 
Donkey α-rabbit Cy5 Abcam 1:500 





TO-PRO 3 (Invitrogen)  
DAPI (Roche)  
EvaGreen (Axon)  
Texas Red-dextran (70 kDa, Invitrogen) 
5.1.9. Primers 
5.1.9.1. Primers for genotyping 
Table 4. Genotyping primers 
Name Number Sequence PCR 
product  
GLAST forward 11984 5'-GAGGCACTTGGCTAGGCTCTGAGGA-3' 
KI 400 bp 
WT 700 bp 
GLAST reverse 11985 5'-GAGGAGATCCTGACCGATCAGTTGG-3' 
CreERT2 reverse 11986 5'-GGTGTACGGTCAGTAAATTGGACAT-3' 
GFAP-CreERT2 forward 4750 5'-CAGGTTGGAGAGGAGACGCATCA-3' 
TG 500 bp 
WT 700 bp 
GFAP-CreERT2 reverse 7963 5'-CGTTGCATCGACCGGTAATGCAGGC-3' 
GLAST forward 11984 5'-GAGGCACTTGGCTAGGCTCTGAGGA-3' 
GLAST reverse 11985 5'-GAGGAGATCCTGACCGATCAGTTGG-3' 
P2Y1 forward 23992 5'-CAAGTTCCAGGTGGCCAGTTTTCTTGG-3' KI 304 bp 
WT 228 bp P2Y1 reverse 23993 5'-AGTTGCCCGCACGTCCTTCAGC-3' 
tdTomato KI forward 27490 5'-GGCATTAAAGCAGCGTATCC-3' 
KI 196 bp 
WT 297 bp 
tdTomato KI reverse 27491 5'-CTGTTCCTGTACGGCATGG-3' 
tdTomato WT forward 27488 5'-AAGGGAGCTGCAGTGGAGTA-3 
tdTomato WT reverse 27489 5'-CCGAAAATCTGTGGGAAGTC-3 
GCaMP3 KI forward 27632 5'-CACGTGATGACAAACCTTGG-3' 
KI 245 bp 
WT 327 bp 
GCaMP3 KI reverse 27496 5'-GGCATTAAAGCAGCGTATCC-3' 
GCaMP3 WT forward 14025 5'-CTCTGCTGCCTCCTGGCTTCT-3' 
GCaMP3 WTreverse 14026 5'-CGAGGCGGATCACAAGCAATA-3' 
Gria1 forward 7975 5'-CACTCACAGCAATGAAGCAGGAC-3' KI 250 bp 
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5.1.9.2. Primers for quantification of mRNA expression 
Table 5. mRNA expression primers 
Name Number Sequence PCR 
product  
b-actin forward 9146 5'-CTTCCTCCCTGGAGAAGAGC-3' 124 bp 
b-actin reverse 9147 5'-ATGCCACAGGATTCCATACC-3' 
P2Y1 forward 24001 5'-CACGAGTTTGTGAAGGCACG-3' 69 bp 
P2Y1 reverse 24003 5'-GCTTCTTCTTGACCTGTGTATGCA-3' 
Aquaporin 4 forward 30574 5'-TGGAGGATTGGGAGTCACC-3' 92 bp 
Aquaporin 4 reverse 30575 5'-TGAACACCAACTGGAAAGTGA-3' 
Aldh1l1 forward 29513 5'-GAGGAAGCAGCCACCTATGA-3' 66 bp 
Aldh1l1 reverse 30582 5'-TGGCTGGTCCCAGTTGAT-3' 
Itgam forward 30576 5'-CAATAGCCAGCCTCAGTGC-3' 65 bp 
Itgam reverse 30577 5'-GAGCCCAGGGGAGAAGTG-3' 
NeuN forward 29474 5'-GAAGAGAATGGCGAGACACTG-3' 67 bp 
NeuN reverse 30580 5'-GGCCCATAGACTGTTCCTACC-3' 
PDGFRα forward 30525 5'-AAGACCTGGGCAAGAGGAAC-3' 67 bp 
PDGFRα reverse 30526 5'-GAACCTGTCTCGATGGCACT-3' 
MBP forward 30529 5'-CCTCAGAGGACAGTGATGTGTTT-3' 62 bp 
MBP reverse 30530 5'-AGCCGACGTCCCATTGTT-3' 
GS forward 30531 5'-CTCGCTCTCCTGACCTGTTC-3'  94 bp 
GS reverse 30532 5'-TTCAAGTGGGAACTTGCTGA-3'  
GLT1 29519 5'-GATGCCTTCCTGGATCTCATT-3'  93 bp 
GLT1 30583 5'-CAGAACTTTCTTTGTCACTGTCTGA-3'  
5.1.9.3. Primers for quantification of DNA recombination 
Table 6. DNA recombination primers 
Name Number Sequence PCR 
product  
b-actin forward 29472 5'-CTGCTCTTTCCCAGACGAGG-3' 137 bp 
b-actin reverse 29473 5'-AAGGCCACTTATCACCAGCC-3' 
NrgIII forward 4767 5'-GTGTGCGGAGAAGGAGAAAACT-3' 120 bp 
NrgIII reverse 4805 5'-AGGCACAGAGAGGAATTCATTTCTTA-3' 
P2Y1 rec. forward 23996 5'-CTTAGATCGGTCGCAGCTCC-3' 127 bp 
P2Y1 rec. reverse 23997 5'-GCGCTTTTGTCGCGTTAATTA-3' 
P2Y1 gain forward 23998 5'-CTTAGATCGGTCGCAGCTCC-3' 154 bp 
P2Y1 gain reverse 24000 5'-TGGCCAGTTTTCTTGGAGACA-3' 
Gria1 gain forward 10466 5’-GTTCAGACAGGGACCCTCTCA-3’ 129 bp 
Gria1 gain reverse 10467 5’-GCCTGCCTGGGTAAAGTGACT-3’ 
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Name Number Sequence PCR 
product  
GCaMP3 loss forward 35304 5’-TCTGGATCTGTCGACCTGC-3 197 bp 
GCaMP3 loss reverse 35305 5’-TGGTGGCGAGATCCTTATCG-3 
GCaMP3 gain forward 35302 5’-GGCAACGTGCTGGTTATTGTG-3’ 237 bp 
GCaMP3 gain reverse 35303 5’-TCGTACAGATCCCGACCCA-3’ 
tdTomato forward STO1357782 5'-ATCATGTCTGGATCCCCATC-3' 218 bp 
tdTomato reverse STO1357783 5'-CGTGGCCGTTCATGGAGCCC-3' 
5.1.10. Animals 
5.1.10.1. Transgenic mice  
TgH (GLAST-CreERT2)GLAC 
The GLAST-CreERT2 mouse line expresses an inducible Cre DNA recombinase variant 
(CreERT2), where the mutant ligand binding domain of the estradiol receptor is fused to 
the Cre DNA recombinase. The CreERT2 fusion protein was inserted into exon 2 of the 
GLAST (glutamate aspartate transporter) locus (slc1a3) leading to an astrocyte specific 




A fragment of the human GFAP promoter controls the expression of the CreERT2 fusion 
protein to achieve a tamoxifen-inducible Cre driver line (CreERT2) in astrocytes 
(Hirrlinger et al., 2006). This mouse line was generated via non-homologous 
recombination (oocyte injection). 
 
TgH (P2Y1fl/fl)P2Y1 
The P2Y1 mouse line carries a floxed exon 1 of the p2ry1 gene (Leon et al., 1999, 
Rudolph et al., 2016). The conditional P2Y1 receptor knockout is achieved by 
crossbreeding this line with GLAST-CreERT2 mice and induction of recombination by 
tamoxifen treatment. Investigated animals were distinguished in controls (con) (slc1a3 
wt/ fl/fl P2Y1) and knockouts (cKO) (slc1a3 ct2/wt/ fl/fl P2Y1). This mouse line was 
kindly provided by Christian Gachet (Strasbourgh).  
 
 




The Gria1 mouse line carries a floxed exon 11 of the gria1 gene, the subunit 1 of the 
AMPA receptors (Fuchs et al., 2007). This mouse line is crossbred to the GLAST-
CreERT2 mice to achieve a conditional knockout when tamoxifen is applied. Analyzed 
animals were distinguished in controls (slc1a3 wt/ fl/fl Gria1) and cKO (slc1a3 
ct2/wt/ fl/fl Gria1). This mouse was kindly provided by Rolf Sprengel (Heidelberg). 
 
TgH (Rosa26-GCaMP3)GCaMP3 
The Ca2+ indicator mouse line Rosa26-GCaMP3 shows an enhanced green fluorescent 
protein (EGFP) signal after the binding of Ca2+ to calmodulin. This mouse line was 
crossbred to the GLAST-CreERT2 mouse line and upon tamoxifen application the Cre 
recombinase leads to the deletion of a floxed STOP cassette ahead of the GCaMP3 
sequence (Paukert et al., 2014). Investigated animals were distinguished in controls 
(slc1a3 wt/ fl/fl GCaMP3) and reporter expressing (slc1a3 ct2/wt/ fl/fl GCaMP3) mice. 




The reporter mouse line Rosa26-tdTomato expresses the red fluorescent reporter 
tdTomato when crossbred to the GLAST-CreERT2 mouse line and tamoxifen application. 
CreERT2 leads to the deletion of a floxed STOP cassette positioned ahead of the 
fluorecent protein sequence (Madisen et al., 2010). Investigated animals were 
distinguished in controls (slc1a3 wt/ fl/fl tdTomato) and reporter expressing (slc1a3 
ct2/wt/ fl/fl tdTomato) mice. The mouse line was kindly provided by Hongkui Zeng 
(Seattle). 
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Table 7. Mouse lines 
Mouse line Costruct Reference 
TgH(GLAST-CreERT2)GLAC 
 
(Mori et al., 2006) 
TgN(hGFAP-CreERT2)GCTF 
 (Hirrlinger et al., 
2006) 
TgH(P2Y1fl/fl)P2Y1  (Leon et al., 1999) 
TgH(Gria1fl/fl)Gria1  (Fuchs et al., 2007) 
TgH(Rosa26-
GCaMP3)GCaMP3  (Paukert et al., 2014) 
TgH(Rosa26-
tdTomato)tdTomato  (Madisen et al., 2010) 
5.1.11. Hard- und Software 
The depicted confocal or AxioScan images of this thesis were made with the Zeiss 
Software Zen (Zeiss). Images were then processed with ImageJ, Adobe Photoshop 
CS7, Adobe Illustrator CS7, Adobe InDesign CS7 (Adobe), Orbit Image Analysis 
(Idorsia Pharmaceuticals Ltd) and Zen lite (Zeiss). 
Quantitative real time PCR results were analyzed with the CFX-Manager software 3.0 
(BioRad). The results (± SD/SEM) were depicted as charts generated with GraphPad 
Prism 7 and processed with Adobe Illustrator. The analysis for statistical significance 
(e.g. unpaired t-test, two tailed), was also performed using GraphPad Prism 7. 
Data base research was done with help of the internet service PubMed of the National 
Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/pubmed). 
5.1.11.1. ImageJ plugin LRoi 
LRoi is a custom made ImageJ plugin (http://imagej.net/User:CIPMM-MolPhys), 
designed to create uniform regions-of-interest (ROIs) with a specific width and height. 
LRoi creates a set of neighboring, non-overlapping ROIs, along a user-drawn guidance 
line (Fig. 7). It allows the user to specify a set of constraints, e.g. the number of ROIs 
and the ROI width. The ROI height is determined by dividing the length of the guidance 
line by the number of ROIs to create. For this reason, the exact length of the guidance 
is also user-adjustable. ROIs are then created based on the user-defined constraints, 
taking the center-point of the guidance line as reference. This allows to create a set of 
ROIs with a defined and uniform area, facilitating analysis and comparability. 
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Additionally, LRoi provides the ability to create ROIs perpendicular to the user-drawn 
guidance line, to create two perpendiculars, cross shaped, sets of ROIs as well as ROI 
grids. LRoi was designed by Gebhard Stopper (Department of Molecular Physiology). 
 
Figure 7. Analysis of SWI experiments of cKO and control animals with the 
ImageJ plugin LRoi 
(A) For SWI experiments P2Y1 cKO and con mice were crossbred with two reporter 
strains (GCaMP3 and tdTomato) and injected with TAM at the age of four weeks and 
SWI was performed 21 dpi (days post injection). After seven days post lesion (dpl) 
mice were perfused, brains cut frontally and slices immunohistochemically stained and 
scanned with the epifluoresence microscope AxioScan.Z1 (Zeiss). Images were 
exported and further processed in ImageJ, with the custom made plugin LRoi. Regions 
of interest (ROIs, 1-25) were created perpendicular to the lesion and another 25 ROIs 
(26-50) were created on the contralateral side. In total these 25 ROIs analyzed an area 
of 2500 µm x 500 µm x 5 µm (L x H x W). Via multi-measurement application LRoi 
quantifies the fluorescence intensities of all stainings at once. Data were converted in 
‰ to simplify the numeric values. 
5.1.11.2. MATLAB-app MSparkles 
MSparkles is a custom made MATLAB-app. It is specifically designed for the analysis 
of Ca2+ signals and provides two analysis modes, classical ROI analysis as well as 
morphological Ca2+-transient analysis. The ROI analysis itself provides four modes of 
operation. Automatic ROI detection, based on temporal derivatives, ROI grid analysis, 
global ROI analysis and analysis of hand-drawn ROIs. For each ROI, the signal trace is 
computed as the mean value per time-step. Then, for each trace a peak detection and 
classification algorithm is executed, which returns the full width at half maximum 
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(FWHM) and signal-peaks (amplitude), grouped by their deviation from the mean (µ) in 
orders of one, two and three standard deviations (1 SD, 2SD and 3 SD). Signals of the 
1 SD represent small signals, 2 SD medium sized signals and 3 SD large signals. The 
same signals of the respective groups are additionally analyzed for their signal 
duration. 
In addition to classical ROI analysis, MSparkles offers morphological signal analysis. 
Here, the dynamic expansion and contraction of Ca2+ waves are computed using 
morphological operators such as opening, closing, erosion and dilation. Thereafter, the 
2D time-dependent image space is treated as a 3D space in which groups of three 
dimensionally connected objects are computed. Each group represents a spatially and 
temporally isolated Ca2+ signal. For purposes of visualization, each signal is assigned a 
unique color, which is scaled in its intensity by the corresponding signal’s peak value. 
Prior to any of these two analysis approaches, images are run through a pre-
processing pipeline. This pipeline performs de-noising using the PURE-LET (Luisier et 
al., 2010) algorithm, drift correction based on cross-correlation, and automatic 
background estimation and de-trended by fitting a low order polynomial in a least 
squares sense. The fitted polynomial is then used as approximation for basal Ca2+ 
level, F0, which is then used for data normalization ∆F/F0. The app was programmed by 
Gebhard Stopper (Department of Molecular Physiology) (Fig. 8). 




Figure 8. 2P-LSM imaging of awake mice and data processing of Ca2+ 
signals via MSparkles 
(A) Mice were injected with TAM at the age of four weeks and the cranial window 
surgery was performed at the age of 20 w. After three days of recovery mice were 
imaged under the 2P-LSM at day 3, 4, 8, 10 and 11. (B) Mice were able to move freely 
on a treadmill with only the head restrained. Therefore special custom-made head 
holders were designed and also the treadmill itself was designed by Gebhard Stopper 
(Department of Molecular Physiology). (C) After the imaging session data were 
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combined to a t-stack via ImageJ and denoised. Movies were uploaded in MSparkles 
(MATLAB-app) and ROIs around cell bodies were drawn manually (yellow circles). (D) 
Automatic ROI detection, ROI grid analysis, global ROI analysis and analysis of 
manually defined ROIs were processed by the software. Here we focused on the ROI 
grid analysis that analysis Ca2+ signals of fine processes (gliapil) and on manual ROIs 
detecting somatic Ca2+ signals. MSparkles generates also individual Ca2+ traces and 
compressed heatmaps of all signals. 
5.1.11.3. Orbit Image Analysis 
The Orbit Image Analysis software is an open source software developed by Manuel 
Stritt, Isabelle Giraud and Ledia Lilaj at Actelion Pharmaceuticals Ltd, now Idorsia 
Pharmaceuticals (Seger et al., 2016, Seger et al., 2018). A major advantage of the 
software is its ability to process large image files having multiple scenes and containing 
several gigabytes of data. Orbit provides many built-in image processing algorithms 
and uses machine learning techniques for tissue quantification as well as object 
segmentation and classification. Therefore, the system needs to be trained for 
individual tasks. For the analysis of the tamoxifen-independent recombination, whole 
slices derived from the AxioScan.Z1 (Zeiss) were processed with Orbit. Individual 
models like an exclusion/inclusion model to distinguish tissue from background were 
created. To measure the fluorescence intensity of recombined cells and DAPI, an 
analysis, building up on the exclusion/inclusion model was used. Different models were 
created for the mouse lines expressing either the reporter tdTomato or GCaMP3. The 
output of Orbit after processing the slices is a fluorescence intensity ratio of the 
recombined reporter expressing cells and DAPI. The results of the fluorescence 
intensities were normalized to animals that express CreERT2 and were injected with TAM 
for three consecutive days of the respective mouse lines (slc1a3 ct2/wt; gctf ct2/wt; 
cspg4 ct2/wt, pcet ct2/wt +TAM) and were further processed using GraphPad Prism7 
and Adobe Illustrater 7.  
5.1.12. Mouse administration 
For mouse administration, the database PyRAT (Python based Relational Animal 
Tracking) from Scionics Computer Innovation GmbH was used. PyRAT is a web based 
"Lab Animal Colony Management Software" which enables comprehensive and 
transparent handling of animal facility data. All relevant informations of the mouse and 
each mouse line are accessible (mouse number (earmark), date of birth, sex, 
genotype, pedigree, license and the current project). 
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5.1.13. Statistical analysis 
The number of analyzed mice for each experiment is stated in the caption. All data 
were tested for normal distribution by the Shapiro-Wilk test and statistical analysis was 
chosen accordingly. For analysis of Ca2+ signals all data were tested for outliers by the 
ROUT-test. Identified outliers were removed from data sets. 
Inter-group comparisons of qRT-PCR data were performed by two-tailed Student t test 
using the GraphPad Prism 7 software (GraphPad Software Inc.). Data are represented 
as means ± SD or ± SEM of natural replicates (mice) with * P < 0.05; ** P < 0.01; 
*** P < 0.001; **** P < 0.0001. Significant outliers were not included into calculations. 
Ca2+ data showed non-normal distribution and were therefore analyzed via Mann-
Whitney test with GraphPad Prism 7. Data are represented as median (minimum 25 %, 
maximum 75 % percentile) of Ca2+ signals (amplitude/ duration) with * P 0.01-0.05; ** P 
0.001-0.01; *** P 0.0001-0.001; **** P > 0.00001. Significant outliers were not included 
into calculations. 
For analysis of the stab wound injury data AxioScan images (at least n = 6) of frontal 
slices were analyzed with LRoi. At least three animals per condition (n=3-7; cKO vs. 
con) were processed and further analysis was performed by two-way Anova. Data are 
represented as means ± SD of measured fluorescence intensities (25 ROIs ipsilateral 
and contralateral) with * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 
Data of the the Orbit image analysis showed non-normal distribution and were 
therefore analyzed by Mann-Whitney test. Data are represented as 
median ± interquartile range of measured fluorescence intensities (ct2/wt/+TAM, 
wt/wt/±TAM; ct2/wt/-TAM; ct2/ct2/-TAM) with * P 0.01-0.05; ** P 0.001-0.01; *** P 
0.0001-0.001; **** P > 0.00001. 
5.1.14. Cell and receptor schemes of the introduction 
Effigos AG (Leipzig) drew figure 1, 2 and 3 of the introductory part. 
 




5.2.1. Tail biopsies 
Mouse tail biopsies were taken at the age of three till four weeks by the animal 
caretakers of the animal facility at the Center for Integrative Physiology and Molecular 
Medicine (CIPMM) in Homburg. The extracted genomic DNA was used for genotyping 
of transgenic mice by PCR analysis. Until further usage the 0.5 cm mouse tail biopsies 
were stored at -20°C. 
5.2.2. Mouse perfusion 
Mice were anesthetized with (ketamine/xylazine; 140 mg/kg and 10 mg/kg body 
weight). The abdomen was opened to reach the diaphragm. Intersection of the 
diaphragm led to a pulmonary collapse. The rips were loosened to the collarbone and 
the thorax was removed. A vein canula was placed into the left ventricle and perfusion 
with a peristaltic pump was started. Mice were perfused with ice cold ACSF (artificial 
cerebrospinal fluid) or HBSS (Hank’s balanced salt solution w/o Ca2+ or Mg2+; Sigma) 
for 2-3 min. Simultaneously, an incision of the vena cava superior was made to drain 
the blood from the body. After perfusion brains were dissected and used for further 
experiments. Brains were either directly separated in several brain regions, frozen on 
dry ice and stored at -80 °C until isolation of DNA, mRNA and protein, directly 
homogenized in 0.9 % NaCl for LC-HR-MS/MS analysis or postfixed over night in 4 % 
paraformaldehyde (PFA) in PBS for vibratome sections. For pharmacokinetic analysis 
blood was withdrawn from the right auricle (400–600 μl) before perfusion and 
centrifuged at 3000 min-1 for 10 min to obtain the serum. Samples were kept in light-
protected 2 ml tubes at −80 °C till further analysis. 
5.2.3. Tamoxifen treatment 
Tamoxifen (TAM) was dissolved in Miglyol (medium-chain triglycerides, Caesar & 
Loretz) at concentration of 10 mg/ml, aliquoted and stored at 4°C. The intraperitoneal 
application of TAM was done by the animal caretakers of the CIPMM. Mice were either 
injected once a day at the age of four weeks for one, two, three or five consecutive 
days or at different intervals: 3x TAM all 8 h or all 48 h. The daily TAM volume was 
dependent on the weight of each mouse (100 mg/kg body weight). Mice were analyzed 
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8 h and 48 h post injection (hpi) or 21 d, 200 d after the first injection (dpi). 
Pharmacokinetic analysis was performed on C57BL/6NRj mice that received a single 
dose of TAM for one or three consecutive days. Brain and serum samples were 
collected at 1 hpi, 4 hpi, 8 hpi, 24 hpi, 2 dpi, 5 dpi, 7 dpi, 14 dpi, 21 dpi or after 3 d, 4 d, 
7 d, 21 d post injection, respectively (Jahn, Kasakow et al., 2018). 
5.3. Sample preparation for LC-HR-MS/MS analysis 
C57BL/6NRj mice were injected with TAM as described before and samples of serum 
and brain homogenates were isolated and further processed by LC-HR-MS/MS 
(Fig. 9). 
 
Figure 9. Treatment protocols for LC-HR-MS/MS analysis 
(A) Samples (serum/brain) of treated C57BL/6NRj wild type (wt) mice were collected 
and were analyzed by LC-HR-MS/MS. (B, C) Mice were injected at an age of 28 d with 
TAM (100 mg/kg) once (B) or for three consecutive days (C, red triangles). Brain and 
blood samples were collected at different time points (indicated with black arrows). 
After processing, samples were analyzed by LC-HR-MS/MS for TAM and its 
derivatives NDM-TAM, 4-OH-TAM and END. 
5.4. LC-HR-MS/MS analysis 
Homogenized brain and serum samples were processed for LC-HR-MS/MS as 
established before (Helfer et al., 2017): brain or serum samples were mixed with an 
internal standard (risperidone) and zinc sulfate (ZnSO4) solution. Samples were 
vortexed, stored shortly at -20 °C and subsequently centrifuged. The supernatant was 
transferred into brown glass vials for LC-HR-MS/MS analysis. The extracts were 
analyzed using an Accela LC system, controlled by the Aria software and coupled to a 
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high resolution Q-Exactive system. Mass calibration was performed according to the 
manufacturer’s recommendations every 72 h using external mass calibration. 
Quantifications were performed with homogenized brain or serum sample calibrators 
spiked with defined concentrations of TAM, as well as its metabolites NDM-TAM, 4-
OH-TAM and END. The spiked concentrations ranked between 0.1 and 1,000 ng/ml 
and were divided into three separate calibration ranges (five calibrators each) from 0.1 
to 10, 10 to 100, and 100 to 1,000 ng/ml with equidistant concentrations, respectively.  
The measurements were performed by Andreas Helfer and Julian Michely (Department 
of Experimental and Clinical Pharmacology and Toxicology, Prof. Dr. Hans H. Maurer 
University of Saarland, Homburg) 
5.4.1. Isolation and analysis of genomic DNA 
5.4.1.1. Isolation of genomic DNA from mouse tails 
The REDExtract-N-AmpTM Tissue PCR Kit (Sigma-Aldrich) was used to extract 
genomic DNA from mouse tail biopsies. Initially the working solution was prepared by 
mixing tissue preparation solution and extraction solution in a ratio 4:1. The mouse tail 
biopsies (0.5 cm) were incubated with 62.5 µl of the working solution for 10 min at 
room temperature (RT) under shaking conditions (Thermomixer comfort, Eppendorf, 
700 min-1). In the next step the samples were heated to 95°C for 20 min in the water 
bath. After adding the neutralization solution B, the extract is ready for PCR. The 
extracted DNA can be used directly or stored at 4°C for a longer period. 
5.4.1.2. Polymerase chain reaction 
The polymerase chain reaction (PCR) is based on specific DNA amplification by certain 
thermal cycling steps (Mullis and Faloona, 1987). The reactions for genotyping were 
executed in 96-well PCR reaction tubes in a peqSTAR Thermo Cycler (peqlab 
Biotechnologie GMBH). 
5.4.1.3. Agarose gel electrophoreses 
For DNA separation, 1.5-2.0 % agarose gels, stained with ethidium bromide (0.015 %), 
were documented with the Quantum gel documentation system (peqlab Biotechnologie 
GMBH). 
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5.4.2. Immunohistochemical analysis 
5.4.2.1. Preparation of vibratome sections 
For preparation of vibratome sections a Leica VT1000S Vibratome (Leica) was used. 
The fixed brains (4 % PFA) were cut sagittally or frontally in 40 µm sections and 
transferred in 24-well culture plates with 1x PBS. After preparation, the slices were 
stored at 4°C or immediately processed for immunohistochemical stainings. 
5.4.2.2. Immunohistochemical staining of vibratome sections 
Slices were treated according to the standard protocol as previously described (Huang 
et al., 2014). Vibratome sections were simultaneously permeabilized and blocked for 
1 h at RT with the permeabilization-and blocking buffer. Primary antibodies were 
diluted (primary antibody solution) and incubated over night at 4°C. The next day 
sections were rinsed 3 x 10 min in 1 x PBS and incubated for 2 h at RT with secondary 
antibodies (diluted in secondary antibody solution). Subsequently, sections were rinsed 
again 3 x 10 min in 1x PBS. Additionally, DAPI (f.c. 1 µg/ml), a specific dye for nucleic 
acids, was added to the secondary antibody incubation. Finally, slices were transferred 
into a water bath and mounted in Aquapoly mount (Polysciences) or Immu-Mount 
(Thermo Scientific). 
5.4.3. Processing of DNA and RNA samples 
5.4.3.1. Isolation of DNA and RNA from mouse tissue or cells 
For isolation of DNA and RNA the AllPrep DNA/RNA Mini Kit or the AllPrep DNA/RNA 
Micro Kit from Qiagen were used (Qiagen). Isolation of genomic DNA was done with 
the Invisorb Spin Tissue Mini Kit (Stratec Biomedical AG). AllPrep DNA/RNA Mini and 
Micro Kits were designed to purify genomic DNA and total RNA simultaneously from 
tissue samples or MACS isolated cells, respectively. The prepared samples from 
mouse brain, including brainstem (bs), cerebellum (cb), cortex (ctx) and hippocampus 
(hc), were stored at -80°C until homogenization (Precellys 24, peqlab Biotechnologie 
GmbH). The frozen tissue was transferred into a Precellys tube filled with an 
appropriate volume sucrose buffer (600 µl for bs, cb and ctx; 300 µl for hc) and 
immediately placed into the Precellys 24. The tissue was homogenized for 2 x 10 s at 
5500 min-1 with 10 s pause in between and then centrifuged for a few seconds at 
10.000 min-1 to reduce the foam. MACS samples were treated equally but 
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homogenized in only 100 µl sucrose buffer. All homogenates were further processed 
with the appropriate kits following manufacturers’ instructions. Purified DNA and RNA 
were stored at -20°C until further processing. DNA from the optic nerve was islolated 
with the Invisorb Spin Tissue Mini Kit (Invitek) by following manufacturers’ instructions. 
DNA was stored at -20 °C until further analysis. 
5.4.3.2. Determination of DNA and RNA concentrations 
DNA and RNA quantifications were either performed with a photometer from Eppendorf 
or with the NanoPhotometer from DeNovix. Due to the absorbance maxima, nucleic 
acids were measured by 260 nm and proteins by 280 nm. For working purposes the 
following OD260-concentration relations were used: 1 OD at 260 nm for double stranded 
DNA = 50 ng/µl of ds DNA, 1 OD at 260 nm for RNA molecules = 40 ng/µl of RNA. 
DNA and RNA samples were diluted 1:50 in either EB buffer or RNase free water and 
transferred into a UV cuvette (UVette, Eppendorf). For the NanoPhotometer 1 µl of the 
undiluted sample was applied. Validation of the purity of the DNA and RNA samples 
was determined by calculating the ratio of absorbances at 260 nm and 280 nm. 
A260/A280 ratios above 1.8 for DNA and 2.0 for RNA indicate pure samples, while lower 
ratio values indicate protein contaminations. 
5.4.3.3. RNA precipitation 
For RNA precipitation 500 to 1000 ng RNA were diluted in 50 µl dH2O, mixed with 1 µl 
Pellet paint and vortexed thoroughly. Next, 25 µl of 7.5 M NH4Ac were added to the 
reaction tube and mixed by vortexing. Ethanol (180 µl of 100 %) was added to each 
sample and vortexed. The reaction tubes were centrifuged for 15 min at 14.000 min-1 
(RT). After centrifugation the supernatant was removed by a vacuum pump (Integra 
Biosciences), the pellet was washed with ethanol (70 %) and centrifuged again for 
5 min at 14.000 min-1. After the washing step, pellets were dried at RT for 10-15 min, 
resolved in 12 µl RNase free water and stored on ice for another 10 min. 
5.4.3.4. First strand cDNA synthesis 
For the cDNA synthesis of 1000 ng RNA a mixture of oligo dT nucleotides and random 
hexamer nucleotides was used. The reaction was performed in a peqSTAR 
Thermocycler (peqlab). RNA from the precipitation step was dissolved in RNase-free 
water, transferred into 96-well PCR reaction tubes and incubated at 65 °C. 
Subsequently, the master mix was added to the RNA template, containing Omniscript 
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reverse transcriptase, dNTPs, buffer RT and RNase inhibitor (Promega). Next, the 
RNA template was incubated at 37 °C with the master mix. The setup of a single PCR 
reaction is stated in table 8. The amplified cDNA was directly diluted 1:10 with RNase 
free water and stored at -20 °C. For quantitative real time PCR the cDNA solution was 
further diluted 1:3.3. 
Table 8. Setup for reverse transcriptase PCR 
Components Volume [µl] 
RNA in RNase-free water 12.2 
Incubation 5 min by 65° C 
dt-Mix Primer [0.6 pmol/µl] 0.8 
N9 Primer [120 pmol/µl] 1.0 
Buffer RT, 10x 2.0 
RNase Inhibitor [10 U/µl] 1.0 
dNTPs (5 M each)  2.0 
Omniscript 200 U/μl  1.0 
Incubation 1 h by 37° C 
5.4.3.5. Real-time qRT-PCR for mRNA expression 
For quantification of PCR products, fluorescent dyes are used (EvaGreen, Axon) that 
intercalate in double-stranded DNA. The fluorescence increases proportional to the 
amount of double stranded DNA. A reliable quantification is only possible during the 
log/exponential phase of the PCR when the reporter fluorescence is greater than the 
minimal detection level. The starting point of this exponential phase is defined by the 
CT value (Cycle Threshold). The CT value is inversely proportional to the amount of 
template, meaning the more template the lower the CT value. The evaluation was done 
with the CFX-Manager software 3.0 (BioRad) and Excel 2013. 
To determine the level of expression of a gene of interest the ∆∆CT method is used. In 
a first step, the CT value of a reference gene (b-actin) is substracted of the CT value of 
the gene of interest resulting in the ∆CT value. Hereby, eventually different amounts of 
starting materials are considered and corrected. Subsequently, the anti-logarithm of 
calculated ∆CT values was taken. The values of inducible cKO animals were 
normalized to the mean value of control animals. The results (± SD/SEM) were 
processed with GraphPad Prism 7 and analyzed for statistically significance (unpaired 
t-test, two-tailed). The reactions took place in 96-well plates (Axon) in the CFX96 Real-
Time PCR Detection System (BioRad). All samples were carried out in triplicates or 
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quadrouplets. The setup of a single reaction and the temperature program are given in 
table 9 and 10. 
Table 9. Components for qRT-PCR for gene expression and DNA recombination 
Component Volume [µl] 
cDNA/DNA 4.0 
5x Master Mix Hot Start Taq  2.0 
forward primer 0.1 
reverse primer 0.1 
dH2O 3.8 
Table 10. qRT-PCR program for the light cycler 
Stage/repetitions Temperature [°C] Time [min] 
1/1 50 2 
2/1 95 15 
3/42 95 0:15 
3/42 → data collection 60 1 
5.4.3.6. Real-time qRT-PCR for DNA recombination 
The qRT-PCR technique for DNA recombination is similar to the analysis of mRNA 
expression with slight variations. The primers were positioned in intron stretches to 
avoid mRNA contamination and the temperature of the PCR program was adapted to 
DNA as template. The samples of brainstem, cerebellum, cortex and hippocampus 
were diluted to 10 ng/µl. Samples of the optic nerve were, based on the lower 
concentration of isolated DNA, diluted to 5 ng/µl. The evaluation was done with the 
CFX-Manager software 3.0 (BioRad) and Excel 2013. For normalization, the endogene 
b-actin was used. The anti-logarithm of calculated ∆CT values was taken and the values 
of inducible cKO animals were normalized to the mean value of control animals or for 
the TAM study to the mean value of animals that received five time’s TAM. The results 
(± SD/SEM) were processed with GraphPad Prism 7 and analyzed for statistically 
significance (unpaired t-test, two-tailed). The reactions took place in 96-well plates 
(Axon) in the CFX96 Real-Time PCR Detection System (BioRad). All samples were 
carried out in triplicates/quadruplets. For the setup of a single reaction refer to table 10. 
The temperature programmes are depicted in table 11. 
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Table 11. qRT-PCR program of tdTomato, p2ry1, gria1 and GCaMP3 for the light cycler 
Stage/repetitions Temperature [°C] Time [min] 
1/1 95 10 
2/1 95 0:15 
3/45 60-62 0:25 
3/45→ data collection 72 0:42 
5.4.3.7. Determination of PCR efficiency 
PCR amplification efficiency is the rate, which defines the amount of amplicons 
generated per cycle in the exponential phase of the PCR amplification. An efficiency of 
100 % corresponds roughly to a doubling in amplicon quantity per cycle. To determine 
the PCR efficiency a dilution series of DNA (undiluted, 1:10; 1:100; 1:1000) was 
performed to generate a standard curve of the target and the endogene (Fig. 10 A-C). 
After running this PCR the threshold cycles were plotted against the logarithm of 
dilution in relative units. The slope of the standard curve is used to determine the 
exponential amplification (A) and the PCR efficiency (E) by the following formula: 
A= 10(-1/slope) 
E= [10(-1/slope)] -1 
Slope = -3.32  100% efficiency 
Slopes more negative than -3.32  < 100 % efficiency 
To achieve reliable quantitative data it is essential that the efficiency of the target and 
of the endogene amplification is almost identical. For each PCR reaction one enogene 
was analyzed to minimize the production of incorrect gene expression data based on 
different amounts of input material (DNA). But to address questions concerning the 
absolute amounts of p2ry1, gria1, GCaMP3 and tdTomato it is absolutely essential to 
determine PCR efficiencies. In conclusion, PCR efficiencies were determined to 
confirm the stable endogene performance and to consider possible differences in the 
PCR performances of the investigated target genes for quantitative analysis. 
An efficiency of 1.03 was determined for the endogene b-actin and 0.88 for the 
endogene NrgIII. The PCR results of the taget genes revealed recombination 
efficiencies of 0.89/1.03, 1.16, 1.01/0.95 and 0.90, respectively. These results were 
used to evaluate the recombination efficiencies of the investigated mouse lines and 
allow now the direct comparison of p2ry1 (loss/gain), gria1 (gain), GCaMP3 (loss/gain) 
and tdTomato (loss) (Jahn, Kasakow et al., 2018). 




Figure 10. Primer efficiencies to amplify various gene loci 
(A) Efficiencies were determined for b-actin (loss), NRGIII (loss/gain), tdTomato (loss), 
p2ry1 (loss), GCaMP3 (loss) and p2ry1 (gain), gria1 (gain) and GCaMP3 (gain). PCRs 
were run on undiluted, 1:10, 1:100 and 1:1000 diluted samples. Threshold cycles of the 
dilution were determined and plotted inversely versus the logarithm of the dilution. Data 
were fitted with a linear regression. The slope was used to determine exponential 
amplification 10(-1/slope), efficiency [10(-1/slope)] -1 of the PCRs and the R2 value as 
indicated. Modified after (Jahn, Kasakow et al., 2018). 
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5.5. Cell sorting 
5.5.1. Magnetic activated cell sorting (MACS) 
Mice were perfused with cold HBSS for blood removal. Brains were dissected into 
cortex and cerebellum and chopped into small tissue pieces. The tissue was 
transferred into Miltenyi C-Tubes and enzyme mix 1 and 2 were added. Dissociation of 
the tissue was done by the GentleMACS octo dissociator with heaters using the inbuilt 
programme 37C_ABDK_01. The tissue was dissociated to a single cell suspension 
using a 1000 µl pipette. The cell homogenate was passed through a strainer (70 µm) to 
remove tissue clots and centrifuged at 300 g for 10 min. The supernatant was 
discarded and cells were dissolved in 1x D-PBS plus debris removal solution and 
overlayed with 1x D-PBS. The gradient was centrifuged at 3000 g for 10 min without 
break. Subsequently, three phases were formed and the upper two were removed 
competely. Cells were washed with D-PBS and centrifuged (1000 g, 10 min). The 
supernatant was removed completely and the cell pellet dissolved in 1x D-PBS with 
0.5 % BSA. Cells were incubated for 10 min with the FcR blocking reagent. Next, the 
Anti-ACSA-2 MicroBeads were added for 15 min. After the incubation, cells were 
washed with 1x D-PBS/BSA buffer and centrifuged (300 g, 10 min). The pellet was 
dissolved in 500 µl 1x D-PBS/BSA buffer and applied to a MACS MS-column placed in 
a magnetic field of the MACS separator. The flow through contained all unlabeld cells. 
The column was washed three times with 1x D-PBS/BSA buffer and removed from the 
separator for final elution of the labeled cells. The cells were directly eluted into 
reaction tubes and centrifuged at 500 g for 10 min. The supernatant was discarded and 
the cell pellet was immediately frozen at -80 °C until further processing. For next 
generation sequencing (NGS) cell pellets were dissolved in 300 µl RLT buffer plus from 
the AllPrep DNA/RNA micro kit (Qiagen) and then frozen at -80 °C. 
5.6. Injury models 
5.6.1. Anesthesia and mouse preparation for injury models 
For all surgeries animals were anesthetized with 5 % isoflorane, 47.5 % O2, 47.5 % 
N2O (Harvard Apparatus equipment) and fixed with earbars on a heating plate to keep 
the body temperature at 37 °C. After sedation, the isoflurane was reduced to 2 % and 
the flow of O2 and N2O to 0.4 l/min (0.8 l/min in total). Eyes were covered with 
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Bepanthen ointment to protect them from exsiccosis. After the surgery all animals 
received painkiller for three consecutive days (dexamethasone hydrochlorid 0.2 mg/kg 
body weight and/or buprenorphine hydrochloride; 0.09 μg/30 g body weight). 
For imaging sessions, mice were equally anesthetized as for the surgery. For awake 
imaging, animals were only slightly anesthetized with 0.5 % isoflurane to fix them in the 
custom-made treadmill. 
5.6.2. Cortical stab wound injury 
The scalp was opened along the rostro-caudal axis and the craniotomy was performed 
with a hand drill (0.7 mm) above the somatosensory cortex (1.5 mm laterally and 2 mm 
caudally, referring to bregma as 0/0). The center of the craniotomy was stabbed with a 
surgical scalpel (#11, B/Braun), parallel to the midline and inserted to a depth of 1 mm 
from the cortical surface. Occuring bleedings were stopped by sponges (Gelastyp, 
Sanofi Aventis). Afterwards the wound was sutured and animals could recover. The 
surgery was performed at the age of eight weeks and mice were analyzed seven days 
post lesion (7 dpl). 
5.6.3. Cranial window 
The head was cleaned with ethanol and the scalp was opened along the rostro-caudal 
axis. The wound was disinfected with ethanol (70 %) and Betaisodona solution. The 
skull was cleaned from remaining hairs and tissue with cortex buffer. At the right 
hemisphere a 3-4 mm circle was performed with a hand drill (0.7 mm) at the level of the 
somatosensory cortex (lateral =1.5 mm and longitudinal =2 mm from the bregma). In 
between drilling bone particles were removed with cortex buffer and bleedings were 
stopped with sponges (Gelastyp, Sanofi Aventis) and cotton swabs. The skull was 
thinned until the bone could be removed easily with a forceps (5 SF, 5S, Fine Science 
Tools). The dura was left intact and kept moist with cortex buffer. A cover slip (5 mm) 
was fixed over the hole by super glue (Loctite, Henkel). In the next step, a custom-
made head holder (5 mm diameter) was fixed to the skull by dental cement (RelyX, 3M 
ESPE). The surgery was performed at the age of 15-20 weeks and mice were imaged 
by 2P-LSM at different days post cranial window surgery (dpw). 




5.6.4.1. Confocal laser-scanning microscopy 
Confocal images were performed at the LSM 710 from Zeiss (Carl Zeiss AG, Jena) 
with a Plan-Apochromat 40x/1.4 Oil DIC (UV) VIS-IR M27 objective. Fluorescent 
proteins were excited with the Lasos argon-ion lasers (454 nm, 514 nm) or helium-
neon lasers (543 nm, 633 nm). The images were aquired using the software Zen 
(Zeiss) and processed with ImageJ (Maximum intensity projections (MIP)).  
5.6.4.2. Digital slide scanner: AxioScan.Z1 
The digital slice scanner AxioScan.Z1 (Zeiss) is an automated microscopy sytem 
optimized for many and large tissue sections. Fixed tissue sections are recorded by 
bright-field and fluorescence illumination. The Axio Scan.Z1 acts as an epifluorescence 
microscope, using an HBO lamp (HXP 120 V, LEJ). For this purpose, only the reflected 
fluorescence light is used. A Plan-Apochromat 10x/0.45 objective is applied for coarse 
focus map on the slides. A Plan-Apochromat 20x/0.8 objective for the fine focus map, 
with appropriate emission and excitation filters, was applied and images were recorded 
in 8 μm thick stacks and a variance intensity projection was prepared for analysis. 
5.6.4.3. In vivo two-photon laser-scanning microscopy (2P-LSM) 
In vivo 2P-LSM was performed by Laura Stopper (Department of Molecular Physiology) 
using a custom-built microscope equipped with a 20x water-immersion objective (1.0 
NA; Zeiss). Scanning and image acquisition were controlled using custom-written 
software (ScanImage, (Pologruto et al., 2003)). To minimize photo damage, the 
excitation laser intensity was kept at a minimum (66-81 mW) for a sufficient signal-to-
noise ratio. Laser wavelength was set at 910 nm (Chameleon Ultra II, Ti: Sapphire 
Laser, Coherent). The emitted light was detected by a photomultiplier tube (R6357, 
Hamamatsu). The chosen ROI covered 15-25 astrocytes and was located in the 
somatosensory cortex. Equal imaging settings were selected for all experiments 
(512x512 px, framerate 0.9-1.5 Hz, pixel time 5.7 µs). 
 
Ca2+ imaging in anesthetized mice 
One week after the cranial window surgery animals were fixed with the metal holder on 
a custom-made head restrainer. Before the imaging session was started, animals were 
injected with Texas Red-dextran (70 kDa, Invitrogen) via tail vein injection to visualize 
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blood vessels in the brain. The marked blood vessels served as a map to image the 
same region of intrest (ROI) over several sessions. The astrocytes were labeled with 
the genetically encoded Ca2+ indicator GCaMP3. The same image was recorded over 
5-10 min to investigate Ca2+ changes during this period. The total duration of one 
imaging session lasted 30-60 min. After each session animals were kept on a heating 
pad until they recovered. All mice were injected with TAM at an age of four weeks and 
cranial window surgery was performed at an age between 16-20 weeks (Fig 11 A). 
Mice were imaged at day 3, 4, 8, 10 and 11 post cranial window (Fig 11 B). 
 
Ca2+ imaging in awake mice 
For Ca2+ imging of awake animals mice were habituated before the imaging session. 
The habituation procedure was adapated from (Guo et al., 2014) and (Kislin et al., 
2014). In the first step of habituation animals were accustomed to the scientist (Laura 
Stopper, Department of Molecular Physiology) therefore, they run freely on the hand for 
10 min every day until they behave normal (max 7-10 d). In a second step animals 
were head restricted but had the opportunity to run freely on a custom-made treadmill 
for 10-15 min or were kept in a tube for 10-15 min (max 7 d). Only normal behaving 
animals were used for imaging sessions. Animals were fixed with the head holder to 
the treadmill, a region of interest was selected in the field of view and anesthesia was 
removed. The same image was recorded over 5-10 min to investigate the Ca2+ 
changes during this period. After 10-20 min animals were released in their cage. All 
mice were injected with TAM at an age of four weeks and cranial window surgery was 
performed at an age between 16-20 weeks (Fig 11 A). Mice were imaged at day 4, 8, 
10 and 11 post cranial window (Fig 11 C). 




Figure 11. TAM injection protocol, surgery and imaging preparation 
(A) Mice were injected at an age of four weeks with TAM for five consecutive days. 
Cranial window surgery was performed at an age between 16 - 20 weeks (grey 
rectangle) and subsequent imaging sessions are indicated by black arrows (days post 
cranial window (dpw)). (B) In vivo imaging anesthetized: Imaging was performed under 
2 % isoflurane. Mice were imaged at day 3, 4, 8, 10 and 11 post cranial window. (C) In 
vivo imaging awake: No anesthesia was used at the time of recording and mice were 
allowed to move freely on a treadmill. Mice were imaged at day 4, 8, 10 and 11 post 
cranial window. 
5.7. Next generation sequencing (NGS) 
To analyze the mRNA expression profile of P2Y1R cKO and control mice (n=5), next 
generation sequencing (NGS) was performed. Mice were perfused with HBSS and 
astrocytes were isolated via MACS as described before. Astrocytes of the cortex and 
the cerebellum were dissolved in RLT buffer plus (Qiagen) and directly frozen at 
− 80 °C. NGS was performed at the Department of Psychiatry in collaboration with 
Prof. Dr. Moritz Rossner (Molecular Neurobiology) at the Ludwig Maximilians 
University, Munich, Germany.  
RNA of cortical and cerebellar samples was extracted, cDNA synthesized and library 
prepared. Equal quantities of single samples were pooled and sequenced on an 
Illumina Sequencer. For transcriptome data analysis, reads were validated for 
sequence- quality and -repeats. Low quality bases and short reads were removed from 
further analysis. The reads were mapped to Mus musculus genome (mm10) and 
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differentially expressed genes (DEGs) were determined. Genes with at least one log2-
fold change and adjusted p-value of ≤ 0.005 were considered as differentially 
expressed.  
5.7.1. Laboratory and animal handling 
Experimental mice were kept in the animal facility of the Institute of Clinical and 
Experimental Surgery or in the animal facility of the CIPMM in Homburg. This study 
was carried out in strict accordance with the recommendations of European and 
German guidelines for the welfare of experimental animals. Animal experiments were 
approved by the Saarland state’s “Landesamt für Gesundheit und Verbraucherschutz" 





6.1. Refined protocols of tamoxifen application for DNA 
recombination in mouse astrocytes 
Induction of DNA recombination in genetically modified mouse lines by application of 
tamoxifen (TAM) is a favored tool in many labs. The exact time course of TAM 
metabolization in the liver and the induction of recombination in the brain is not well 
defined. The concentration of TAM and its metabolites was therefore investigated in a 
time dependent manner in serum and brain, as well as the influence of varying TAM 
doses on the DNA recombination efficiency (Jahn, Kasakow et al., 2018). 
6.1.1. Fast uptake and clearance of tamoxifen and its bioactive 
metabolite 4-OH-TAM 
To analyze the contribution and time course of TAM and its metabolites N-desmethyl-
tamoxifen (NDM-TAM), 4-hydroxytamoxifen (4-OH-TAM) and endoxifen (END) for cell 
type-specific recombination their pharmacokinetic profile was determined by liquid 
chromatography-high resolution-mass spectrometry (LC-HR-MS/MS). After a single 
intraperitoneal injection of TAM, metabolite concentrations were determined in serum 
and brain at 1, 4, 8, 24 h and 2, 5, 7, 14 and 21 d post injection (pi). In addition, the 
concentrations were determined after injection of TAM for three consecutive days. 
Days post injection (dpi) always means time after the first injection, not time after the 
end of the injection period. 
TAM and 4-OH-TAM showed a fast partitioning in the brain reaching maximal levels 
already at 8 hpi. The metabolite 4-OH-TAM entered the brain equally fast, although it 
required prior enzymatic hydroxylation of TAM in the liver by cytochrome P450 
cyclooxygenases (Fig. 12 A, B). Corresponding TAM samples from the serum 
displayed profound variability, which was less pronounced for 4-OH-TAM (Fig. 13 B). 
We attributed this variability to variations of tissue and blood absorption after individual 
intraperitoneal injections. Both, TAM and 4-OH-TAM were efficiently cleared from brain 
and blood within 7 dpi (Fig. 12 A, B, Fig. 13 A, B, Table 12). In the brain, TAM was 
approximately six times enriched in comparison to 4-OH-TAM at 8 hpi as well as at 
48 hpi (Fig. 12 A, B). The other two metabolites, NDM-TAM and END, required three to 




Fig. 13 C, D, Table 12). Nevertheless, both were cleared completely at 7 dpi (Fig. 12 C, 
D, Fig. 13 C, D). As expected from its biophysical properties (i.e. also being highly 
lipophilic), TAM displayed the highest concentration in the brain followed by NDM-TAM 
and 4-OH-TAM. END showed the lowest concentration (Fig. 12, Fig. 13, Table 12).  
Several consecutive injections of TAM are used frequently to achieve a higher 
recombination efficiency of floxed alleles as well as for lineage studies. Therefore, we 
injected TAM for three consecutive days and determined the concentrations of TAM 
and its metabolites at four different time points focusing at the time required for 
clearance (Fig. 12 E-H). All four TAM derivatives showed the highest concentration 
24 h after the last injection (3 dpi). While TAM and 4-OH-TAM were only slightly 
enriched, the two metabolites NDM-TAM and END were about 5-fold enriched in 
comparison to a single injection (Fig. 12 E-H, Table 12). Consecutive injections 
increased the level of biological active derivatives in the brain and enhance the 
recombination efficiency. 
We determined clearance rates (t1/2) from the brain at 9.9 h, 15.8 h, 19.9 h and 33.2 h 
for TAM, 4-OH-TAM, NMD-TAM and END after one injection, respectively. The 
clearance rates increased after three daily injections to 26.1 h, 20.7 h, 30.5 h and 
41.2 h for TAM, 4-OH-TAM, NMD-TAM and END. Although, levels of TAM and its 
metabolites were highly variable in the serum, all four compounds were cleared with 
similar rate constants as in the brain (Fig. 13 A-D and Table 12). This also helds true 
for consecutive injections over three days (Fig. 13 E-H and Table 12). 
In summary, LC-HR-MS/MS data revealed a well-defined time window for optimal 
bioactivity of TAM and its metabolites, between 4 and 24 h post injection for single 
applications and 4 h to 5 d for applications over three consecutive days (Fig. 12 and 
Table 12). All metabolites were cleared effectively to negligible levels at 7 dpi.  
Figure 12. Brain concentrations of TAM and its derivatives peaked between 8 
and 24 hpi and showed clearance within 7 dpi 
(A) TAM and (B) 4-OH-TAM peaked at 8 hpi after one TAM injection with 6x more TAM 
than 4-OH-TAM and subsequent clearance to ineffective levels at 7 dpi. (C) NDM-TAM 
and (D) END concentrations peaked after one TAM injection later at 24 hpi with 17x 
more NDM-TAM than END, but were also cleared 7 dpi. Insets show the last three to 
four examined time points in a higher resolution and half-lives (t1/2) are indicated for 
each derivative. Three consecutive TAM injections led to a prolonged TAM (E), 4-OH-
TAM (F), NDM-TAM (G) and END (H) enrichment in the brain with a delayed clearance 
compared to single TAM injections. The brain concentrations of all TAM derivatives are 
plotted against the time. Data are shown ± SD with n = 3-9, depicted as single points 


















Figure 13.  Serum concentrations of TAM and its metabolites 
(A) Levels of TAM were highly variable after the first 8 hpi in serum after a single TAM 
injection, while after 24 hpi more uniform levels could be detected. (B) 4-OH-TAM 
peaked 8 hpi and showed subsequently lower levels at 5 dpi. (C) NDM-TAM and (D) 
END concentrations peaked after one TAM injection at 24 hpi with only slightly more 
NDM-TAM than END. Both are equally cleared after 7 dpi. Three consecutive TAM 
injections led to a higher concentration of TAM (E), 4-OH-TAM (F), NDM-TAM (G) and 
END (H) up to 48 hpi in the serum with longer half-lives compared to single TAM 
injections. Serum concentrations of all TAM derivatives are plotted against time. Data 
are shown ± SD with n = 3-9, depicted as single points and with colors (red, green and 
grey) indicating independent experiments.  
Table 12. Brain and serum concentrations of TAM and its metabolites 




















single injection                 
1 hpi 3067.76 520.01 67.48 0.90 8744.90 65.66 63.38 1.82 
4 hpi 13771.25 2055.34 1269.06 36.12 2949.65 120.06 85.08 16.15 
8 hpi 27950.56 4373.59 5555.54 156.19 5479.48 426.71 334.40 89.82 
24 hpi 9106.04 2513.90 8690.12 504.79 557.63 304.17 381.41 253.13 
2 dpi 1875.14 340.05 3901.47 436.85 183.04 28.53 211.26 131.56 
5 dpi 9.17 1.28 1.69 3.63 3.75 0.08  −  − 
7 dpi 77.57 12.37 5.21 0 2.44 0.29 0.41 0 
14 dpi 0.71 0.87 −   − 0.44 0  − −  
21 dpi 3.04 0.86 3.18 0 1.01 0 0.75 0 
3 injections                 
3 dpi 28853.49 5278.55 21889.77 1925.07 2419.20 242.97 763.76 437.54 
5 dpi 17375.64 2457.76 15249.50 1867.61 1068.96 161.36 530.05 382.72 
7 dpi 317.43 58.35 999.57 142.47 6.05 0.63 7.45 14.13 
21 dpi 5.60 1.72 6.63 0 1.65 0.27 1.94 0 
6.1.2. Maximal recombination levels are reached by three or five days of 
TAM injections in cortex or cerebellum, respectively 
According to the LC-HR-MS/MS data, substantial levels of TAM and its metabolites 
were detected in the time window of 1 to 5 dpi depending on the application protocol. 
To determine the in vivo efficiency of TAM to activate CreERT2, the recombination of two 
floxed gene loci, p2ry1 (P2Y1 receptor) and gria1 (AMPA receptor subunit GluA1) in 
two different areas of the brain, the cerebellum (cb) and the cortex (ctx), was studied. 




affinity glutamate aspartate transporter (GLAST; slc1a3) locus (GLAST-CreERT2 x-
 Gria1fl/fl x P2Y1fl/fl, Fig. 14 C), generating triple transgenic mice.  
Mice received 1, 2, 3 and 5 injections of TAM (100 mg/kg body weight) on consecutive 
days. Samples were analyzed at 8 hpi, 21 dpi and 200 dpi (Fig. 14 A). After TAM 
injection recombination of floxed loci was analyzed by qRT-PCR (gain of function, 
(Fig. 14 B), where successful recombination is indicated by an amplified PCR product. 
After three TAM injections, both alleles (p2ry1 and gria1) were almost completely 
recombined in ctx (n = 4, Fig. 14 D, Table 13), and in cb (n = 4, Fig. 14 E, Table 13). 
Recombination could slightly be enhanced in the cortex for gria1 when five consecutive 
injections were applied. This protocol also revealed a difference for p2ry1 in the 
cerebellum (n = 4, Table 2).  
As expected from LC-HR-MS/MS data, increasing the time period between induction 
and analysis of recombination from 21 to 200 d did not positively influence the 
recombination efficiency for both gene loci (n = 2, Table 13). Analyzing the successful 
recombination already at 8 hpi after a single TAM injection revealed large differences in 
recombination efficiencies within the different brain regions, but also between the 
different gene loci. In the ctx only a small percentage of floxed alleles was recombined 
(n = 3, 14 % p2ry1, 3 % gria1), while in the cb (n = 3, 36 % p2ry1, 33 % gria1) the 
recombination rate was higher (2.5 x and 11 x higher, respectively). As expected from 
the longer bioavailability of its metabolites, higher degree of recombination was 
observed at 21 dpi (n = 4) in comparison to 8 hpi (n = 3) after a single TAM injection; 
(p2ry1 and gria1) in ctx (Table 13). Similarly, three (n = 4) TAM injections were more 
efficient than only two (n = 3) at 21 dpi (Table 13). 
At early time points after TAM injections, (8 hpi) large differences in recombination 
efficiencies between different alleles and brain regions were detected. Cortical 
recombination of the p2ry1 alleles was more than four times larger than gria1 alleles. In 
contrast, in the cerebellum almost no difference between the two alleles was detected 
(Fig. 14 D, E, Table 13). Simultaneously, cerebellar recombination rate was much 
higher than cortical. At 21 dpi after a single TAM injection, we found more than twice as 
many recombined p2ry1 than gria1 alleles in the ctx. This difference disappeared, 
when three consecutive injections were applied (Fig. 14 D, E). In addition, both target 
genes showed different recombination kinetics in ctx and cb. In general, the cb showed 
faster recombination kinetics as the ctx after one or two injections with comparable 





Figure 14. Three to five daily TAM injections give maximal DNA 
recombination depending on the brain region 
A) For determination of efficient recombination different TAM injection protocols were 
used varying between single and five consecutive injections (indicated by red triangles) 
and were analyzed at different time points (black arrows). (B) DNA isolation from 
cortical and cerebellar tissue was used for subsequent quantitative RT-PCR (qRT-
PCR) from (C) GLAST-CreERT2 x P2Y1fl/fl x Gria1fl/fl mice. Primers (for the p2ry1 and 
gria1 gene) span both loxP sites with amplification of the flanked sequence after 
recombination. (D, E) Differences in recombination efficiency between both analyzed 
alleles, but also both brain regions could be observed with the lowest cortical and 
cerebellar recombination observed at 8 hpi. Cortical recombination (D) was higher after 
five consecutive injections for for gria1, while for p2ry1 three injections were sufficient. 
Highest cerebellar recombination (E) could be reached already after three consecutive 
injections for gria1 and could be further increased by five injections for p2ry1. Per 
injection protocol three to four animals (exception 200 d, n = 2) were analyzed (colored 
points) and ΔCT-values were normalized to the mean value of animals which received 
5x TAM. The error bars correlate to the SD of the biological replicates (n = 2-4, 




Additionally, a two-day interval protocol of three consecutive TAM injections, inspired 
by the rapid drop of 4-OH-TAM at 48 hpi (Fig. 15) and an 8 h interval protocol of three 
consecutive injections, due to the peak of 4-OH-TAM (Fig. 15), were tested. Based on 
the LC-HR-MS/MS data that identified a fast clearance in less than 48 h, an interval 
protocol with one-day pause between injections (i.e. injections at every 2nd day) is 
expected to be less efficient than the daily-injection protocol (Fig. 13, Fig. 15 B, C). 
Indeed, the interval protocol revealed less recombined alleles in the cortex, with a 
reduction of 38 % (p2ry1) and 61 % (gria1) compared to the 5 x injection protocol 
(100 ± 5% and 100 ± 9%, respectively) (n = 4, Fig. 15 B). In the cerebellum, the 
recombination was only decreased for the gria1 locus by 18 % with the interval 
protocol, while no change was detectable for the p2ry1 locus. Recombination 
efficiencies of the interval protocol also reflects again the general higher cerebellar 
recombination efficiency for both floxed alleles (n = 4, Fig. 15 C). 
The other interval protocol, three times every 8 h, was expected to be more efficient 
based on the LC-HR-MS/MS data. Peak concentrations were reached after 8 h 
therefore we assumed, that an injection at that time point will increase TAM and 4-OH-
TAM concentrations, leading to a higher recombination efficiency. Samples were 
collected either 48 h after the last injection or 21 d after the first injection (Fig. 15 B, C). 
In the cortex about 77 ± 21 % of the p2ry1 alleles were recombined and 43 % of gria1 
alleles after 48 h. Compared to the five times injection protocol recombination efficiency 
was reduced by 57 % for gria1 alleles (Fig. 15 B). In the cerebellum recombination 
efficiency was increased for the p2ry1 locus (126 ± 17 %), while gria1 showed less 
recombined alleles (40 ± 6 %) (Fig. 15 C). After 21 dpi recombination efficiency of the 
p2ry1 locus was not changed in cortex and cerebellum compared to the 5 x injection 
protocol. For the gria1 locus recombination efficiencies were less efficient in both brain 
regions. In the cortex only 53 ± 24 % of the alleles were recombined and 35 ± 0.7 % in 
the cerebellum, respectively (Fig. 15 B, C). These data suggest an impact of the 
circadian rhythms on the accessibility of the respective floxed loci, with p2ry1 favoured 





Figure 15. Interval injections every second day or every 8 h revealed 
differences in recombination efficiencies of floxed loci 
(A) Interval injection protocols of TAM application (red triangles) and sample 
preparation after different time points (black arrows). (B) Significant lower cortical 
recombination of gria1 alleles in all protocols. Recombination efficiency was reduced 
for the p2ry1 locus for the injection protocol every second day, but reached similar 
levels with the 8 h interval protocols. (C) In the cerebellum all tested interval protocols 
for the gria1 locus were less effective than the 5 x injection protocol. P2ry1 with no 
difference for the injection protocol every second day, but the 8 h injection protocol 
revealed an increase in recombination efficiency after 48 h. Three to four animals were 
analyzed (colored dots) and ΔCT-values were normalized to the mean value of animals 
which received 5 x TAM. The error bars correlate to the SD of the biological replicates 
(n = 3-4, * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired t-test). 
In summary, single TAM injections are not sufficient to achieve maximum 
recombination in cortex and cerebellum. The best recombination efficiency requires 
three to five days TAM injections. These results indicate that three injections for p2ry1 
in the cortex are sufficient to achieve maximal recombination, whereas in the 
cerebellum five injections are needed. Exactly the opposite is true for gria1, with five 
injections for cortex and three injections for cerebellum for maximal recombination 




revealed even higher recombination efficiencies for the p2ry1 locus, but is more 
elaborated in scheduling and more stressful for the mice. 






analysis p2ry1 [%] gria1 [%] 
ctx 1x - 8 hpi 14±3 3±1 
  1x - 21 dpi 54±2 20±7 
  2x 24 h 21 dpi 50±15 20±11 
  3x 24 h 21 dpi 93±1 80±12 
  3x 24 h 204 dpi 79±4 67±6 
  5x 24 h 21 dpi 100±5 100±9 
 3x 48h 21 dpi 62±13 39±15 
 3x 8 h 48 hpi 77±21 43±9 
 3x 8 h 21 dpi 97±19 53±24 
cb 1x - 8 hpi 36±1 33±2 
  1x - 21 dpi 55±9 76±2 
  2x 24 h 21 dpi 48±1 69±15 
  3x 24 h 21 dpi 77±9 87±14 
  3x 24 h 204 dpi 74±1 89±5 
 5x 24 h 21 dpi 100±3 101±15 
 3x 48h 21 dpi 74±13 82±4 
 3x 8 h 48 hpi 126±17 40±6 
  3x 8 h 21 dpi 124±32 35±0.7 
6.1.3. GLAST-CreERT2 mediated DNA recombination to quantify astroglial 
cell numbers 
Genomic recombination can be determined by qRT-PCR either by generating (1) an 
amplimer across the newly formed (recombined) genomic DNA with increasing levels 
of amplimers indicating progress of recombination (Fig. 14, gain), or (2) an amplimer 
across a single loxP site of the non-recombined locus where reduced amplimer levels 




determine the percentage of CreERT2-expressing cells. If CreERT2 is expressed in a cell 
type-specific manner, the proportion of this cell type in a given tissue region can be 
determined. Using the GLAST-CreERT2 mouse line, recombination efficiencies of two 
different floxed alleles (stopfl/fl tdTomato and p2ry1fl/fl) in different brain regions (bs, cb, 
ctx, hc, opt) were compared and the decrease of non-recombined loxP sites by qRT-
PCR was quantified.  
Samples from both genders were combined for analysis since no differences were 
detected (Jahn, Kasakow et al., 2018). Analyzing the floxed p2ry1 alleles revealed 
recombination rates between 6 % and 33 % in the brainstem (bs), cb, ctx, 
hippocampus (hc) and optic nerve (opt) (Figure 16 C). Similar results were obtained for 
the tdTomato allele (bs (89 %), cb (94 %), ctx (79 %), hc (79 %) and opt (73 %)). No 
differences were found for most brain regions (cb (6 %), ctx (20 %), hc (27 %) and opt 
(29 %)) (Fig. 16 D, E). In the brainstem, however, the tdTomato locus was less 
recombined than the floxed p2ry1. Based on these data, the percentage of GLAST-
CreERT2-positive cells (a rough estimate of astrocytes) varied from 6 to 29 %, dependent 
on the brain region.  
To confirm the qRT-PCR analysis, the number of recombined cortical tdTomato-
positive cells was counted. Of all cells (TO-PRO-3 labelled nuclei) 21 ± 5 % were 
tdTomato-positive (Fig. 16 F), a value well correlating to DNA recombination in the 
cortex (20 %). In addition, no differences of tdTomato-positive cells could be detected 
in the cortices of males and females (21 ± 6 %, 20 ± 4 %, respectively (Jahn, Kasakow 
et al., 2018)). Our results show that qRT-PCR data of recombined loxP sites obtained 
from tissue homogenates correlates well to counting of individual recombined cells. 
Therefore, the recombination rate reflects the percentage of GLAST-positive cells 






Figure 16. Recombination efficiencies were constant for target and reporter 
genes 
(A, B) GLAST-CreERT2 mice crossed to tdTomatofl/fl and P2Y1fl/fl mice were used for 
quantification of floxed, non-recombined alleles by qRT-PCR. Arrows indicate the 
position of primers after TAM injection for three consecutive days and analysis at 
21 dpi. Reduction of floxed p2ry1 alleles (C) and floxed reporter (floxed stop cassette) 
(D) in bs, cb, ctx, hc and opt of transgenic animals compared to non-recombined 
alleles (100 %) showed (E) no differences in all brain regions with the exception of the 
bs, where the reporter allele was recombined at a lower level than the floxed receptor 
gene. The error bars correlate to the SEM of the biological replicates (n = as indicated 
in bars (C, D), *p<0.05, **p< 0.01, ***p<0.001, unpaired t-test). (F) Micrograph of a 
representative cortical vibratome section prepared from a GLAST-CreERT2 x tdTomato 
mouse showing the extent of fluorescent recombined astrocytes. Colored squares 
represent the position of confocal images for stereological analysis. The scale bar 
corresponds to 500 µm. Counting of TO-PRO-3+ and tdTomato+ cells in cortices of 
GLAST-CreERT2 x tdTomato vibratome sections resulted in 21 (± 3) % tdTomato 




In summary, already at 8 hpi 28 % of the injected, non-metabolized TAM (100 %) 
partitioned into brain tissue. In addition, 10% of injected TAM reached the brain as the 
liver metabolites NDM-TAM (5.6 %), 4-OH-TAM (4.4 %) and END (0.2 %) (36.1 ng/g). 
While more than one third of TAM accumulated in the brain quickly, only 4-OH-TAM 
and END are bioactive and can induce DNA recombination. At 24 hpi significant 
portions of TAM and the major bioactive metabolite 4-OH-TAM were already cleared 
from the brain (decrease of TAM to 9.1 % and of 4-OH-TAM to 3 %). Simultaneously, 
NDM-TAM (9 %) and END (0.5 %) piled up (Fig. 17 A).  
For maximal cortical or cerebellar recombination (driven by CreERT2 expression under 
control of the GLAST locus), the ideal injection protocol depends on the investigated 
floxed loci: p2ry1 (cb) and gria1 (ctx) five TAM injections; p2ry1 (ctx) and gria1 (cb) 
three TAM injections (Fig. 17 B).  
We determined the percentage of astrocytes in a given brain region (by defining 
GLAST-CreERT2 positive cells largely as astrocytes): 17 % (n=10) in the brainstem; 6 % 
(n=9) in the cerebellum; 20 % (n=14) in the cortex; 27 % (n=10) in the hippocampus 






Figure 17. Inducible DNA recombination in mouse astroglia 
(A) Concentrations of TAM and its derivatives after single TAM injections revealed that 
about 28 % of the originally injected TAM could be detected in the brain while only 4 % 
4-OH-TAM, 6 % NDM-TAM and negligible amount of END could be found at 8 hpi. 
While TAM (9 %) and 4-OH-TAM (3 %) decreased 24 hpi, NDM-TAM (9 %) and END 
(3x higher) increased their concentrations in the brain. (B) The optimized injection 
protocol for GLAST-CreERT2 mice: 5xTAM for p2ry1 (cb) and gria1 (ctx); 3xTAM for 
p2ry1 (ctx) and gria1 (cb). (C) In a brain of a young adult mouse, astrocytes account 
for 17 % (n=10) in the bs, 6 % (n=9) in the cb, 20 % (n=14) in the ctx, 27 % (n=10) in 
the hc and 29 % (n=10) in the optic nerve (setting GLAST-positive cells as astrocytes. 
6.2. Tamoxifen-independent recombination 
Tamoxifen-independent recombination of floxed alleles, mediated by the inducible Cre 
DNA recombinase, was observed during control experiments for the recombination 
study (6.1). Therefore, several CreERT2 driver lines were tested for tamoxifen-
independent recombination by expression of two different reporter lines to evaluate the 
impact of non-induced recombination for our experiments. Here, homologous as well 
as non-homologous recombined mouse lines were compared. Percentage of 
tamoxifen-independent reporter expression was measured and compared to injected 
animals and to CreERT2 wildtype controls. 
6.2.1. IHC analysis and quantification of different astrocyte-specific 
CreERT2 driver lines crossbred to the reporter mouse lines GCaMP3 
and tdTomato 
To study tamoxifen-independent recombination, two different CreERT2 driver lines were 
compared and analyzed by immunohistochemical analysis after reporter 
recombination. As astrocyte-specific mouse lines with CreERT2 expression: GLAST-
CreERT2 as a knockin and GFAP-CreERT2 (CreERT2 expression controlled by a part of the 
human GFAP-promoter) were compared. Lines were crossbred with both reporters to 
investigate any impact of the reporter on tamoxifen-independent recombination. The 
GCaMP3 signal was stained with α-GFP due to the loss of signal during the fixation of 
the brain. For better comparison, the tdTomato signal was additionally stained with α-
DsRed. The percentage of recombined cells in both mouse lines was investigated 
using the Orbit image analysis software. Therefore, raw images (czi files) of whole 
sagittal brain slices, generated by the AxioScan, were used. Inclusion and exclusion 




recombined cells. Fluorescence intensities were converted into percentage reporter 
expression with the injected, CreERT2 expressing mice set to 100 % (positive control) 
and all other conditions were standardized (Fig. 20 and 23).  
All mice were analyzed at an age of seven weeks (Fig. 18-23 A). Animals 
heterozygously expressing CreERT2 (ct2/wt) and injected for three consecutive days with 
TAM (+TAM) represent maximum reporter expression (positive control, ct2/wt/+TAM 
(1)). Wildtype animals without CreERT2 served as negative controls (wt/wt/±TAM (2)) 
with no apparent recombination. Some of these animals were also injected with TAM to 
exclude any recombination in the absence of CreERT2 induced by TAM (± TAM). The 
other two tested conditions expressed CreERT2 either heterozygously (ct2/wt/-TAM (3)) 
or homozygously (ct2/ct2/-TAM (4); only tested for knockin line) and did not receive 
TAM. Reporter lines were only used homozygously floxed. For the GFAP-CreERT2 line, 
generated by non-homologous recombination, the fourth group (ct2/ct2/-TAM) was 
excluded. 
Sagittal brain overviews of all seven genotypes and magnifications of cortex (corpus 
callosum, hippocampus) and cerebellum (Fig. 18-23) were analyzed. 
6.2.1.1. Non-induced recombination of GLAST-CreERT2 mice 
TAM injected GLAST-CreERT2 animals crossbred to GCaMP3 reporter showed an 
expected overall expression of the reporter in astrocytes with a very high expression in 
the cerebellum (Fig. 18 B) (Jahn et al., 2015, Saab et al., 2012). Positive (Fig. 20 C, 
102.4 %) and negative controls (Fig. 20 C, 1.9 %) revealed expected results, with high 
recombination compared to no reporter expression. In heterozygous mice without 
induction (ct2/wt/-TAM) only a few cells were recombined in the forebrain, while main 
tamoxifen-independent recombination could be found in the cerebellum (Fig. 18 D, 
9.3 % for whole brain (Fig. 20 C)). The number of recombined cells in non-induced 
homozygous mice (ct2/ct2/-TAM) was slightly increased in forebrain and cerebellum 






Figure 18. Tamoxifen-independent recombination of the GLAST-CreERT2 line 
indicated by high GCaMP3 reporter expression 
(A) GLAST-CreERT2 mice crossbred to the reporter line Rosa26-GCaMP3, were 
injected with TAM (positive control) at an age of four weeks and analyzed 21 dpi. (B-E) 
Whole sagittal brain slices with four different CreERT2 genotypes and magnifications of 
cortex and cerebellum. (B) The positive con (ct2/wt/+TAM) revealed an overall high 




(wt/wt/±TAM). (D) Heterozygous non-induced animals (ct2/wt/-TAM) with single 
recombined astrocytes in the fore- and midbrain and high cerebellar reporter 
expression. (E) Homozygous non-induced animals (ct2/ct2/-TAM) showed more 
astrocytes, with even comparable cerebellar reporter expression to the positive con. 
ctx: cortex; cc: corpus callosum; hc: hippocampus; cb: cerebellum. Scale bars 
correspond to 500 µm in sagittal overviews and 100 µm in magnifications, respectively.  
The GLAST-CreERT2 driver line crossbred to the tdTomato reporter showed similar 
results compared to GCaMP3, with high astrocytic tdTomato expression after TAM 
treatment all over the brain (101.1 % reporter expression, Fig. 19 B and 20 C). No 
reporter was expressed in the negative control (wt/wt/±TAM, 0.7 %, Fig. 19 C and 
20 C). Non-injected animals, expressing CreERT2 either heterozygously or 
homozygously, showed few recombined astrocytes in the forebrain, but an overall high 
reporter expression in the cerebellum (5.3 % and 9.7 % reporter expression, 
respectively, Fig. 19 D, E and 20 C). Direct visual comparison of expressed GCaMP3 
and tdTomato in GLAST-CreERT2 mice revealed a higher expression level of the 
GCaMP3 reporter.  
The reporter GCaMP3 was additionally stained with α-GFP. To exclude higher 
fluorescence intensities due to antibody labeling, also tdTomato was stained with α-
DsRed (IHC data not shown), revealing a higher fluorescence signal compared to the 
original signal: (1) 100.6 %; (2) 8.6 %; (3) 16.8 %; (4) 30.1 %. But also the background 
signal for the negative control was increased due to staining from 0.7 % to 8.6 % 





Figure 19. Tamoxifen-independent recombination of GLAST-CreERT2 x Rosa26-
tdTomato mice 
(A) GLAST-CreERT2 mice were crossbred to the reporter line Rosa26-tdTomato, 
injected with TAM (positive control) at an age of four weeks and analyzed 21 dpi. (B-E) 
Whole sagittal brain slices of four different CreERT2 genotypes and magnifications of 
cortex and cerebellum, of original tdTomato signal without additional staining. (B) 




while (C) the negative con (wt/wt/±TAM) expressed no reporter. (D) Heterozygous non-
induced animals (ct2/wt/-TAM) with only few recombined astrocytes in the fore- and 
midbrain and a high cerebellar reporter expression. (E) Homozygous non-induced 
animals (ct2/ct2/-TAM) revealed more recombined astrocytes in cortex and cerebellum 
compared to heterozygous animals. ctx: cortex; cc: corpus callosum; hc: hippocampus; 
cb: cerebellum. Scale bars correspond to 500 µm in sagittal overviews and 100 µm in 
magnifications, respectively. 
 
Figure 20. Quantification of tamoxifen-independent recombination of the 
GLAST-CreERT2 driver line revealed high reporter expression 
(A) Animals were injected with TAM at the age of four weeks for three consecutive 
days and analyzed 21 dpi (positive con; ct2/wt/+TAM) (B) GLAST-CreERT2 driver line 
crossbred to reporter lines GCaMP3 and tdTomato. (C) Analysis of recombination 
(Orbit) in GLAST-CreERT2 mice revealed a difference between ct2/wt/+TAM animals 
compared to the negative con (wt/wt/±TAM), the heterozygous (ct2/wt/-TAM) and the 
homozygous (ct2/ct2/-TAM) condition for both reporter and the additional reporter 
staining. Differences in reporter expression between wt compared to the heterozygous 
and homozygous condition could be found. Homozygous non-induced animals 
revealed for tdTomato expression and α-DsRed staining a higher recombination than 
heterozygous animals, while GCaMP3 expression was comparable (p = 0.0555). The 
error bars correlate to the median ± interquartile range of the biological replicates 




6.2.1.2. Tamoxifen-independent recombination is mainly absent in GFAP-
CreERT2 mice 
To evaluate if tamoxifen-independent recombination occurs in astrocyte-specific 
CreERT2 driver lines, non-homologous TgN (hGFAP-CreERT2) mice (Hirrlinger et al., 
2006) were analyzed. Injected animals of the GFAP-CreERT2 line showed reporter 
positive (GCaMP3) astrocytes all over the brain with a higher expression rate in the 
hindbrain (Fig. 21 B) and less recombination efficiency in cortex and cerebellum 
compared to GLAST-CreERT2 mice (Jahn et al., 2015, Jahn, Kasakow et al., 2018). IHC 
data and Orbit image analysis revealed no reporter expression in negative controls 
(Fig. 21 C and 23 C). Heterozygous CreERT2-expressing animals showed only isolated 
recombined cells in cortex and cerebellum (Fig. 21 D), also reflected by only 1.1 % 
reporter expression (Fig. 23 C). Therefore, this mouse line showed less tamoxifen-
independent recombination in heterozygous mice than the GLAST-CreERT2 mouse line, 
using the GCaMP3 reporter (1.1 % to 9.3 %, respectively).  
 
Analysing tdTomato reporter expression in GFAP-CreERT2 mice revealed similar results 
compared to GCaMP3 but with higher background signal in negative controls (5.5 %) 
(Fig. 22 C and 23 C). Positive controls showed reporter expression all over the brain 
with highest recombination in midbrain and brainstem and only sparse cortical and 
hippocampal recombination (Fig. 22 B). The negative control did not recombine 
(Fig. 22 C). Heterozygous, non-injected animals showed almost no TAM-independent 
recombination. Less than 50 cells per sagittal section could be detected (Fig. 22 D). 
These findings were also reflected by Orbit image analysis, revealing 2.1 % reporter 
expression (Fig. 23 C). Staining with α-DsRed antibody revealed higher fluorescence 
signals compared to the original signal, revealing (1) 102.2 %; (2) 19.2 % and (3) 
22.1 %. However, background signal for the negative control was again increased due 






Figure 21. Negligible non-tamoxifen-induced recombination of GCaMP3 in 
GFAP-CreERT2 mice 
(A) Mice were injected with TAM (positive control) at an age of four weeks and 
analyzed 21 dpi. GFAP-CreERT2 mice were crossbred to the reporter line Rosa26-
GCaMP3, and (B-D) sagittal brain slices with three different CreERT2 genotypes and 
magnification of cortex and cerebellum. (A) The positive con (ct2/wt/+TAM) revealed 
an overall high expression of the GCaMP3 in astrocytes with a different expression 
pattern compared to the GLAST-CreERT2 line. More astrocytes are recombined in the 
mid- and hindbrain, while cortical recombination was sparse. (C) Negative con 
(wt/wt/±TAM) with no expression of the reporter. (D) Heterozygous non-induced 
animals (ct2/wt/-TAM) with single recombined astrocytes in midbrain and only sparsely 
recombined Bergmann glia cells. ctx: cortex; cc: corpus callosum; hc: hippocampus; 






Figure 22. Fewer cells expressed tdTomato in GFAP-CreERT2 mice 
(A) GFAP-CreERT2 mice were crossbred to the reporter line Rosa26-tdTomato, injected 
with TAM (positive control) at an age of four weeks and analyzed 21 dpi. (B-D) Sagittal 
brain slices with three different CreERT2 genotypes and magnification of cortex and 
cerebellum. (B) The positive con (ct2/wt/+TAM) revealed a similar expression pattern 
to GCaMP3 in astrocytes but less bright. (C) No reporter expression was detected in 
negative con (wt/wt/±TAM). (D) Heterozygous non-induced animals (ct2/wt/-TAM) 
showed almost no tdTomato reporter positive cells in forebrain, midbrain and 
cerebellum. Here, the original tdTomato signal without additional staining is depicted. 
ctx: cortex; cc: corpus callosum; hc: hippocampus; cb: cerebellum. Scale bars 





Figure 23. Quantification of low reporter expression after tamoxifen-
independent recombination in GFAP-CreERT2 mice 
(A) Animals were injected with TAM at an age of four weeks for three consecutive days 
and analyzed 21 dpi (positive con; ct2/wt/+TAM) (B) GFAP-CreERT2 driver lines were 
crossbred to reporter lines GCaMP3 and tdTomato. (C) Comparison of reporter 
expression in GFAP-CreERT2 mice (GCaMP3 (α-GFP), tdTomato, tdTomato (α-DsRed)) 
of positive con (ct2/wt/+TAM), negative con (wt/wt/±TAM) and the heterozygous 
condition (ct2/wt/-TAM). GCaMP3 expression of heterozygous non-injected animals 
was higher compared to negative con, while tdTomato expression was lower and α-
DsRed staining revealed no difference. The error bars correlate to the 












Fluorescence intensities (median) of all mouse lines are depicted in table 14, 
respective statistical analysis is stated in table 15. 
Table 14. Percentage of fluorescence intensities of the GLAST-CreERT2 and GFAP-CreERT2 
mouse lines (median; standardized to ct2/wt/+TAM) 
GCaMP3   slc1a3 [%] gctf [%] 
ct2/wt  + TAM 102.4 84.0 
wt/wt ± TAM 1.9 0.4 
ct2/wt - TAM 9.3 1.1 
ct2/ct2 - TAM 10.0 - 
tdTomato   slc1a3 [%] gctf [%] 
ct2/wt  + TAM 101.1 97.2 
wt/wt ± TAM 0.7 5.5 
ct2/wt - TAM 5.3 2.1 
ct2/ct2 - TAM 9.7 - 
tdTomato   slc1a3 α-DsRed [%] gctf α-DsRed [%] 
ct2/wt  + TAM 100.6 102.2 
wt/wt ± TAM 8.6 19.2 
ct2/wt - TAM 16.8 22.1 
ct2/ct2 - TAM 30.1 - 
Table 15. Statistical comparison of the different mouse lines and CreERT2 genotypes 
 
Genotype TAM wt/wt / ±TAM ct2/wt / -TAM ct2/ct2 / -TAM 
GLAST-CreERT2/GCaMP3 
ct2/wt (+) **** **** **** 
wt/wt  (±)    **** **** 
ct2/wt  (-)     ns (p=0.0555) 
GLAST-CreERT2/tdTomato 
ct2/wt  (+)  **** **** **** 
wt/wt  (±)    **** **** 
ct2/wt  (-)     *** 
GLAST-CreERT2/α-DsRed 
ct2/wt  (+)  **** **** **** 
wt/wt  (±)    *** **** 
ct2/wt  (-)     **** 
GFAP-CreERT2/GCaMP3 
ct2/wt  (+)  **** ****   
wt/wt  (±)    **   
GFAP-CreERT2/tdTomato 
ct2/wt  (+)  **** ****   
wt/wt  (±)    *   
GFAP-CreERT2/α-DsRed 
ct2/wt  (+)  **** ****   





6.2.2. Quantitative real time PCR analysis of the same mouse lines 
confirm results of Orbit image quantification 
Tamoxifen-independent recombination was additionally investigated by qRT-PCR 
analysis. Separately analysis of cortex and cerebellum was performed to address 
regional expression differences. Cortex and cerebellum of the GLAST-CreERT2 x and 
GFAP-CreERT2 x Rosa26-GCaMP3 mouse line were dissected and genomic DNA 
isolated (Fig. 24 A, B). The same three/four groups of animals were investigated: (1) 
ct2/wt/+TAM, (2) wt/wt/±TAM, (3) ct2/wt/-TAM and (4) ct2/ct2/-TAM by gain of function 
qRT-PCR. All animals were homozygously floxed for the gcamp3 alleles. Data were 
normalized to tamoxifen-injected animals (positive control/ ct2/wt/+TAM (1)) as for the 
immunohistochemistry quantification (Orbit). Wildtype animals for CreERT2 (wt/wt/±TAM 
(2)), were used as negative controls. All negative controls of the gene loci in cortex and 
cerebellum showed less than 0.5 % recombination and were therefore estimated as not 
recombined. 
GLAST-CreERT2 induced reporter expression revealed in non-induced heterozygous 
animals (ct2/wt/-TAM) only 1.7 % recombined cortical gcamp3 alleles, while in 
homozygous (ct2/ct2/-TAM) animals around 14 % were recombined. A higher 
tamoxifen-independent cerebellar recombination was detected as already seen in the 
IHC data (Fig. 18, 19). Cerebellar homozygous non-induced (ct2/ct2/-TAM) animals 
reached similar recombination of floxed alleles (63 %) as the injected positive controls 
(ct2/wt/+TAM). Heterozygous animals showed recombination of 22 % floxed alleles 
with a high SD (± 15) (Fig. 24 C, Table 16). 
 
In contrast, GFAP-CreERT2 induced GCaMP3 expression was absent in cortex and 
cerebellum of non-injected animals. In cortex, heterozygous non-induced animals 






Figure 24. Primarily GLAST-CreERT2 driven tamoxifen-independent 
recombination of the reporter GCaMP3 in the cerebellum 
(A) Mice were injected with TAM at an age of four weeks and were analyzed 21 dpi. 
(B) GLAST-CreERT2 and GFAP-CreERT2 crossbred to the Rosa26-GCaMP3 line. (C, D) 
Quantitative real-time PCR results of gcamp3 recombination in cortex and cerebellum. 
Three/four groups of animals, depending on the mouse line, were investigated: (1) 
ct2/wt/+TAM, (2) wt/wt/±TAM, (3) ct2/wt/-TAM and (4) ct2/ct2/-TAM. (C) Cortical 
tamoxifen-independent recombination revealed less than 2 % recombined gcamp3 
alleles in heterozygous animals, while homozygous animals revealed 14 %. In the 
cerebellum 22 % (ct2/wt/-TAM) and 63 % (ct2/ct2/-TAM) floxed alleles were 
recombined, respectively. Homozygous non-induced animals revealed similar 
cerebellar recombination efficiencies as TAM-induced mice (ct2/wt/+TAM), while 
cortical non-induced recombination was negligible. (D) Minor GFAP-CreERT2 driven, 
non-induced recombination of gcamp3 alleles in heterozygous animals in cortex and 
cerebellum. Three animals were analyzed per group and ΔCT-values were normalized 
to the mean value of animals which received 3x TAM (table 16). The error bars 
correlate to the SD of the biological replicates (n = 3, * p < 0.05, ** p < 0.01, 







Table 16. GLAST-CreERT2 and GFAP-CreERT2 driven recombination of gcamp3 alleles  
    GLAST-CreERT2 ctx GFAP-CreERT2 ctx 
ct2/wt  + TAM 101 ± 12 102 ± 21 
wt/wt ± TAM 0.03 ± 0.02 0.2 ± 0.02 
ct2/wt - TAM 1.7 ± 0.1 0.2 ± 0.09 
ct2/ct2 - TAM 14.2 ± 6.6 - 
    GLAST-CreERT2 cb GFAP-CreERT2 cb 
ct2/wt  + TAM 102 ± 22 102 ± 22 
wt/wt ± TAM 0.4 ± 0.3 0.5 ± 0.3 
ct2/wt - TAM 22 ± 15 0.2 ± 0.09 
ct2/ct2 - TAM 63 ± 16 - 
 
In addition, GLAST-CreERT2 x P2Y1fl/fl x Gria1fl/fl x Rosa26-GCaMP3 mice were 
investigated (Fig. 25 A; B) to evaluate the extent of non-induced recombination on 
floxed target alleles. As shown before, recombination efficiencies of floxed alleles differ 
after tamoxifen-induced recombination. All animals were homozygously floxed for 
p2ry1, gria1 and gcamp3 and the same CreERT2 genotypes were analyzed as described 
before. Tamoxifen-independent recombination of the p2ry1 locus was almost absent in 
the cortex (0.5 % recombined alleles in heterozygous non-induced mice (ct2/wt/-TAM) 
and 4 % in homozygous non-induced mice (ct2/ct2/-TAM)) (Fig. 25 C). Higher 
recombination was detected in the cerebellum of non-injected animals for p2ry1, with 
around 6 % recombined alleles in heterozygous (ct2/wt/-TAM), and almost three times 
more (16.5 %) recombined alleles in homozygous (ct2/ct2/-TAM) animals without TAM 
(Fig. 25 D). Cerebellar recombination was twelve times higher in heterozygous 
(ct2/wt/-TAM) mice and four times higher in homozygous mice (ct2/ct2/-TAM) 
compared to cortical recombination, respectively. TAM-induced recombination of the 
gria1 locus was, compared to p2ry1, less efficient (Fig. 14). Lower recombination was 
also observed for non-induced recombination. At the gria1 locus non-injected animals 
(ct2/wt or ct2/ct2) showed no cortical recombination (Fig. 25 C). Cerebellar 
recombination of the gria1 locus was also negligible in heterozygous and homozygous 
non-induced mice (≤1 %) (Fig. 25 D). Only 1.7 % of cortical GCaMP3 alleles were 
recombined in non-injected heterozygous animals (ct2/wt/-TAM), whereas almost 10 % 
of the alleles were recombined in the cortex of homozygous animals without TAM 
(ct2/ct2/-TAM) (Fig. 25 C). These data are well in line with reporter recombination data 




found for the reporter in GLAST-CreERT2 x P2Y1fl/fl x Gria1fl/fl mice compared to GLAST-
CreERT2 mice. In the cerebellum, one quarter (26.5 %) of the alleles was recombined in 
heterozygous animals without TAM (ct2/wt/-TAM). GLAST homozygous animals 
without injection (ct2/ct2/-TAM) showed a very high recombination rate of GCaMP3 
alleles, revealing no difference to the positive control (Fig. 25 D). Similar results were 
found for the GLAST-CreERT2 mouse line, revealing 22 % and 63 % recombined 
reporter alleles in heterozygous and homozygous mice, respectively. Recombination 
efficiency of homozygous mice reached comparable levels as the positive control. All 
these data show a higher recombination rate of the reporter in the cerebellum 
compared to cortex for the three floxed alleles, while target gene alleles remained 
unaffected. Mean values ± SD and statistical analysis are stated in table 17 and 18, 
respectively.  
In summary, non-induced recombination rate of the cerebellum was higher than cortical 
recombination and more p2ry1 alleles were recombined compared to gria1 alleles 
without TAM. These data represent the same tendencies already observed in data of 
the tamoxifen-induced recombination. Negligible target allele recombination (p2ry1, 
gria1) was found for the cortex without TAM. For following experiments, mainly 





Figure 25. Tamoxifen-independent recombination of the floxed reporter 
(A) Mice were injected with TAM at an age of four weeks and analyzed 21 dpi. (B) 
Constructs of GLAST-CreERT2 x P2Y1fl/fl x Gria1fl/fl x Rosa26-GCaMP3 line with location 
of respective gain of function primers for qRT-PCR. (C) Four groups of animals were 
investigated: (1) ct2/wt/+TAM, (2) wt/wt/±TAM, (3) ct2/wt/-TAM and (4) ct2/ct2/-TAM. 
Cortical tamoxifen-independent recombination was almost absent in GLAST 
heterozygous animals of all investigated floxed loci. In GLAST homozygous non-




The gria1 locus was not recombined in ct2/wt/-TAM (3) and ct2/ct2/-TAM (4) mice. (D) 
Cerebellar qRT-PCR results of the same animals. Tamoxifen-independent 
recombination in GLAST heterozygous animals revealed recombination of about 6 % 
for p2ry1, 0.1 % for gria1 and 27 % for gcamp3 alleles. In GLAST homozygous animals 
without TAM 17 % of p2ry1, 1.0 % of gria1 and 120 % of gcamp3 alleles were 
recombined. Three animals were analyzed per group and ΔCT-values were normalized 
to the mean value of animals which received 3x TAM. The error bars correlate to the 
SD of the biological replicates (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired t-
test, table 17). 
Table 17. Recombination of floxed p2ry1, gria1 and gcamp3 alleles in ctx and cb 
    p2ry1 ctx gria1 ctx gcamp3 ctx 
ct2/wt  + TAM 104 ± 38 110 ± 59 102 ± 25 
wt/wt ± TAM 0.2 ± 0.1 0.01 ± 0.0 0.03 ± 0.0 
ct2/wt - TAM 0.5 ± 0.1 0.02 ± 0.01 1.7 ± 1.0 
ct2/ct2 - TAM 4.1 ± 2.4 0.01 ± 0.0 9.9 ± 6.4 
    p2ry1 cb gria1 cb gcamp3 cb 
ct2/wt  + TAM 101 ± 9 100 ± 8 118 ± 72 
wt/wt ± TAM 0.01 ± 0.0 0.02 ± 0.01 0.03 ± 0.0 
ct2/wt - TAM 6.3 ± 3.6 0.12 ± 0.18 26.5 ± 8.8 
ct2/ct2 - TAM 16.5 ± 6.9 1.03 ± 0.7 120 ± 71 
Table 18. Statistical comparison of the floxed alleles with different GLAST genotype 
 
Genotype TAM wt/wt / ±TAM ct2/wt / -TAM ct2/ct2 / -TAM 
p2ry1 ctx 
ct2/wt (+) ** ** ** 
wt/wt  (±)    * * 
ct2/wt  (-)     ns (p=0.0563) 
p2ry1 cb 
ct2/wt  (+)  *** *** *** 
wt/wt  (±)    * ** 
ct2/wt  (-)     ns (p=0.0703) 
gria1 ctx 
ct2/wt  (+)  * * * 
wt/wt  (±)    ns (p=0.1349) ns (p=0.1390) 
ct2/wt  (-)     ns (p=0.1805) 
gria1 cb 
ct2/wt  (+)  **** **** **** 
wt/wt  (±)    ns (p=0.3861) ns (p=0.0535) 
ct2/wt  (-)   ns (p=0.0770) 
gcamp3 ctx 
ct2/wt  (+)  ** ** *** 
wt/wt  (±)    * * 
ct2/wt  (-)   ns (p=0.0822) 
gcamp3 cb 
ct2/wt  (+)   *  ns (p=0.0947) ns (p=0.9748) 
wt/wt  (±)   ** * 




6.2.3. Pathological conditions can trigger tamoxifen-independent 
recombination in GFAP-CreERT2 mice 
GFAP upregulation was induced by two independent pathological models: (1) stab 
wound injury (SWI) model and (2) cuprizone treatment. To prove that pathological 
conditions can induce tamoxifen-independent recombination, GFAP-CreERT2 x Rosa26-
tdTomato mice were analyzed after SWI (Laura Caudal, Department of Molecular 
Physiology). Under physiological conditions GFAP-CreERT2 mice without TAM did not 
recombine. However, after SWI recombined astrocytes could be observed at the lesion 
site (Fig. 26 E). Another pathological model revealed similar results. Feeding 
cuprizone, mimics multiple sclerosis (MS) and induced recombination without TAM 
application in the demyelinated and astroglial activated corpus callosum of GFAP-
CreERT2 x Rosa26-tdTomato mice (Alyssa Price, Department of Molecular Physiology) 







Figure 26. Tamoxifen-independent recombination after GFAP upregulation 
under pathological conditions 
(A) GFAP-CreERT2 x Rosa26-tdTomato mice were investigated with two pathological 
models. (B) Mice were injected with TAM at an age of eight weeks for three 
consecutive days, treated with cuprizone to induce demyelination for three consecutive 
weeks and analyzed with 13 weeks. (C) The same mouse line was injected with TAM 
at an age of four weeks for three consecutive days. SWI was performed at an age of 
seven weeks and animals were analyzed seven days later. (D) Animals without TAM 
but with cuprizone treatment (ct2/wt/-TAM/+cuz), revealed high non-induced reporter 
expression in the hippocampus and particularly in the corpus callosum, where 
cuprizone leads to demyelination (Gudi et al., 2014). (E) Mice without TAM injection 
but SWI showed GFAP upregulation around the lesion core, indicating tamoxifen-
independent recombination under pathological conditions. Scale bars correspond to 
500 µm in sagittal overviews and 100 µm in magnifications, respectively. 
6.3. P2Y1 receptor cKO mice 
As previously described, optimal TAM injection protocols are crucial to induce maximal 
DNA recombination of floxed loci. Three to five injections are sufficient to reach 
maximal recombination. In addition, tamoxifen-independent recombination was mainly 
absent in the cortex for the floxed p2ry1 locus. 
6.3.1. High reduction of P2Y1R mRNA on astrocytes 
Homogenates of P2Y1R cKO and control mice were analyzed for expression of p2ry1 
mRNA. After TAM application, exon 1 of the p2ry1 gene is excised, leading to no PCR 
product (loss of function) (Fig. 27 B). Mice were injected for three consecutive days 
with TAM at an age of four weeks and were analyzed 21 dpi. mRNA was isolated from 
total tissue homogenates of brainstem (bs), cerebellum (cb), cortex (ctx) and 
hippocampus (hc) (Fig. 27 A). P2Y1 control mice without CreERT2 expression 
represented 100 % mRNA expression and cKO animals were calculated accordingly. In 
all brain regions a reduction in mRNA expression could be achieved (22 % in bs, 63 % 
in cb, 50 % in ctx and 43 % in hc) (Fig. 27 C). As shown before (Fig. 16) tamoxifen-
induced P2Y1R cKO also led to a reduction in all brain regions at the DNA level (23 % 





Figure 27. Reduction of P2Y1R mRNA in homogenates of various brain 
regions 
(A) GLAST-CreERT2 x P2Y1 fl/fl mice were injected with TAM at an age of four weeks 
and analyzed 21 dpi later. (B) Primers were positioned in exon 1 of the p2ry1 gene. 
Upon CreERT2 activity exon 1 is excised and no PCR product generated. (C) Total 
homogenates of bs, cb, ctx and hc of con and cKO mice were analyzed. Reductions in 
mRNA expression to 78 % in bs, 40 % in cb, 55 % in ctx and 61 % in hc compared to 
con animals were detected. Six to seven animals were analyzed and ΔCT-values were 
normalized to the mean value of con animals. The error bars correlate to the SD of the 








6.3.2. DNA data of MACS isolated astrocytes and mRNA expression data 
from NGS confirm observations of total homogenates 
P2Y1R ablation was additionally investigated on purified astrocytes. Astrocytes were 
isolated from tissue homogenates by magnetic activated cell sorting (MACS). Genomic 
DNA of isolated astrocytes from cKO and control mice was further analyzed by qRT-
PCR to evaluate recombination efficiency of cortical and cerebellar floxed p2ry1 loci. In 
addition, reduction in mRNA expression after induction of the cKO was investigated by 
next generation sequencing (NGS).  
Controls and cKOs of GLAST-CreERT2 x P2Y1 fl/fl mice (Fig 28 B) were injected at an 
age of four weeks for five consecutive days and analyzed 21 dpi (Fig 28 A). Cortical 
and cerebellar astrocytes were separated from other cell types by MACS. Genomic 
DNA was isolated and further analyzed by qRT-PCR as previously described. Control 
animals without CreERT2 expression represent 100 % floxed alleles (no recombination) 
and cKO samples were calculated accordingly (loss of function qRT-PCR strategy). 
Identically isolated astrocytes were diluted in RLT buffer plus and further analyzed by 
NGS. 
In the cortex, a reduction of 60 % of floxed p2ry1 alleles was detected in the cKO, while 
in the cerebellum a reduction of 30 % was determined (Fig 28 C). Compared to control 
animals a reduction in cKO mice could be achieved for both brain regions, but no 
absolute receptor ablation. Expression data of isolated astrocytes revealed a reduction 
of p2ry1 mRNA of about 50 % for both investigated brain regions (Fig 28 D). In line with 
the DNA data, a total ablation of the P2Y1R on astrocytes could not be achieved. 
In total homogenates 20 % (ctx) and 6 % (cb) reduction of p2ry1 alleles could be 
detected (Fig 16 C), leading to an increase in reduction of 30 % and 24 % in MACS 





Figure 28. Reduction of floxed p2ry1 alleles at the DNA and mRNA level of 
MACS isolated astrocytes 
(A-B) GLAST-CreERT2 x P2Y1 fl/fl mice were injected at an age of four weeks with TAM 
for five consecutive days and were analyzed 21 dpi. (C) A reduction of floxed p2ry1 
alleles to 40 % in cortex and 70 % in cerebellum was achieved compared to con 
animals. (D) mRNA expression was reduced about 50 % in cKOs of cortex and 
cerebellum. Four con and cKO animals were analyzed and ΔCT-values were 
normalized to the mean value of con animals / five animals for con and cKO were 
processed for NGS. The error bars correlate to the SD of the biological replicates 
(n = 4-5, * p < 0.05, ** p < 0.01, *** p < 0.001, unpaired t-test). 
The mRNA of sorted astrocytes was analyzed for expression of astroglial (Glutamate 
transporter-1 (Glt1), Aldehyde dehydrogenase 1 family member l1 (Aldh1l1), Glutamine 
synthetase (GS) and Aquaporin4 (Aqp4)), microglial (Itgam), neuronal (NeuN), NG2 
glial (PDGFRα) and oligodendroglial (MBP) markers, to evaluate contamination of 
astrocytic population with other neural cell types after sorting (Fig 29). A contamination 
with neurons or other glial cells could explain the incomplete P2Y1R ablation. mRNA 
expression was normalized to the ubiquitous astrocyte marker Glt1 and all other 
markers were calculated accordingly. Aldh1l1 (41 %), was less expressed compared to 
Glt1 (100 %), GS (140 %) and Aqp 4 (140 %). Other cell markers like Itgam (5.5 %), 




astrocytic cell population. These data indicate a contamination of the astroglial 
population with microglia, neurons, NG2 glia and oligodendrocytes.  
Almost the same markers (GLAST instead of Aldh1l1) were investigated using the NGS 
data. GLAST (116 %), was higher expressed compared to Glt1 (100 %), GS (26 %) 
and Aqp 4 (29 %). The other cell markers like Itgam (0.06 %), MBP (8 %), PDGFRα 
(0.15 %) and NeuN (1.1 %) could also be detected in the astrocytic cell population. 
NGS data revealed lower mRNA expression of other neural cell types compared to 
qRT-PCR results, but also the astrocytic markers GS and Aqp4 were lower expressed. 
In general, we could demonstrate an enrichment of astrocytic markers, but the purity of 
the sorting process should be further improved.  
 
Figure 29. Contamination of astrocytic population after MACS with microglia, 
neurons, NG2 glia and oligodendrocytes 
(A) Mice were injected for five consecutive days with TAM and analyzed 21 dpi. 
Cortical and cerebellar astrocytes were purified via MACS and analyzed by qRT-PCR 
or NGS. mRNA of purified astrocytes was analyzed for astrocytic, microglial, 
oligodendroglial, NG2 glial and neuronal cell markers. (B, C) mRNA expression of all 
markers was normalized to the ubiquitous astrocytic marker Glt1. Data revealed high 
mRNA expression of astrocytic markers, but also of other neural cells. The error bars 




6.3.3. Differentially expressed genes after P2Y1R ablation 
The mRNA expression profile of P2Y1R cKO and control mice was investigated by next 
generation sequencing (NGS) to identify changes in expression pattern of other 
astrocytic receptors and to determine signaling pathways involved in the adaption to 
the cKO condition. Cortical astrocytes were isolated by MACS as described before and 
samples were processed by NGS. 
Volcano plot revealed profound differences in gene expression between control and 
cKO of cortical astrocytes. Several genes are differentially expressed in the cKO 
condition (Fig. 30 C). Some genes like Ddn (Dendrin) and Rims4 (Regulating synaptic 
membrane exocytosis 4) were upregulated (red dots), while Ttr (Transthyretin), Doc2b 
(Double C2 domain beta) and Plin4 (Perilipin 4) were downregulated (blue dots) in the 
cKO.  
Representative astrocytic markers were not changed in cKOs, with the expected 
exception of the GLAST locus. Here, 50 % reduction was detected for the cKO due to 
the knockin of CreERT2 (Fig. 30 D, Saab et al., 2012).  
Expression of several P2Y and P2X receptors were compared, revealing 50 % 
reduction at the p2ry1 locus and an increase of p2rx6 mRNA after P2Y1R ablation 
(Fig. 30 E). Molecules involved in the downstream signaling cascade of the P2Y1R 




Figure 30. Next generation sequencing revealed 50 % reduction of p2ry1 
alleles in the cKO and an upregulation of p2rx6 
(A) Mice were injected with TAM at an age of four weeks for five consecutive days and 
cortical astrocytes were isolated by MACS. (B) P2Y1R cKO and control mice were 
analyzed by NGS. (C) Volcano plot revealed differential expressed genes (up- or 
downregulated) in cKO mice compared to controls. (D) High expression of astrocytic 
markers indicate an enriched astrocytic population. Expression of these markers were 
comparable between control and cKO, with exception of the GLAST locus. cKOs 
revealed a reduction of 50 %, due to the heterozygous expression of CreERT2 at the 
GLAST locus. (E) Expression of P2Y1R revealed about 50 % reduction in the cKO, 
while other P2Y receptors remained unchanged. Expression of the P2X6 receptor was 
increased in the cKO, while P2X7 remained unaltered. (F) Several genes involved in 
P2Y1R signaling were not changed in cKO mice. Five cKO and control animals were 
analyzed. The error bars correlate to the SD of the biological replicates (n = 5, 












6.4. Astroglial P2Y1 receptor knockout had no impact on acute 
injuries 
The influence of the astroglial P2Y1R under pathological conditions was analyzed by 
stab wound injury (SWI) experiments. SWI was performed 21 d after TAM treatment 
and animals were analyzed 7 d post lesion (dpl) (Fig. 31 A and 33 A, respectively). 
Coronal vibratome sections (40 µm) were prepared and stained with DAPI, GFP, GFAP 
and Iba1. P2Y1 cKO mice were crossbred with either the reporter mouse line tdTomato 
or GCaMP3, respectively. For controls, either littermates without CreERT2 (tdTomato) or 
animals without floxed p2ry1 alleles (GLAST-CreERT2 x Rosa26-GCaMP3) were used 
(Fig 31 B and 33 B).  
cKO animals showed expression of the reporter tdTomato (Fig. 31 C), whereas control 
animals were not recombined. GCaMP3 expressing mice were additionally stained with 
α-GFP (Fig. 33 C (A-E)). All sections (n = 4-7; 6 sections per animal) were analyzed 
using the ImageJ Plugin LRoi (Fig. 7). Fluorescence intensities across the lesion site of 
the respective reporter and the markers Iba1 for microglia and GFAP for activated 
astrocytes were simultaneously analyzed ipsi- and contralaterally. On the ipsilateral 
side the lesion core defines the mid position of the 25 ROIs (Fig. 32 and 34).  
6.4.1. Loss of astroglial P2Y1 receptors without impact on acute brain 
injury 
cKOs and controls of P2Y1fl/fl x Rosa26-tdTomato mice revealed no differences for the 
astroglial marker GFAP on the ipsilateral side. Both, cKOs and controls, showed higher 
fluorescence intensities due to an increase in astrocyte cell number at the lesion core 
with a GFAP upregulation. On the contralateral side fluorescence intensities were 
similar without any peak in fluorescence (Fig. 32 A). The microglial marker Iba1 
showed higher fluorescent intensities compared to GFAP, because more microglia 
cells surround the lesion site and were also equally distributed contralaterally without 
difference between cKO and control. Ipsilaterally, a peak in Iba1 fluorescence of cKO 
and control sections could be detected with no difference (Fig. 32 B). The tdTomato 
reporter showed a peak in cKO mice due to cell activation but no increase in 
fluorescence on the contralateral side. No fluorescence could be detected ipsi- and 








Figure 31. No difference between cKO and control mice after SWI on glial 
activation 
(A) Mice were injected at the age of four weeks for three consecutive days. Stab 
wound injury was performed 21 dpi and mice were analyzed 7 d post lesion (dpl). Con 
animals did not express the reporter tdTomato (CreERT2 negative). (B) Mouse 
constructs of the investigated mouse lines: GLAST-CreERT2, floxed P2Y1 and floxed 
tdTomato. (C) Frontal brain slices depicting the lesion site. Sections were stained for 
DAPI, Iba1 and GFAP. cKOs showed tdTomato expression, while con were reporter 
negative. The two upper panels depict cKO and con of overviews, lower panels the 
magnification of the highlighted region (yellow rectangle). An increase of cells (DAPI+) 
could be detected surrounding the lesion site (A) with an alike upregulation of Iba1 (B) 
and GFAP (D) in con and cKOs. The scale bars correspond to 500 µm in overviews 




Figure 32. Quantification of astroglial and microglial activation after acute 
injury revealed no differences between cKO and control mice 
Frontal slices of cKO and con were analyzed with the ImageJ plugin LRoi to calculate 
fluorescence intensities of 25 ROIs along the lesion site (ipsilateral) as well as on the 
contralateral side. Three different proteins were analyzed in parallel: GFAP, Iba1 and 
tdTomato. (A) Fluorescence intensities of GFAP increased ipsilaterally in cKO and con 
mice due to astrocytic activation. Contralaterally, fluorescence intensities of cKO and 
con were similar. (B) Iba1 was upregulated in the lesion site without differences 
between cKOs and con. (C) The reporter signal was decreased ipsilaterally and 
contralaterally in con due to lack of reporter expression. The cKO revealed an 
upregulation in fluorescence intensity at the lesion site. The error bars correlate to the 
SD of the biological replicates (n = 4-7, *p<0.05, **p< 0.01, ***p<0.001, 2way Anova). 
6.4.2. GCaMP3 reporter expression led to an increase in GFAP 
expression upon astroglial P2Y1R ablation 
The analysis of cKO and control mice by LRoi revealed ipsilaterally differences 
between α-Iba1 and α-GFAP stained sections. GFAP expression was upregulated in 
the lesion core of cKO sections while Iba1 expression was downregulated (Fig. 34 A, 
B). The reporter GCaMP3 revealed no change in fluorescence intensity in cKOs and 
con at the lesion site (Fig. 34 C). On the contralateral side GFAP expression was two 
times higher in cKO mice, while Iba1 expression was alike in cKO and control mice 
(Fig. 34 A, B). Cotralaterally, fluorescence intensities of the reporter in cKO sections 










Figure 33. Differences between cKO and control mice after SWI on glial 
activation when GCaMP3 is expressed 
(A) Mice were injected at an age of four weeks for three cosecutive days. Stab wound 
injury was performed 21 dpi and and mice were analyzed 7 d post lesion (dpl). (B) 
Mouse constructs of the investigated mouse lines: GLAST-CreERT2, floxed P2Y1 and 
floxed Rosa26-GCaMP3. Here, cKO and con mice expressed the reporter due to 
CreERT2 activity and tamoxifen-induction. (C) Frontal brain slices depicting the lesion 
site. Sections were stained for DAPI, GFP, GFAP and Iba1. GCaMP3 was additionally 
stained with α-GFP. The two upper panels depict cKO and con of overviews, lower 
panels the magnification of the highlighted region (yellow rectangle). An increase of 
cells (DAPI+) could be detected surrounding the lesion site (A) with an upregulation of 
GFAP (C) and a downregulation of Iba1 in cKOs, while GCaMP3 expression (α-GFP, 
B) was alike in cKOs and con. The scale bars correspond to 500 µm in overviews and 




Figure 34. GFAP upregulation ipsilaterally and contralaterally of P2Y1R cKO 
mice 
Frontal slices of cKO and con were analyzed with the ImageJ plugin LRoi to calculate 
fluorescence intensities of 25 ROIs along the lesion site (ipsilateral) as well as on the 
contralateral side. Three different proteins were analyzed in parallel: GFAP, Iba1 and 
GCaMP3 (α-GFP). (A) Fluorescence intensities revealed an GFAP upregulation at the 
lesion site of cKO and con with higher signals in cKO mice. Contralaterally, 
fluorescence intensities of the GFAP staining were increased in the cKO. (B) Iba1 was 
upregulated in the lesion site of con, while contralaterally expression was similar in 
cKO and con. (C) GCaMP3 (α-GFP) signal revealed ipsilaterally no difference between 
cKO and con. Contralaterally, a higher reporter expression was detected in cKO mice. 
The error bars correlate to the SD of the biological replicates (n = 5-7, *p<0.05, **p< 
0.01, ***p<0.001, 2way Anova). 
6.5. Ca2+ signaling in astrocytes 
Ca2+ signaling in astrocytes represents one of the main communication routes between 
astrocytes and other cells. To functionally evaluate, if this signaling is disturbed upon 
P2Y1R ablation, in vivo Ca2+ signals of astrocytes expressing the Ca2+ indicator 
GCaMP3 were analyzed by 2-photon laser-scanning microscopy (2P-LSM).  
6.5.1. Smaller and shorter Ca2+ signals in cKO mice under anesthetized 
and awake conditions 
P2Y1R cKO and control mice were investigated by 2P-LSM to analyze changes in Ca2+ 
signaling upon P2Y1R ablation in vivo. Mice were injected with TAM at an age of four 
weeks for five consecutive days. Cranial window surgery was performed at an age of 
16-20 weeks. Several imaging sessions per animal were performed and Ca2+ data 
were pooled and depicted as box plots. Investigated parameters were amplitude (signal 
strength) and duration (signal length). Ca2+ signals of analyzed astrocytes were divided 
into signals of the processes (gliapil) and signals of the cell bodies (soma). Ca2+ signals 
were additionally divided into three signal types that represent the magnitude of the 
respective signals. Therefore, each graph shows signals of the first (1 SD), second 
(2 SD) and third standard deviation (3 SD), representing the small, medium sized and 
large Ca2+ signals, relating to strength not size. Ca2+ signals were automatically 
classified by MSparkles. Signal amplitudes of the three classes were also analyzed for 
their duration. MSparkles also calculated the percentage of each Ca2+ signal class, 
resulting in the signal composition (Fig 35-37) and generated heatmaps for each 




6.5.1.1. Smaller and shorter Ca2+ signals in anesthetized P2Y1R cKO mice 
Animals were treated and prepared for 2P-LSM and imaging sessions were performed 
3, 4, 8, 10 and 11 days after cranial window surgery (days post window surgery, dpw). 
During the imaging sessions animals were constantly anesthetized with 2 % isoflurane 
(0.8 l/min in total) (Fig 35 A).  
Ca2+ signals of the gliapil were smaller in their amplitudes in P2Y1 cKO mice compared 
to controls for all classes of Ca2+ signals. Small signals were about 1.5 x smaller, while 
medium sized and large signals were twice as weak as the respective control signals. 
Signal durations were also changed in cKO mice with shortened small and medium 
sized signals, while large signals remained unaltered (Fig. 35 B). 
Ca2+ amplitudes of the soma showed similar results compared to the gliapil. In cKO all 
observed Ca2+ signals had smaller amplitudes compared to controls. However, the 
duration of small and medium sized signals was not changed, while large signals were 
shorter in cKOs (Fig. 35 C). Signal composition of control and cKO in the gliapil 
revealed the highest percentage of small (1 SD) signals (52 % and 49 %, respectively) 
followed by medium sized (2 SD) (26 % and 29 %) and large (3 SD) signals (22 % and 
22 %). Signal composition of the soma was comparable in control and cKO with 54 % 
and 56 % small signals, 23 % and 26 % medium sized signals and 23 % and 18 % 
large signals, respectively (Fig. 35 D). Overall, no differences between cKOs and 








Figure 35. Anesthetized P2Y1 cKO mice had smaller and shorter Ca2+ signals 
in gliapil and soma 
(A) Animals were injected at an age of four weeks for five consecutive days with TAM. 
Cranial window surgery was performend between 16-20 weeks and imaging sessions 
were performed 3, 4, 8, 10 and 11 dpw. (B) Ca2+ signals of the gliapil were smaller in 
cKO compared to con in all three classes of signals. Respective signal durations of 
small and medium sized signals were shorter, while large signals were not changed in 
P2Y1 cKO. (C) Somatic signals were smaller after astroglial P2Y1R deletion in all 
classes of Ca2+ signals, while signal durations were shorter in large Ca2+ signals and 
not changed in small and medium sized signals. (D) The overall signal composition 
revealed no difference between cKO and con in gliapil and soma with the highest 
percentage of small signals (1 SD) followed by medium sized and large signals. The 
error bars correlate to the median ± interquartile range of the biological replicates 
(n = 1-2, * p 0.01-0.05; ** p 0.001-0.01; *** p 0.0001-0.001; **** p > 0.00001, Mann-
Whitney test). 
6.5.1.2. Ca2+ signals of awake P2Y1R cKO mice were smaller in gliapil and 
soma and overall shorter  
Animals were treated and prepared for 2P-LSM as described before. Imaging sessions 
were performed 4, 8, 10 and 11 dpw. Before the first imaging session animals were 
habituated to the experimentator and the setup (Fig 8 and Fig. 36 A). 
Signal strength of the gliapil was weaker in small (1 SD) and large (3 SD) Ca2+ signals 
and not changed in medium sized (2 SD) signals of cKO. The signal duration was not 
changed in small signals but medium sized and large signals were shortened in P2Y1 
cKO animal (Fig. 36 B). Compared to anesthetized mice, signal amplitudes of controls 
and cKO were generally stronger in awake mice, while signal duration was shorter or 
unaltered (Appendix Fig. 45). Somatic medium sized (2 SD) and large (3 SD) signals 
were again smaller in the cKO compared to controls, while amplitudes of small signals 
did not change. The length of small Ca2+ signals was not changed between control and 
cKO mice, while the medium sized and large signals were shorter (Fig. 36 C). 
Comparison to anesthetized mice revealed stronger somatic signals in awake mice, 
while their signal duration was not changed (Appendix Fig 45). Signal composition of 
gliapil and soma revealed for controls the highest percentage of small signals 
(52 %/ 57 %) followed by medium sized (26 %/ 24 %) and large (22 %/ 19 %) signals. 
Small, medium sized and large signals (32 %/ 35 %, 29 %/ 30 % and 39 %/ 35 %, 
respectively) were equally distributed in cKO mice (Fig. 36 D). In awake mice, the 
signal composition changed in gliapil and soma of cKO, revealing a higher proportion of 
large signals and therefore less small signals, while under anesthetized conditions the 








Figure 36. Smaller and shorter Ca2+ signals of awake P2Y1R cKO mice in 
gliapil and soma 
(A) Animals were injected at an age of four weeks for five consecutive days with TAM. 
Cranial window surgery was performend between 16-20 weeks and imaging sessions 
were performed 4, 8, 10 and 11 dpw. (B) Small and large signals of the gliapil were 
smaller in cKOs, whereas medium sized signals were not changed. Medium sized and 
large signals were shorter in cKO mice, while signal duration of small signals was not 
changed. (C) Somatic signals of medium sized and large signals were smaller in cKOs, 
but no changes occurred in small signals. The cKO had shorter medium sized and 
large signals, but no changes in small signals. (D) Signal composition of the cKO 
revealed a similar distribution of small, medium sized and large signals for gliapil and 
soma, while in con mice more small signals were found followed by medium sized and 
large signals. The error bars correlate to the median ± interquartile range of the 
biological replicates (n = 1-2, * p 0.01-0.05; ** p 0.001-0.01; *** p 0.0001-0.001; 
**** p > 0.00001, Mann-Whitney test). 
6.5.1.3. Stimulation of purinergic receptors by ATP application led to higher 
signal amplitudes under control conditions 
A control mouse (wt for P2Y1R) was injected at an age of four weeks with TAM for five 
consecutive days. Cranial window surgery was performed at an age of 16 w and the 
animal was imaged with and without ATP application 22 d after the surgery. The animal 
was anesthetized with 2 % isoflurane during imaging sessions (Fig. 37 A). 
After ATP application to the brain of the control animal, Ca2+ signals of all classes in the 
gliapil were larger. All classified signal amplitudes increased after ATP application 
about four to five times, while signal durations were shorter (1.5 x to 2.4 x times) 
(Fig. 37 B). 
Somatic signals were increased (about 2.4 x to 4.5 x) in all classes of Ca2+ signals upon 
ATP treatment. Duration of small and medium sized signals remained unaltered, while 
large signals were shorter (Fig. 37 C). 
The signal composition of the gliapil revealed before ATP application similar distribution 
of small, medium sized and large signals as anesthetized control animals (Fig. 35 D). 
After ATP treatment the percentage of large (20 %) signals increased, while the 
percentage of small signals decreased (49 %). Highest percentage of small signals 
was found in the soma with or without ATP, but medium sized and large signals 
increased after ATP application (Fig. 37 D).  
Here, we demonstrated the influence of a non-selective P2Y1R agonist on Ca2+ signals 
in a control mouse, revealing stronger but shorter signals. The opposite effect was 
observed for Ca2+ signals of a cKO mouse without ATP stimulation, revealing smaller 








Figure 37. Stronger and shorter Ca2+ signals in gliapil and soma  
(A) Animals were injected at an age of four weeks for five consecutive days with TAM 
and cranial window surgery was done at an age of 16 w. Imaging sessions were 
performed 22 dpw with or without ATP application. (B) Signal amplitudes of the gliapil 
were increased after ATP application in all classified Ca2+ signals, while duration was 
shortened. (C) Somatic signal amplitudes were stronger after ATP application in all 
groups of Ca2+ signals. Large signals were shortened, while small and medium sized 
signals remained unaltered. (D) Signal composition of the gliapil revealed a higher 
percentage of large signals after ATP application. In the soma medium sized and large 
signals increased after ATP application. The error bars correlate to the 
median ± interquartile range of the biological replicates (n = 1, * p 0.01-0.05; 





Main results of this thesis: 
1. Identification of an optimal tamoxifen injection protocol to induce maximal 
gene recombination. 
2. Tamoxifen-independent recombination of the GLAST-CreERT2 driver line does 
not affect cortical target genes. 
3. Profound changes of Ca2+ signaling in P2Y1R cKO in vivo. 
4. High P2Y1R expression on astrocytes revealed by mRNA expression data. 
5. Under pathological conditions no effect of P2Y1R ablation. 
7.1. Tamoxifen-induced recombination  
For efficient genomic DNA recombination protocols in the brain, a precise knowledge of 
the bioavailability of tamoxifen (TAM) and its metabolites is fundamental. Here, the 
GLAST-CreERT2 knockin mouse line was used for optimization of induction protocols for 
DNA recombination. The bioavailability of TAM and its metabolites in brain and serum 
by liquid chromatography-high resolution-mass spectrometry (LC-HR-MS/MS) was 
analyzed and compared to the recombination efficiencies of gene loci in different brain 
regions after various TAM injection protocols. The main goal was to establish a TAM 
protocol with the best recombination efficiency using the lowest TAM concentration to 
reduce side effects. In addition, the CreERT2/loxP system was used to determine the 
proportion of astroglia in various brain regions (Fig. 38).  
7.1.1. Pharmacokinetic profile of tamoxifen and its metabolites revealed 
fast accumulation and clearance of all metabolites in the brain 
TAM and 4-OH-TAM showed peak values already 8 hpi after a single injection, while 
the other metabolites NMD-TAM and END peaked at 24 hpi (Jahn, Kasakow et al., 
2018). All four compounds were cleared within 7 dpi (Fig 38 B), similar to a recent 
study, where different doses of TAM (up to 400 mg/kg body weight within 24 h) were 
compared (Valny et al., 2016). Within the first 40 h all four substances were reduced by 
half after a single dose of TAM. 4-OH-TAM concentrations were quite high after a 
single injection (4.4 µg/g brain weight at 8 hpi), while others (Valny et al., 2016) 
observed after two injections only 2.1 µg/g at 6 hpi. After three consecutive injections, 




our standard TAM concentration for injections of 100 mg/kg revealed a low mortality 
rate of 3.7 % in adult mice (older than 21 days, n = 4.080). The general mortality rate of 
our animal facility over the last five years was not significantly lower (3.4 %; 
n = 25.731). Hence, the here used TAM protocol does not increase the mortality rate of 
injected animals. 
The minimal effective concentration of 4-OH-TAM has been determined at 38 ± 22 ng/g 
(Valny et al., 2016). This value is slightly lower than the concentration we detected in 
the brain at seven days when TAM was injected for three consecutive days (58.4 ng/g, 
7 dpi). Long presence of 4-OH-TAM is important for genetic experiments in which 
extended gene excision is required. Recent studies revealed END as another TAM 
metabolite with high affinity to estrogen receptors (Ahmad et al., 2010). END and 4-
OH-TAM have a 100 times stronger affinity to estrogen receptors compared to TAM 
(Katzenellenbogen et al., 1984, Robertson et al., 1982). Regarding CreERT2-driven 
recombination END has a similar induction capacity as 4-OH-TAM (Felker et al., 2016, 
Benedykcinska et al., 2016). END is higher in serum and brain compared to 4-OH-TAM 
48 hpi (single) or 7 dpi (three injections), showing either a slower excretion for END or 
a prolonged generation from TAM in line with published data (Valny et al., 2016). 
Therefore, it is conceivable that late recombination is not only due to 4-OH-TAM, still 
present in the brain, but also to slow accumulation of END. 
In summary, our tamoxifen study revealed that upon application the metabolization to 
4-OH-TAM in the liver by diverse cytochrome P450 isoenzymes (CYPs) takes place 
within 8 h (Fig. 38 A, B). The other effective TAM metabolite endoxifen showed a 
delayed peak after 24 h. In the brain mainly 4-OH-TAM induces the translocation of 
CreERT2 into the nucleus to mediate recombination. All metabolites were cleared from 
the brain within 7 d, although the largest amount was already gone during the first 48 h 






Figure 38. Overview and conclusion of the tamoxifen study 
(A) TAM is metabolized in the liver to 4-OH-TAM and END. 4-OH-TAM induces DNA 
recombination in the brain. (B) Upon TAM application it took 8 h for the TAM and its 
active metabolite 4-OH-TAM to reach maximal level in the brain. Within 48 h the 
concentration of TAM and 4-OH-TAM decreased and was cleared from the brain after 
7 d. (C) TAM protocols for p2ry1 and gria1 revealed differences for the two floxed 
alleles and the investigated brain region. (D) Quantitative analysis of two floxed alleles 
revealed the total amount of recombined astrocytes in different brain regions with: 
20 % in cortex, 6 % in cerebellum, 27 % in hippocampus, 17 % in brainstem and 29 % 
in the optic nerve. 
7.1.2. TAM injections for three or five consecutive days revealed highest 
recombination efficiencies dependent on brain region and floxed 
allele 
DNA recombination efficiency of different floxed alleles (p2ry1, gria1) was analyzed by 
qRT-PCR. Three to five days of consecutive injections of TAM (100 mg/kg) induced 
maximal recombination, while fewer injections (once or twice) were less efficient (Jahn, 




injections (three injections with a pause of 48 h in between) since TAM and 4-OH-TAM 
were eliminated too quickly as observed by the LC-HR-MS/MS data. Application of 
TAM every eight hours for three consecutive injections revealed profound differences in 
recombination efficiencies for p2ry1 and gria1. We expected, due to the application of 
TAM at the concentration peak, higher recombination efficiencies. Recombination of 
p2ry1 alleles was comparable to the five times injection protocol or even higher, while 
gria1 alleles were poorly recombined. These findings indicate different accessabilities 
of the gene loci for recombination during the injection period of 24 h. Gria1 undergoes 
diurnal rhythms of expression (6 am and 6 pm) (Parekh et al., 2017). For the eight 
hours interval protocol, mice were injected at 6 am, 2 pm and 10 pm, leading to less 
efficient TAM doses during ideal gene accessability. In conclusion, circadian rhythms of 
respective genes play an important role in gene accessability.  
Kinetic differences in gene recombination based on different brain regions and/or 
floxed alleles were compensated after 21 days with at least three injections, but not 
after a single or two injections. Differences in recombination kinetics between (1) gria1 
and p2ry1 and (2) the different brain regions (ctx vs. cb) could be caused by different 
chromatin structures, leading to less accessible gria1 locus for CreERT2 than p2ry1. 
Local chromatin structure and consequently, the potential for gene expression, are 
regulated by a number of post-translational, covalent modifications of histone-amino 
terminals, like methylation or acetylation (Takizawa & Meshorer, 2008, Namihira et al., 
2008, Imamura et al., 2014). Within euchromatin structures the degree of condensation 
or DNA accessibility varies depending on gene activity (Allen, 2008). Different DNA 
modifications of p2ry1 and gria1, in combination with structural changes dependent on 
the circadian rhythms, but also between ctx and cb, could lead to the observed different 
recombination efficiencies. Therefore, for each new allele-of-interest a thorough DNA 
recombination analysis should be performed to reach maximal recombination. 
Taken together, recombination efficiency after different TAM injection protocols is 
highly dependent on the floxed loci and the time point of analysis after the injection. 
Also the investigated brain region has to be taken into account. For the p2ry1 gene five 
injections and 21 dpi led to maximal recombination in the cerebellum whereas three 
injections were sufficient for the cortex. For the gria1 gene the contrary is the case: 





7.1.3. GLAST-CreERT2-driven recombination to determine the percentage 
of astrocytes in different brain regions 
Exact numbers and proportions of different glial cell types (astrocytes, 
oligodendrocytes and microglia etc.) in various brain regions are missing in the 
literature. Therefore, we quantified the number of astrocytes in the murine brain based 
on DNA recombination. The loss of floxed alleles was taken as a measurement for 
astrocytes (GLAST+ cells) in a given brain region. Data revealed that in brainstem 
17 %, in cerebellum 6 %, in cortex 20 %, in hippocampus 27 % and in optic nerve 29 % 
of all cells account for astrocytes (Fig. 38 D). In line with these data, cell counting of 
tdTomato+ cells resulted in 21 % astrocytes in the cortex (Jahn, Kasakow et al., 2018). 
Similar to our data, counting of S100B+ cells in rat cortex revealed 18.5 % astrocytes 
(Ren et al., 1992). We regarded GLAST+ cells as astrocytes and neglected different 
patterns of GLAST expression in astrocytic subpopulations or expression in neurogenic 
radial glia (Jahn et al., 2015). The advantage of this cell quantification approach is the 
possible use of simple homogenates to estimate the total amount of astrocytes 
obtained from defined brain regions.  
7.2. Tamoxifen-independent recombination had no effect on 
floxed receptor alleles in the cortex 
Non-induced recombination was mainly present in GLAST-CreERT2 expressing mice, 
while in GFAP-CreERT2, PLP-CreERT2 and NG2-CreERT2 mice almost no tamoxifen-
independent recombination was observed. In addition, the impact of unintendend 
recombination seemed to be higly dependent on the chosen floxed loci.  
Orbit image analysis of whole sagittal slices of the GLAST-CreERT2 mouse line 
crossbred to the GCaMP3 or tdTomato reporter revealed highest non-induced 
expression in GCaMP3 reporter mice.  
GFAP-CreERT2 induced tamoxifen-independent recombination was lower but detectable 
for both tested reporter lines. The low non-induced reporter expression of GFAP-
CreERT2 mice indicates that tamoxifen-independent recombination is not an astrocyte-
driver dependent phenomenon. GFAP-CreERT2 mice were, in contrast to GLAST-
CreERT2 mice, generated via non-homologous recombination. To evaluate, if non-
induced recombination is influenced by the type of gene insertion (homologous vs. non-




CreERT2) and TgH (NG2-CreERT2). Both mouse lines revealed less reporter expression 
than GLAST-CreERT2 mice (Appendix Fig. 41).  
Taken together, non-induced recombination is not caused by astrocyte-specific CreERT2 
driver lines, because GFAP-CreERT2 mice remained unaffected. Influence of mouse 
generation strategy via homologous or non-homologous recombination could also be 
excluded, because NG2-CreERT2 mice were not recombined without TAM. All these 
data indicate that tamoxifen-independent recombination is mainly dependent on 
GLAST-CreERT2 driven recombination in combination with the reporter GCaMP3.  
Protein data were confirmed by non-induced recombination of GCaMP3 at the DNA 
level. Therefore, the GLAST-CreERT2, GFAP-CreERT2 and NG2-CreERT2 mouse lines 
were analyzed for non-induced recombination of floxed reporter alleles (Fig. 24 C, D 
and Appendix Fig 41 E). Data revealed highest tamoxifen-independent recombination 
of floxed alleles in the cerebellum of GLAST-CreERT2 mice, with almost the same 
recombination efficiency as the tamoxifen-induced positive control. In contrast, GFAP- 
and NG2-CreERT2 driven recombination was mainly absent. DNA recombination data 
substantiate the results at the protein level and demonstrate a brain region dependent 
recombination with higher cerebellar non-induced recombination due to higher GLAST 
expression in Bergmann glia cells compared to GFAP (based on NGS, Data not 
shown). 
Non-induced GLAST-CreERT2 activity was additionally evaluated for the target genes 
p2ry1 and gria1 in comparison to reporter recombination. Heterozygous and 
homozygous GLAST-CreERT2 mice revealed the expected high recombination of 
gcamp3 alleles, while p2ry1 and gria1 alleles were less recombined. qRT-PCR data 
also revealed significant differences between cortex and cerebellum, as already seen 
in IHC data of sagittal slices. Cerebellar non-induced recombination at the p2ry1 locus 
of heterozygous mice was similar to cortical recombination, while in homozygous mice 
a four times higher recombination could be detected. Still, compared to the tamoxifen-
induced positive control, recombination rate of homozygous mice at the p2ry1 locus 
was very low. Recombination of the gria1 locus was low in both brain regions and could 
be neglected, while cerebellar recombination of gcamp3 alleles was higher in 
heterozygous and homozygous mice compared to the negative control.  
In general, homozygously CreERT2 expressing mice revealed always higher non-induced 
recombination than heterozygous mice independent of the floxed locus with the highest 




One explanation for high reporter expression could be the length of the floxed region 
(Fig. 39). We compared the number of base pairs in between loxP sites of the p2ry1, 
gria1, gcamp3 and tdtomato locus and an increasing length of floxed base pairs 
resulted in lower tamoxifen-independent recombination. Floxed regions of the reporter 
alleles include less base pairs than floxed p2ry1 and gria1 alleles. Although the largest 
floxed region was found for the p2ry1 locus, gria1 was even less recombined without 
TAM application. These findings are in line with the tamoxifen-induced recombination 
data, revealing a less accessible gene structure at the gria1 locus due to circadian 
rhythms. Our data indicate that not only accessible DNA structure, but also the length 
of the floxed sequence influence recombination efficiency. Increase of non-induced 
recombination with shortening of floxed sequence length, was also observed by others 
(oral discussion with Amit Agarwal, Institute for Anatomy and Cell Biology, Heidelberg 
University). In general, it is crucial to evaluate the correlation between length of the 
floxed loci and the extent of unintended recombination with other floxed alleles.  
 
Figure 39. Length of floxed sequence influences tamoxifen-independent 
recombination 
The length of floxed alleles differs between receptor knockouts and reporter mice. 
Floxed exon 1 of the p2ry1 gene reveals an excision product of 1641 bp. For gria1 
exon 11 is flanked by loxP sites and led to an excision product of 1318 bp. The floxed 
STOP cassettes of the reporter lines tdTomato (836 bp) and GCaMP3 (760 bp) differ 
from each other only by 76 bp. The length of the floxed allele can be associated with 
the degree of non-induced recombination. 
The glutamate aspartate transporter (GLAST) is highly expressed by astrocytes 
(Anderson & Swanson, 2000). As described before, our NGS data revealed high a 
expression level of GLAST mRNA in astrocytes, thus also CreERT2 is highly expressed 
in GLAST-CreERT2 mice. This could lead to cytosolic unbound CreERT2 molecules, due to 
an imbalance of CreERT2 and HSP90 molecules. Higher non-induced cerebellar 




this region (Mori et al., 2006; NGS data). In NG2-CreERT2 mice, no tamoxifen-
independent recombination was detected. NG2 is only weak expressed in adult OPCs 
(Niehaus et al., 1999), leading to low CreERT2 expression. In the healthy cortex, GFAP 
expression is also very limited (Middeldorp & Hol, 2011), therefore no tamoxifen-
independent recombination in GFAP-CreERT2 mice can be detected, due to less hGFAP 
promoter controlled CreERT2 expression (Hirrlinger et al., 2006).  
We investigated the effect of GFAP upregulation under pathological conditions (SWI or 
cuprizone model) and observed tamoxifen-independent recombination. Under 
physiological conditions GFAP-CreERT2 mice without TAM did not recombine. However, 
after SWI or cuprizone treatment, recombined astrocytes could be observed in GFAP-
CreERT2 mice. GFAP is highly upregulated in activated astrocytes (Sofroniew & Vinters, 
2010), leading to an upregulation of CreERT2. Overexpression of CreERT2 causes an 
imbalance between HSP90 and CreERT2, resulting in unbound CreERT2 molecules 
translocating into the nucleus and causing non-induced recombination.  
Inducible Cre DNA recombinases (CreER/CreERT) can cause recombination in absence 
of TAM in diverse tested target and reporter mouse lines with different manifestation 
(Liu et al., 2010, Vooijs et al., 2001). Tamoxifen-independent recombination was 
observed in three different reporter/target mice, analyzed by IHC of cryosections or 
western blot. A correlation between promoter activity and extent of ligand-independent 
recombination was observed. They concluded that due to backcrossing of the mouse 
line the randomly inserted transgene expression was enhanced, leading to higher 
independent recombination. Lower non-induced recombination (e.g. in reporter line) 
was explained by the insertion into a region with less accessible chomatin structure. 
Taken together, mouse lines with overall lower recombination efficiency also show less 
tamoxifen-independent recombination (Liu et al., 2010). We could confirm these 
findings by higher induced and independent recombination of p2ry1 alleles compared 
to gria1. In addition, tamoxifen-independent recombination is highly variable in different 
mouse lines and tissues (Vooijs et al., 2001). CreERT2 is known to have a low non-
induced Cre activity (Zhong et al., 2015). Here, we report tamoxifen-independent 
recombination in CreERT2 mice in dependence of the locus activity controlling CreERT2 
expression.  
Therefore, each new floxed mouse line has to be investigated in combination with the 
respective CreERT2 driver line to estimate the percentage of tamoxifen-independent 




are unaffected, while for the cerebellum it is important to observe CreERT2 activity at the 
chosen floxed loci. 
7.3. P2Y1 receptor ablation and its impact on astrocytes 
As described previously, highest recombination efficiency of the p2ry1 locus was 
achieved by three to five TAM injections dependent on the brain region. Recombination 
efficiency was even increased after an interval injection protocol every eight hours, 
indicating a favourable accessability of the locus during injection period. In addition, the 
locus mainly remained unaffected from tamoxifen-independent recombination. mRNA 
expression data of total homogenates revealed 50 % to 60 % p2ry1 mRNA expression 
by astrocytes in cerebellum and cortex, indicating an important role of the receptor for 
physiological astrocyte function.  
P2Y1R ablation was further analyzed on sorted astrocytic populations of cortex and 
cerebellum, revealing a reduction of 60 % and 30 % at the DNA level, respectively. It 
was expected to achieve a total reduction in cKOs compared to controls in purified 
astrocytes. Based on our mRNA data of total homogenates, which revealed a high 
expression of p2ry1 mRNA in cortex and cerebellum, we expected a higher reduction in 
the pure astrocytic population of cKOs. The percentage of non-recombined alleles 
indicates that not all astrocytes are recombined. Heterogeneity among astrocytic 
populations is well known. Therefore, epigenetic modifications (DNA-methylation) of a 
certain percentage of astrocytes at the p2ry1 locus could explain the incomplete 
receptor ablation.  
Contamination of the astrocytic population with other cell types was evaluated by 
mRNA expression of typical cell markers of microglia, neurons, NG2 glia and 
oligodendrocytes. We found in MACS isolated astrocytes, analyzed by either qRT-PCR 
or next generation sequencing (NGS), only low expression of other cell type markers. 
Additionally tested astrocytic markers (Glt1, Aldh1l1, GLAST, GS and Aqp4) were 
highly enriched in the astrocytic population. P2ry1 mRNA is highly expressed by 
neurons and OPCs (Zhang et al., 2014), low contamination with these cell types could 
therefore increase the amount of non-recombined p2ry1 alleles. Astrocytic 
heterogeneity is well known and is also displayed by different expression profiles of 
astrocytic populations for other markers like GFAP (Sofroniew & Vinters, 2010). The 
isolation of astrocytes was executed with the Miltenyi ACSA-2 micro bead kit (astrocyte 




(ATPase transporting subunit beta 2), ubiquitously expressed by cortical and cerebellar 
astrocytes during adulthood (Batiuk et al., 2017). ACSA-2 is a reliable antibody to purify 
astrocytes (Feldmann et al., 2014), but mRNA sequencing data have shown that 
ATP1B2 is also highly expressed by neurons and OPCs (Zhang et al., 2014). These 
findings are well in line with our data after MACS procedure and display the limitations 
of the system to purify astrocytes. 
Next generation sequencing (NGS) analysis of P2Y1R cKO mice confirmed data of the 
DNA recombination and mRNA expression in total homogenates and MACS isolated 
astrocytes. In line with previous results, a reduction of about 50 % in the cKO was 
achieved. Most metabotropic P2Y and ionotropic P2X receptors were not altered. Only 
the ionotropic P2X6R was upregutated, indicating a compensational mechanism in 
cKO mice. P2rx6 mRNA is highly expressed by astrocytes compared to other cell 
types, leading to Ca2+ and Na+ influx upon ATP binding (Zhang et al., 2014). Analysis of 
astrocytic markers, like GFAP or Glt1, revealed no changes in mRNA expression in 
cKOs. Molecules of the downstream signaling cascade (PLA, PLC) of P2Y1 receptors 
were not altered. Volcano plot analysis revealed several differential expressed genes in 
cKOs. Up- and downregulated genes will help to further characterize changes at the 
molecular level after P2Y1R ablation.  
 
Astrocytic P2Y1 receptors play an important role for the generation of Ca2+ signals. 
Overexpression of the receptor led to larger Ca2+ signals upon ligand application 
(Shigetomi et al., 2018). P2Y1R are also involved under pathological conditions like 
ischemia. Inhibition of the receptor led to a reduction in infact volume (Kuboyama et al., 
2011). Invasive injury models, like SWI, differ from non-invasive models, like ischemia, 
mainly in their proliferative cell responses, whereas hypertrophy and GFAP-
upregulation of astrocytes are comparable (Sirko et al., 2013). The release of 
glutamate or proinflammatory cytokines (IL-6) and modulation of transcription are well 
known functions (Sun et al., 2008, Fujita et al., 2009) of astrocytic P2Y1R. Taken 
together P2Y1R participate in various ways in physiological and pathological 
mechanisms of astrocytes.  
The role of P2Y1R under pathological conditions is controversly discussed in the 
literature, reaching from beneficial to aggravating effects. Upon traumatic brain injury 
the first cells that become activated are microglia. ATP released from injured cells is 




like TNF-α, IL-1β and IL-6 that induce and regulate the activation of astrocytes and 
therefore trigger astrogliosis. Microglial cells are also responsible for the 
downregulation of P2Y1R expression in astrocytes. This downregulation has many 
positive effects like facilitation of scar formation, reduction of reactive oxygen species 
(ROS) production and release, suppression of leukocyte infiltration and repair of the 
blood brain barrier (BBB). All these effects are beneficial for neuronal survival 
(Shinozaki et al., 2017, Safiulina et al., 2006). It was also reported that acute injury 
stimulates P2Y1R that directly participate in glutamate-mediated excitotoxicity. Non-
selective P2 receptor antagonists reduce the size of the lesion and decrease neuronal 
and astrocytic cell death (Lämmer et al., 2011).  
The stimulation of P2Y1R on astrocytes leads to a reduction of cytotoxic endema, 
necrosis and neuronal cell death after Rose Bengal induced lesions. Activation of 
astrocytic P2Y1R stimulates the mitochondrial metabolism which leads to an increase 
in ATP production (Zheng et al., 2010). The neuroprotective effect of ATP production 
after P2Y1R activation on astrocytes was also shown after stimulation with the specific 
agonist 2MeSADP that induces the release of the neuroprotective molecule IL-6 (Fujita 
et al., 2009). In Alzheimer´s disease, astroglial hyperactivity is mainly mediated by 
P2Y1R activity. This effect could be weakened by the non-selective purinergic 
antagonist PPADS (Pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid tetrasodium 
salt) as well as by blocking of intracellular Ins-P3 receptors. In contrast, an increase in 
ADP concentration led to an enhancement of astrocytic hyperactivity. Highest P2Y1R 
expression is present in reactive astrocytes surrounding plaques. These are also the 
areas of astrocytic hyperactivity (Delekate et al., 2014).  
Here, we performed SWI experiments on GLAST-CreERT2 x P2Y1 fl/fl x Rosa26-
tdTomato/ or GCaMP3 mice to investigate the role of P2Y1R ablation on astrocytes 
under an acute injury model. Reporter expression (tdTomato or GCaMP3), α-GFAP 
and α-Iba1 stainings were analyzed for changes in fluorescence intensities at the 
lesion site. Ipsilaterally and contralaterally, no differences in GFAP or Iba1 
fluorescence intensities of cKO and control mice with tdTomato expression were 
detected. Here, we could not detect any influence of P2Y1R ablation on lesion size or 
on cell types responsible for glial scar formation. In contrast to other publications, 





The same injury model applied to cKOs with Rosa26-GCaMP3 as reporter revealed 
changes in GFAP and Iba1 expression between cKO and control on the ipsilateral side. 
GFAP expression of the cKO was upregulated, while Iba1 expression was 
downregulated. Higher GFAP and GCaMP3 expression was detected on the 
contralateral side of the cKO. It was shown that GCaMP3 influences gating and 
signaling of voltage-gated Ca2+ channels, changes transcription signaling, cell 
morphogenesis and the global physiology of cells (Yang et al., 2018). Astrocytes seem 
to be more vulnerable to stress induced by SWI when GCaMP3 is expressed, as a 
result to lower concentrations of intracellular Ca2+. These reactive astrocytes may also 
act on microglia, leading to a reduction of these cells at the lesion site. The Ca2+ 
dependent release of gliotransmitters by astrocytes under pathological conditions, 
needs the collaboration of activated microglia, reactive astrocytes and inflammatory 
molecules, released by both cell types (Agulhon et al., 2012). Astrocytic Ca2+ waves 
and the release of ATP pass the information of an occurred injury to healthy brain 
regions. This leads to the activation of microglial purinergic receptors and the release 
of cytokines, influencing the Ca2+ wave (Schipke et al., 2002). In P2Y1R cKO mice, less 
activated microglia were found due to disturbed purinergic signaling.  
In summary, these concerted signaling pathways are highly dependent on intracellular 
astrocytic Ca2+ levels and intact purinergic signaling, therefore the combination of low 
intracellular Ca2+ levels and the loss of P2Y1R could disturb the communication of 
astrocytes with micoglia after brain injury.  
7.4. Ca2+ signaling of astrocytes in vivo  
Ca2+ changes in P2Y1 receptor cKO and control mice were investigated by 2P-LSM. 
Mice were imaged anesthetized, awake or under influence of exogenous applied ATP. 
Profound differences in Ca2+ signaling were found between cKO and control, but also 
between awake and anesthetized conditions. 
7.4.1. Differences in astrocytic Ca2+ signaling after P2Y1 receptor 
ablation in gliapil and soma 
Anesthetized mice revealed smaller Ca2+ signals in P2Y1 cKO mice in all classes of 
Ca2+ signals in the gliapil. Duration of small and medium sized Ca2+ signals was 




were smaller in all signal classes. In contrast, duration was only shortened in large Ca2+ 
signals, while small and medium sized signals were not changed.  
In awake mice similar results were found, revealing smaller and shorter Ca2+ signals in 
gliapil and soma of the cKO. Comparison of anesthetized and awake animals revealed 
a high influence of isoflurane on amplitude size of Ca2+ signals in gliapil and soma 
(Thrane et al., 2012). Signal amplitudes of awake mice were higher in all classes of 
Ca2+ signals in gliapil and soma, while duration was shortened or remained unchanged 
(see Fig. 45, Appendix). The signal composition remained unaffected in anesthetized 
control and cKO mice in gliapil and soma, with the highest percentage of small signals 
followed by medium sized and large signals. Under awake conditions the signal 
composition changed in cKO animals in gliapil and soma, revealing a higher 
percentage of large signals than small and medium sized signals. Control animals 
displayed the same signal composition as under anesthetized condition. These findings 
are well in line with published data. Under anesthesia, Ca2+ signals were completely 
different compared to signals of awake mice. Types of Ca2+ signals like bursts and 
flares were abolished and also smaller signals like sparkles were significantly reduced 
as shown before (Nimmerjahn et al., 2009). It was also reported that anesthesia 
reduces astrocytic network activity, Ca2+ transients, spontaneous Ca2+ signals and Ca2+ 
responses to external stimuli or agonist application (Thrane et al., 2012). Therefore, the 
switch to larger Ca2+ signals in awake mice is reflecting the increased network activity 
in non-anesthetized mice.  
Shortening of signal duration in anesthetized and awake cKOs can be explained by 
missing metabotropic signaling of P2Y1R on astrocytes. Metabotropic signaling 
induces a second messenger cascade which then leads to the release of Ca2+ from the 
endoplasmic reticulum (ER), being more slowly than ionotropic signaling (Burnstock, 
2014). The effect of P2Y1R ablation was expected to be more pronounced, but based 
on our mRNA data P2Y1R is not completely abolished. It seems probable that a 
number of astrocytes still expressed p2ry1 mRNA. 
Additionally, the influence of the ligand ATP on a P2Y1R control mouse was 
investigated. Application of the ligand to anesthetized mice induced an increase in 
amplitude size in all classes of Ca2+ signals in gliapil and soma. Duration was 
shortened upon ATP treatment in small, medium sized and large signals of the gliapil, 
while in the soma only large signals were shorter. ATP is a non-specific ligand for P2Y 




astrocytes via P2 receptors to release ATP that initiates and propagates astroglial Ca2+ 
signals either to activate neighboring astrocytes or to influence synaptic transmission 
(Abbracchio et al., 2009). Therefore, an increase in Ca2+ signal strength was expected 
upon ATP application. 
In summary, our data revealed differences in Ca2+ signals of anesthetized and awake 
animals as well as between controls and P2Y1R cKOs. We could demonstrate the 






In this study we demonstated the astrocyte specific deletion of the purinergic receptor 
P2Y1 at the molecular level. At the DNA level, the loss of floxed p2ry1 alleles was 
shown in total tissue homogenates and after purification of astrocytes via MACS. A 
profound amount of sorted cells still expressed p2ry1 DNA after tamoxifen-induced 
recombination, therefore we will further optimize the sorting procedure to exclude 
contamination with other p2ry1 expressing cells. In addition, the amount of non-
recombined astrocytes has to be evaluated.  
The mRNA expression profile of P2Y1R cKO and control mice was investigated in the 
cortex by next generation sequencing (NGS). We observed changes in expression 
patterns of astrocytic receptors (p2ry1, p2rx6) in cKO mice but no alterations in the 
downstream signaling. NGS data will be used to perform pathway enrichment analysis 
of P2Y1R cKOs. In addition, the same comparison of cKO and control will be done for 
the cerebellum. It will be also possible to elucidate expression differences of cortical 
and cerebellar astrocytes. 
We could demonstrate the influence of P2Y1R ablation also in vivo by changed Ca2+ 
signals. We will extend the characterization of these signals by applying diverse P2Y1R 
agonists and antagonists to cKO and control mice.  
Our data demonstrate that each mouse line has to be evaluated for its recombination 
efficiency and sensitivity to non-induced recombination. To verify, if an increased 
number of CreERT2 molecules is the reason for tamoxifen-independent recombination in 
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10. APPENDIX ǀ 
10.1. No tamoxifen-independent recombination of non-astrocytic 
CreERT2 driver lines 
Next to the astrocyte-specific CreERT2 driver lines we investigated the PLP-CreERT2 
mouse line, as a non-homologous recombined transgenic line, specific for 
oligodendroglial recombination, and the NG2-CreERT2 knockin mouse line that 
recombines oligodendrocyte precursor cells (OPCs; NG2 glia). Non-induced tdTomato 
(α-DsRed) or GCaMP3 (α-GFP) expression were quantified by Orbit image analysis.  
The PLP-CreERT2 line had less recombined cells compared to GLAST-CreERT2, but more 
than NG2-CreERT2 mice, where almost no tamoxifen-independent recombination was 
detected. Only a few cells were recombined in the homozygous condition (1.3 %). The 
PLP-CreERT2 mouse line showed less than 3 % reporter expression of heterozygous 
non-injected animals compared to the negative control (2.7 % to 0.4 %, respectively) 
(Fig. 40 C, D).  
Tamoxifen-independent recombination at the DNA level was determined for cortex and 
cerebellum of the NG2-CreERT2 line by quantification of recombined gcamp3 alleles 
(Fig. 40 E). Highest recombination efficiency for gcamp3 alleles was found in the 
positive control, while negative control, heterozygous and homozygous animals 
remained unaffected for both brain regions. 
Figure 40. Negligible tamoxifen-independent recombination of the PLP- and 
NG2-CreERT2 driver line 
(A) Animals were injected with TAM at an age of four weeks for three consecutive days 
and analyzed 21 dpi (positive control). (B) PLP-CreERT2 and NG2-CreERT2 driver lines 
were either crossbred to the reporter line tdTomato or GCaMP3, respectively. (C) PLP-
CreERT2 line revealed highest tdTomato (α-DsRed) expression in the positive control, 
while no expression could be found for the negative control. Heterozygous animals 
revealed less than 2.7 % reporter expression. (D) NG2-CreERT2 line revealed highest 
reporter expression in the positive control, while negative control, heterozygous and 
homozygous animals were mainly unaffected. (E) DNA recombination of the gcamp3 
locus was determined for cortex and cerebellum of the NG2-CreERT2 line. Highest 
recombination efficiency for gcamp3 alleles was found in the positive control, while 
negative control, heterozygous and homozygous animals remained unaffected. (C, D) 
The error bars correlate to the median ± interquartile range of the biological replicates 
(n = 3, * p 0.01-0.05; ** p 0.001-0.01; *** p 0.0001-0.001; **** p > 0.00001, Mann-
Whitney test). (E) Three animals were analyzed per group and ΔCT-values were 
normalized to the mean value of animals which received 3x TAM. The error bars 
correlate to the SD of the biological replicates (n = 3, * p < 0.05, ** p < 0.01, 






10.2. Heatmaps of in vivo Ca2+ imaging 
Heatmaps generated by MSparkles for all in vivo Ca2+ data sets (Fig. 35-37) of gliapil 
and soma. Heatmaps show the magnitude of the signal (y-axis; amplitude or duration) 
over the time (x-axis). Each single imaging session is depicted in an extra heatmap 






























Figure 41. Heatmaps of in vivo Ca2+ data revealed no pattern changes in Ca2+ 
signals 
(A) Heatmaps of Ca2+ data of five times injected animals either anesthetized, awake or 
with ATP treatment. (B-D) Heatmaps were separated for gliapil and soma as well as for 
con and cKOs at different imaging days. All heatmaps indicate the regions of intrest 
(ROIs; left y-axes), timeline (frames) and ∆F/F0. Heatmaps depict radomized Ca2+ 
signals with no obvious pattern.  
10.3. Detailed procedure of Ca2+ imaging analysis using MSparkles 
For clearer understanding of how Ca2+ data were processed for the results part data of 
figure 35 were shown in detail (Fig. 42 and 43). Mice were injected and prepared for 
imaging as described before (Fig. 35). Data are depicted in bar charts with dot plots. 
Each bar represents a single imaging session on one day and every dot represents a 
single Ca2+ signal. Imaging days and investigated animals are indicated beneath x-
axes. Colorcode of bars indicate if animals were P2Y1 controls (grey) or cKOs (red). 
Figures are divided in gliapil (Fig 42) and soma (Fig 43) and in amplitude (Fig. 42 and 
43 A) and duration (Fig. 42 and 43 B) of respective Ca2+ signals. Data are further 
divided in small, medium sized sized and large signals (1 SD, 2 SD and 3 SD), 
respectively. For comparison compressed data (as box plot) of figure 35 are shown on 





Figure 42. Composition of Ca2+ data representing each imaging session, 
animal and Ca2+ signal of the gliapil 
(A) Mice were injected and prepared for imaging as described before. (B) Signal 
amplitudes of the gliapil depiced as bar chart with box plots representing single 
animals at different imaging days and single measured Ca2+ signals (dots). On the right 
side same data are depicted in a compressed version as used in the results part. (C) 
Signal durations of the gliapil depicted as described before (see B). Con animals and 
cKOs were indicated by different colors. All data were further divided in small, medium 





Figure 43. Composition of Ca2+ data representig each animal, imaging session 
and Ca2+ signal of the soma 
(A) Mice were injected and prepared for imaging as described before. (B) Signal 
amplitudes of the soma depiced as bar chart with box plots representing single animals 
at different imaging days and single measured Ca2+ signals (dots). On the right side 
same data are depicted in a compressed version as shown in the results part. (C) 
Somatic signal duration depicted as described before (see B). Con animals and cKOs 
were indicated by different colors. All data were further divided in small, medium sized 




10.4. Comparison of anesthetized and awake Ca2+ signals revealed 
higher signal amplitudes in gliapil and soma 
Comparison of Ca2+ data of anesthetized (Fig 35) and awake (Fig. 36) P2Y1 control 
and cKO mice, injected with TAM for five consecutive days at an age of four weeks. 
Cranial window was performed between 16-20 weeks and mice were imaged at day 3, 
4, 8, 10 and 11 after surgery (Fig. 44 A). Ca2+ signals of the gliapil of anesthetized and 
awake controls and cKOs revealed higher signal amplitudes in all classes of Ca2+ 
signals (1 SD, 2 SD and 3 SD) in awake control and cKO mice. Duration of small 
signals in awake control animals was shortened, while duration of cKOs was unaltered. 
Duration of medium sized signals was shortened in awake controls and cKOs 
compared to anesthetized controls and cKOs. Large signals did not change in duration 
of the controls under anesthetized and awake conditions, but were reduced in cKOs 
under awake condition (Fig. 44 B). Somatic signal amplitudes of small (1 SD) Ca2+ 
signals were higher in awake controls and cKOs compared to the anesthetized 
condition. Amplitudes of medium sized signals were only increased in awake cKOs 
compared to anesthetized cKOs, while amplitudes of large signals were only higher in 
awake controls. Signal duration was not changed in small and large Ca2+ signals of 
anesthetized vs. awake controls and cKOs. Duration of medium sized somatic signals 





Figure 44. Differences of Ca2+ signals in gliapil and soma between 
anesthetized and awake mice 
(A) Mice were injected with TAM at an age of four weeks for five consecutive days. 
Cranial window surgery was performed at an age between 16-20 w and mice were 
imaged at day 3, 4, 8, 10 and 11 after surgery (dpw). Data of anesthetized and awake 
con and cKO mice were compared. (B) Signal amplitudes of the gliapil revealed higher 
amplitudes of all classes of Ca2+ signals under awake condition of con and cKOs. 
Duration of small signals was shortened in con under awake condition. Medium sized 
signals revealed shortened duration of awake con and cKOs, while large signals were 
only shortened in awake cKOs. (C) Somatic signal amplitudes of small signals were 
enlarged in awake con and cKO animals compared to the respective anesthetized 
condition. Amplitudes of medium sized signals were only higher in awake cKO animals, 
while amplitudes of large signals were increased in awake con. Signal duration of small 
and large signals did not change in con and cKOs under both conditions, while 




The error bars correlate to the median ± interquartile range of the biological replicates 
(n = 1-2, * p 0.01-0.05; ** p 0.001-0.01; *** p 0.0001-0.001; **** p > 0, Mann-Whitney 
test). 
10.5. Raw data of in vivo Ca2+ imaging 
All raw data of in vivo Ca2+ imaging are listed in tables 19-21. The number of measured 
Ca2+ signals (n) of gliapil and soma, respective median ± 25 % percentile and 
75 % percentile are listed. 
Table 19. Data of Figure 35 
gliapil amplitude 1 SD con 1 SD cKO 2 SD con 2 SD cKO 3 SD con 3 SD cKO 
n 842 254 408 154 359 116 
25 %ile 0.1155 0.08751 0.2499 0.1253 0.4559 0.2098 
median 0.1779 0.1053 0.2983 0.1491 0.6284 0.296 
75 %ile 0.2305 0.1334 0.3694 0.1919 0.8925 0.6248 
gliapil duration       
n 829 235 417 161 415 146 
25 %ile 6.112 4.85 8.672 5.387 5.343 4.214 
median 7.977 6.804 12.09 7.543 7.084 5.656 
75 %ile 10.99 10.72 16.13 11.64 9.216 11.07 
soma amplitude       
n 92 57 40 27 40 18 
25 %ile 0.2682 0.1165 0.4689 0.1582 0.8679 0.4672 
median 0.4061 0.1355 0.7322 0.1985 1.132 0.7439 
75 %ile 0.5425 0.1741 1.109 0.3517 1.409 1.298 
soma duration       
n 91 57 40 28 39 15 
25 %ile 5.448 5.223 5.621 4.784 4.216 3.547 
median 7.243 6.629 9.054 6.897 6.445 4.79 
75 %ile 10.84 10.29 12.86 12.19 8.015 6.213 
Table 20. Data of Figure 36 
gliapil amplitude 1 SD con 1 SD cKO 2 SD con 2 SD cKO 3 SD con 3 SD cKO 
n 731 176 358 161 311 215 
25 %ile 0,3446 0,3021 0,4329 0,5176 1,133 0,7893 
median 0,4965 0,3858 0,6406 0,6263 1,519 0,9567 
75 %ile 0,666 0,4802 0,8755 0,7858 1,986 1,185 
gliapil duration       
n 720 195 365 165 342 251 




median 6,953 7,84 8,083 7,021 7,234 4,173 
75 %ile 10,57 11,97 11,96 10,17 9,3 6,324 
soma amplitude       
n 91 31 39 27 31 31 
25 %ile 0,3343 0,3512 0,4634 0,4708 1,493 0,6832 
median 0,5793 0,4159 0,7843 0,558 1,893 0,8906 
75 %ile 0,8237 0,5028 1,135 0,6332 2,358 1,027 
soma duration       
n 86 31 39 27 31 34 
25 %ile 4,719 4,583 7,32 3,792 4,732 3,155 
median 7,607 8,152 10,75 6,977 6,357 4,671 
75 %ile 11,17 11,92 15,96 10,48 9,587 5,83 
Table 21. Data of Figure 37 
gliapil amplitude 1 SD -ATP 1 SD +ATP 2 SD -ATP 2 SD +ATP 3 SD -ATP 3 SD +ATP 
n 347 330 189 193 78 106 
25 %ile 0.09941 0.3674 0.1581 0.5731 0.2 0.9709 
median 0.1179 0.4848 0.1869 0.7402 0.2517 1.384 
75 %ile 0.1399 0.6488 0.2308 1.005 0.3154 2.131 
gliapil duration       
n 328 307 184 179 87 135 
25 %ile 6.985 5.589 8.124 6.277 7.062 4.053 
median 13.29 8.638 16.27 8.982 13.13 5.413 
75 %ile 20.04 13.7 29.98 13.18 18.61 7.432 
soma amplitude       
n 40 21 12 11 10 8 
25 %ile 0.1397 0.4743 0.242 0.5346 0.6862 1.937 
median 0.2333 0.5554 0.3979 1.003 0.7346 3.312 
75 %ile 0.3477 0.9088 0.5648 1.154 0.8587 9.184 
soma duration       
n 38 21 12 11 10 9 
25 %ile 5.313 7.321 8.36 8.116 6.684 2.71 
median 9.296 12.97 18.89 10.43 10.37 4.445 




11. APPENDIX ǁ 
11.1. List of Publication 
11.1.1. Publication 
Published: 
Jahn, H. M.#, Kasakow, C. V.#, Helfer, A., Michely, J., Verkhratsky, A., Maurer, H. H., Scheller, 
A. & Kirchhoff, F. 2018. Refined protocols of tamoxifen injection for inducible DNA 
recombination in mouse astroglia. Sci Rep 8:5913. 
 # equal authorship 
 
Publications in preparation 
Kasakow, C.V.#, Stopper, L.#, Caudal, L. C., Linder, S., Stopper, G., Price, A. M., Guo, Q., 
Huang, W., Scheller, A, , Kirchhoff, F. Comparison of tamoxifen-independent genomic 
recombination in various CreERT2 transgenic mice. 
 # equal authorship 
Welle, A., Kasakow C.V., Nordström, K., Salhab, A., Gasparoni G., Scheller, A., Kirchhoff, F., 
Walter J. Epigenetic and transcriptional landscape shape astroglial diversity. 
Kasakow, C.V., Stopper, L., Linder, S., Stopper, G., Scheller, A, Kirchhoff, F.: The role of P2Y1 
receptor ablation for astrocytic Ca2+ signalling in vivo. 
11.1.2. Posters/ Oral presentations 
International Symposia 
Bohn CV, Jahn HM, Schlosser L, Stopper G, Scheller A, Kirchhoff F (2017) Analysis of 
astrocyte-specific P2Y1 receptor gene deletion –gene excision, receptor ablation, Ca2+ 
signaling-. Poster presentation at the XIII European Conference on Glial Cells in Health and 
Disease in Edinburgh, Scotland. 
Bohn CV, (2016) Analysis of purinergic P2Y1 receptor function in cortical astrocytes and 
cerebellar Bergmann glia. Oral presentation at the 12th Göttingen Meeting of the German 
Neuroscience Society in Göttingen, Germany. 
Bohn CV, Jahn HM, Bai X, Scheller A, Kirchhoff F (2016) Impact of the glial P2Y1 receptor 
under pathological conditions. Role of P2Y1 receptors in cortical astrocytes and cerebellar 
Bergmann glia. Poster presentation at the 1st Young Glia Meeting in Tokio, Japan. 
Bohn CV, (2015) Analysis of astrocyte-specific gene recombination in vivo. Oral presentation at 
the DAAD-CAPES workshop in Campinas, Brasil. 
Bohn CV, Jahn HM, Bai X, Scheller A, Kirchhoff F (2015) Analysis of purinergic P2Y1 receptors 
in cortical astrocytes and cerebellar Bergmann glia. Poster presentation at the XII European 
Conference on Glial Cells in Health and Disease in Bilbao, Spain. 
Bohn CV, Jahn HM, Scheller A, Kirchhoff F (2013) Analysis of astrocyte-specific gene 
recombination in vivo. Poster presentation at the XI European Conference on Glial Cells in 






First, I would like to thank Prof. Dr. Frank Kirchhoff for giving me the opportunity to 
complete my PhD in his research group. Thank you for five challenging years full of 
new experiences, interesting projects and intense scientific discussions. Thank you for 
the possibility to travel the world for international meetings and new collaborations.  
I would also like to thank Prof. Dr. Carola Meier for taking over the second referee of 
my PhD thesis.  
My special thank goes to Dr. Anja Scheller for the supervision of my complete scientific 
career, staring with by Bachelor thesis until now. Thank you for your unrestricted 
support, helpful project plans, proofreading of all theses and for your friedship beyond 
the lab work. You always brought light into complicated experimental results. 
I am grateful to Dr. Hannah M. Jahn for supervision and support during my Master 
thesis and the first years of my PhD. Thereby always having a sympathetic ear for 
experimental problems and challenging results. 
Further, I would like to thank all members of the research group of the Molecular 
Physiology, for an enjoyable working atmosphere and for having a lot of fun at work. I 
would like to thank Wenhui Huang, Na Zhao, Phillip Rieder, Davide Gobbo, Qilin Guo, 
Michael Schweigmann, Katrin Bauer and Ute Legler for their accompaniment and 
support on numerous occasions during my PhD.  
Particularly, I would like to thank Frank Rhode for his support and creative ideas in 
managing daily laboratory work as well as Daniel Rhode and the animal facility 
members for taking care of my mice. Especially, I would like to thank Svenja Linder for 
her invaluable help during the last months of my thesis.  
I would particularly like to thank my “Glia Girls”: Cai (Xianshu Bai), Laura Stopper and 
Minime (Laura Caudal). Thank you for giving me the feeling to work with friends and for 
many unforgettable moments in- and outside of the lab. 
A special thank goes to Laura Stopper for helping me with the trials and tribulations of 
calcium data, for her organizational skills in any situation and for being a friend and a 
fellow in misery during our PhD. Thank you for your accompany in good times as in 
bad. I would also like to thank Gebhard Stopper for his time saving software 





Ganz besonders möchte ich mich bei meiner gesamten Familie bedanken, die mir 
immer Rückhalt gibt und mich in jeder Lebenslage unterstützt. Ihr gebt mir die Kraft das 
zu erreichen, was ich mir in den Kopf gesetzt habe.  
Ich danke meinen Eltern für ihr Vertrauen, ihre Liebe und ihre uneingeschänkte 
Unterstützung zeit meines Lebens. Ich danke auch meinem kleinen Bruder für lustige 
Gespräche und die richtigen Worte, wenn es nötig war.  
Ich möchte mich auch bei meinen Freunden für ihre langjährige und aufrichtige 
Freundschaft bedanken, allen voran Tiffie, Steffi, Michelle, Ralf, Bernhard, Micha und 
Jochen. Vielen Dank, dass ihr immer für mich da seid. 
Besonders möchte ich mich auch noch bei meinem Ehemann Georg bedanken, der 
seit Jahren mein Anker und Lebensmittelpunkt ist. Vielen Dank, dass du mich 
unterstützt, erdest, aufbaust und mich so akzeptierst wie ich bin. Ich kann es kaum 
erwarten mit dir unser neues Projekt zu erleben und zu meistern.  
